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SUMMARY
Murine models of graft-versus-host disease (GvHD) provide important 
information relevant to clinical bone marrow transplantation (BMT), as well as to 
other types of T cell-mediated pathology. The nature of the GvHD which develops in 
(C57BL/6 X DBA/2)Fj (BDFJ mice injected with parental lymphocytes is dependent 
on whether C57B1/6 (B6) or DBA/2 parental donor cells are used. BDFi mice injected 
with B6 donor cells (B6 => BDFJ develop an acute GvHD with early lymphoid 
hyperplasia and NK cell activation, followed by immunosuppression, activation of 
anti “host cytotoxic T lymphocytes (CTL), weight loss and early death. In contrast,
BDFi mice given DBA/2 donor cells (DBA/2 => BDFJ exhibit a chronic, stimulatory 
GvHD, characterised by B cell hyperreactivity, autoantibody production and immune 
complex-mediated glomerulonephritis (ICON).
Previous studies have shown that the distinct forms of GvHD in BDF, 
recipient mice are associated with different patterns of cytokine production. Whereas 
acute GvHD is characterised by production of high levels of Thl cytokines, chronic 
GvHD is associated with a preferential Th2 response. Therefore, it was suggested that
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the two forms of GvHD may reflect differential activation of distinct subsets of CD4^
T helper (Th) cells. However, when and why such T cell polarisation should occur 
has remained unclear, A number of recent studies have demonstrated that cytokines 
produced by cells of the non-specific immune system during the early phase of an
'immune response can strongly influence the type of specific response which develops 
subsequently. The main aim of this thesis was to explore the role of these early 
immune mediators in determining the outcome of the GvHD in BDFi mice.
The initial series of experiments described in Chapter 3 detailed the kinetics of 
acute and chronic GvHD in order to determine at what point the cytokine response 
becomes polarised towards a preferential Thl or Th2 phenotype. I found that acute 
GvHD in B6 => BDF, mice is a biphasic disease, in which Thl cytokines and intense
U
illymphoid hyperreactivity progress into a destructive disease characterised by death 
and immunesuppression. In contrast, chronic GvHD is an initailly milder, but 
ultimately more persistent disorder, which appears to involve a mainly Th2-type 
immune response. These results confirmed previous reports that differential cytokine 
production is associated with acute and chronic GvHD and extended them by showing 
that the responses elicited by B6 and DBA/2 parental donor cells diverged very 
rapidly.
IL-12, a heterodimeric cytokine produced by APCs, plays a key role in the 
early polarisation of Th cell responses in a variety of disease models by selectively 
promoting the growth and differentiation of Thl cells. In Chapters 4 -6 ,1 therefore 
examined directly the role of IL-12 in determining the outcome of the GvHD in BDFj 
mice, by investigating the effect of neutralising IL-12 in vivo. A single injection of 
neutralising anti-IL-12 antibody abrogated many of the early proliferative features of 
acute GvHD, including splenomegaly and NK cell activation, but these effects were 
transient. Neutralising endogenous IL-12 in B6 => BDF, mice for a longer period had 
a more dramatic effect on the development of acute GvHD, as repeated administration 
of anti-IL-12 during the first 8 days of the disease prevented all subsequent 
immunosuppression, weight loss and mortality. Anti-IL-12 not only conferred long­
term protection from the disease, but also permitted full repopulation with donor B6 
lymphocytes. The cytokine response of anti-IL-12 treated surviving mice was 
permanently polarised towards a Th2 phenotype similar to that observed in DBA/2 ^
SBDF, mice. However, long-term survivors did not develop the autoimmune pathology 
associated with the chronic form of disease. These results show that early production 
of IL-12 plays a critical role in acute, but not chronic GvHD. In contrast, neutralising 
IL-12 had no effect on the chronic GvHD in DBA/2 => BDF, mice.
To explore further the influence of IL-12 in acute vs chronic GvHD, in 
Chapter 7 ,1 examined the effects of giving rm IL-12 to both B6 => BDF, and DBA/2
m
IL-12 over a longer period.
The principal immunomodulatory role of IL-12 is to induce IFN-y production
IV
,
=> BDF, mice. Administration of IL-12 converted chronic GvHD into a more acute ■j'
type of disease, with a characteristic pattern of early hyperplasia followed by late
:¥
immunosuppression and destruction. Exogenous IL-12 also provoked anti-host CTL V''
activity, weight loss and mortality in DBA/2 => BDF, mice and converted the cytokine 
profile towards the Thl pattern usually seen during acute GvHD. IL-12 also 
exacerbated the systemic acute GvHD in B6 => BDF, mice. Although these results 
confirmed the important role of IL-12 in acute GvHD, enhanced levels of IL-12 were 
produced by spleen cells from both B6 => BDF, and DBA/2 => BDF, mice in 
response to LPS in vitro. However, B6 => BDF, cells produced higher amounts of
by CD4+ and CDS' T eells and NK cells. In Chapter 8 ,1 therefore examined directly 
the role of IFN-y in acute GvHD, both in unmanipulated B6 => BDF, mice and in 
DBA/2 => BDF, mice given IL-12, Depletion of IFN-y ameliorated many of the 
destructive features of both diseases, including weight loss, mortality and suppression 
of lymphoid responses, as well as reducing splenomegaly and increasing Th2 
cytokine production. In contrast, IFN-y was not required for CTL activation, |
induction of IFN-y production and inhibition of B cell activity.
The source of the different cytokines produced in GvHD were examined in 
Chapters 9 and 10. CD4+ T cells were the principal source of IL-2, IFN-y, IL-5 and 
IL-10 in both acute and chronic GvHD, although CDS' T cells and other cells also 
contributed to some of the cytokine production. In particular, during acute GvHD,
CD4', CDS' and non-CD4'CD8' populations all appear to contribute to the high levels 
of IFN-y produced by spleen cells from B6 => BDF, mice. However, the exact source 
of IFN-y appeared to vary at different times and I found evidence that several 
populations can produce or regulate the production of many of the critical cytokines 
involved in GvHD.
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»Finally, since NK cells are important during other models of GvHD and are a 
source of IFN-y in various models of T cell-mediated immunity. In Chapter 10 I
examined the involvement of NK cells in polarising immune effector responses early 
in acute GvHD. Depletion of NK cells with a single injection of anti-ASGM-1 
antibody had no consistent effect on either the progression of the disease or the 
cytokines produced during its course. Thus, NK cells may not be involved in the 
initial polarisation of acute vs chronic GvHD.
My results thus extend previous findings on the distinct forms of 
immunopathology which develop in BDF, mice with acute and chronic GvHD. In 
addition, my studies have demonstrated the importance of individual cytokines in 
polarising the allogeneic T cell response and determining its pathological outcome. In 
particular, they emphasise the role of ID-12 in Thl cell activation. These studies of the 
cellular and molecular interactions involved in murine GvHD have implications for 
understanding the pathogenesis of clinical GvHD and the development of specific 
therapy following BMT. In addition, they provide an important insight into the 
regulation of immune responses during other immunologically-mediated diseases.
:
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CHAPTER 1: INTRODUCTION
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Graft-versus-host reactions (GvHR) are initiated when mature T
lymphocytes are transferred into allogeneic recipient animals, thereby provoking
the development of a multi-organ inflammatory syndrome termed graft-versus-
host disease (GvHD). Experimental GvHD was first described by Billingham,
Brent & Medawar [1, 2], who found that newborn mice inoculated with allogeneic
lymphocytes developed a "runt disease", associated with malabsorption, growth
retardation, and damage to the liver, skin, intestinal tract and lymphoid organs.
Although initially described as a disorder of experimental animals [1-3], GvHD
.was subsequently found to be a common and often fatal, complication of human
allogeneic bone marrow transplantation (BMT) [4-6]. Human acute GvHD closely 
resembles acute GvHD in mice, and similar pathological changes in the skin, gut
and liver are observed [3,4,7-9]. Clinical chronic GvHD can evolve directly from 
primary acute disease or develop "de novo" [10]. In either case, the clinical 
manifestations of chronic GvHD are similar to those of collagen vascular diseases, 
such as systemic lupus erythematosous (SLE) or scleroderma [11, 12].
Since BMT remains the treatment of choice for a variety of diseases, 
including aplastic anaemia, severe combined immunodeficiency (SCID) and 
leukaemia [5, 6, 13-15], GvHD presents an obstacle in the therapeutic use of 
BMT. Despite the introduction of immunosuppressive agents such as 
Cyclosporine A and more recently, FK506 and rapamycin, as GvHD prophylaxis 
[10, 16], clinically significant GvHD develops in up to 60% of patients receiving 
an HLA-matched sibling BMT [9, 13]. Conversely, the more selective approach 
of depleting T cells from the donor BM to prevent GvHD [17-19] leads to failure 
of engraftment and causes leukaemic relapse [20]. Alternative GvHD preventative 
strategies are clearly needed and a better understanding of the complex interactions 
involved in GvHD will assist their development. Several animal models have 
therefore provided experimental systems to explore the pathogenesis of clinical
y
GvHD and other forms of T cell-mediated pathology in the relevant tissues [8, 21- 
23].
EXPERIMENTAL MODELS OF GvHD
Murine models of GvHD allow experimental manipulation of effector 
mechanisms in a broad range of donor/host strain combinations of distinct genetic 
backgrounds. Furthermore, the pathological alterations of acute murine GvHD 
correlate well with those in the human disease and has provided important insights 
into its pathogenesis. The essential requirements for induction of GvHD in 
experimental animals are as follows:- 1) The donor inoculum must contain 
immunocompetent T lymphocytes, since their depletion from allogeneic bone 
marrow grafts prevents GvHD initiation [17], 2) The donor and host must be 
genetically incompatible i.e. the host must express minor or major 
histocompatibility (MHC) antigens which are lacking in the donor inoculum and 
so are recognised by the donor T cells as foreign. 3) The host mice must be 
unresponsive to the injected donor cells, either because they are 
immunocompromised, or because they are genetically tolerant to the donor.
There are two principal models of experimental GvHD:-
1). Irradiated model:- the immune system of recipient mice is deliberately 
destroyed by irradiation (or chemotherapy). The subsequent injection of bone 
marrow and low numbers of donor T cells initiate a very severe, often lethal 
GvHD.
2). Parent => Fi model:- occurs when unirradiated, immune competent Fi 
hybrid mice are given parental donor T cells. In this case, donor lymphocytes can 
respond to the non-shared host MHC antigen(s), whereas host T cells are 
genetically tolerant to the injected cells. The severity of this form of GvHD is 
dependent on factors such as the nature of the donor and host MHC disparity [21, 
24-29], the phenotype of the cell population used to induce the GvHR [30, 31], 
and the microbiological status of the host [32-35]. This was the model of GvHD
IMMUNOPATHOGENESIS OF ACUTE GvHD
The acute GvHD which develops in B6 => BDFi mice is characterised by
chosen for the studies contained in this thesis, which focuses on the events 
involved in the induction and development of GvHD in unirradiated (C57B1/6 x 
DBA/2)Fi (BDFi) recipient mice injected with either C57B1/6 (B6) or DBA/2 
parental donor spleen cells.
The BDFi model of GvHD is particularly useful because the nature of the 
disease can be modified by using either C57B1/6 (B6) or DBA/2 parental donor 
cells. B6 (H"2^) donor cells provoke an acute GvHD, with early lymphoid 
hyperplasia, followed by immunosuppression, lymphoid atrophy, activation of 
anti-host cytotoxic T lymphocytes (CTL), weight loss and early death [21, 24, 27,
28, 30, 31]. In contrast, DBA/2 (H-2^) donor cells elicit a chronic, stimulatory 
GvHD, characterised by B cell hyper-reactivity, autoantibody production and 
Immune Complex mediated Glomerulonephritis (ICGN) [23 , 24, 36-40].
Previous studies have shown that the distinct forms of GvHD which develop in 
BDFi host mice are associated with different patterns of cytokine production.
Acute GvHD is characterised by production of high levels of IFN^ and IL-2 [41-
45], while chronic GvHD is associated with production of the Th2-type cytokines,
IL-4, IL-5 and IL-10 [42, 46-48]. Thus, it has been suggested that the two forms
'of GvHD reflect differential activation of CD4+ T helper (Th) cell subsets [42,
46]. However, the reason for this polarisation has remained unclear.
.The spectrum of pathological alterations observed in acute and chronic GvHD is 
illustrated in Fig. 1.1.
an initial period of immune stimulation, during which donor T cells expand in the 
host lymphoid organs [27, 29, 45] and enhanced NK cell activity is observed 
[49]. However, the early hyperplasia is rapidly replaced by suppressive 
manifestations, including loss of B and T cell function, hypogammaglobulinaemia 
and destructive pathology in the skin, liver, small intestine and lymphoid tissue [7,
frequency of stem cells [50], these survivors are eventually repopulated with 
donor-derived lymphohaemopoeitic cells [33, 51, 52].
The cellular requirements for initiation of acute GvHD have been studied
3
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3321,24, 27,28]. The host lymphohaemopoietic system is destroyed, severe weight
.loss is evident and the majority of animals die from an increased susceptibility to 
secondary infection and/or shock [21]. However, a small number of mice survive
ïv:acute GvHD and because the initial splenic donor inoculum contains a high
:'ï3:Iextensively. Optimal induction of the disease requires the presence of both CD4+ 
and CD8+ T cells in the donor inoculum [30] and incompatibility in the Fi 
recipient at both MHC class I and class II loci [25, 26, 29]. The 
immunosuppression and lethality can be inhibited by depleting either CD4+ or 
CD8+ T cells from the inoculum, [26, 30, 31] and CD8 depletion converts the 
acute disease into a chronic, stimulatory GvHD, similar to that found in 
unmodified DBA/2 => BDFi mice [31]. The use of F% mutant mouse strains 
which differ from donor mice solely at class I and/or class II MHC loci also 
shows that acute GvHD is characterised by sequential activation of class II- 
specific donor CD4+ T cells, followed by class I-specific CD8+ T cells [21, 29].
Although both CD4+ and CD8+ T cells are required for acute GvHD 
progression, the relative role of each of these populations in disease pathology is 
still not fully understood and remains very controversial. The main effector 
function of CD4+ T cells is to secrete cytokines and they can be divided into two 
subsets depending on the pattern of these mediators they secrete [53]. T helper 
type-1 (Thl) cells are responsible for cell-mediated immunity, while T helper type- 
2 (Th2) cells mediate humoral responses. Recent studies have suggested that 
during acute GvHD, activated Th cells appear to differentiate preferentially 
towards a Thl phenotype [42-44, 54]. Using semi-quantitative polymerase chain 
reaction (PCR) to detect cytokine mRNA, Allen et al. [42] demonstrated that 
spleen cells from acute GvHD mice produced much higher levels of IFN-y mRNA 
than did cells from either chronic GvHD or control mice. Furthermore, Troutt et
%al. [54] observed that up to 70% of spleen cells in B6 => BDFi mice were 
producing IFN-y mRNA compared with < 1% of normal cells. Several studies
have also suggested that acute GvHD is critically dependent on the high levels of
*
Thl cytokines produced during its development [55-57]. Administration of anti- 
IL-2 monoclonal antibody (mAb) to B6 =»- BDFi mice inhibits anti-host CTL 
cytotoxicity and prevents the destruction of host B cells usually observed [57]. 
The intestinal pathology associated with this model can also be prevented by 
neutralising IFN-y in vivo [55].
Thl cytokines could account for several features of acute GvHD. Firstly, 
IFN-y activates macrophages (m<j>s) [58] and induces the release of inflammatory 
mediators such as IL-1, IL-6, TNF-a and nitric oxide (NO) [59, 60]. Cells from 
mice with acute GvHD show an enhanced capacity to produce IL-1, IL-6 and 
TNF-a when stimulated with LPS in vitro [41, 43,61] and inhibition of IL-1 [62, 
63] or TNF-a [64, 65] in vivo reduces the severity of the disease. Similarity, 
injection of the NO synthesis inhibitor LP-monomethyl-arginine (L-NMMA) to 
mice with GvHD prevents enteropathy [66]. Further potential functions of Thl 
cytokines in acute GvHD include activating NK cells, providing help for CTL 
responses and contributing to immunosuppression. IL-2 and IFN-y act 
synergistically to trigger NK cells to secrete cytokines and develop into activated 
killer cells [67,68], while IL-2 is required for CD8+ cells to differentiate into anti­
host CTL during acute GvHD [57]. The final way in which IFN-y may be 
important in the acute disease is by suppressing lymphoid cell responses. Several 
mechanisms have been implicated in GvHD-asociated immunosuppression, 
including the destruction of lymphoid tissue by CTL [23, 31] and deficient 
lymphopoiesis of new B and T cell populations secondary to GvHD-attack on the 
thymus and bone marrow [50,69,70]. However, active suppression of lymphoid 
responses, demonstrated by the ability of GvHD cells to reduce B or T cell 
responses of cocultured normal host or donor cells, also occurs [27, 28, 30] and 
has been linked consistently to the production of IFN-y [71-73]. IFN-y has
cytostatic properties in vitro [74] and anti-IFN-y has been shown to prevent much 
of the suppression by GvHD cells in vitro [71, 73]. IFN-y may act by inducing 
release of additional immunosuppressive agents such as transforming growth 
factor-p (TGF-P) [71] or NO [75] which then modulate immune responses.
Although it is not clear why IFN-y production predominates in acute GvHD, IL-
12 has been shown to be central to its induction in other systems [76-82].
CD8+ T cells are also critical for the development of acute GvHD, although
their exact role is unknown. The disease can be prevented by depleting CD8+ cells
from the donor inoculum [30,31] and CD8+ T lymphocytes from mice with acute
GvHD can lyse host alloantigen bearing target cells in vitro [24, 27, 31]. The
kinetics of this CTL response correlate with destruction of host lymphoid cells in |
vivo [31], while chronic GvHD in DBA/2 ^  BDFi mice is not associated with
either tissue destruction or detectable CTL activity [23, 24,27,31]. However, the
presence of CTL does not always correlate with tissue damage and lethality [24,
27, 83]. An alternative possibility is that allospecific CD8+ T cells act by 
producing mediators which inhibit immune function and/or cause tissue damage.
These cells were first described as "allosuppressor" T cells in both murine and 
clinical GvHD, based on their ability to inhibit the function of other lymphocyte 
populations in vitro. [27, 30, 84]. Recent studies in other systems have also 
suggested that CD8+ T cells produce IFN-y [85-88] and TGF-p [89], both with 
known inhibitory properties. Finally, it should be noted that under certain 
conditions, CD8+ cells can also produce a variety of other cytokines, including IL- 
4, IL-5 and IL-10 [90-94] and it therefore remains important to define the role(s) 
of CD8- T cells directly.
A widely described feature of murine and clinical GvHD is NK cell 
activation [7,49,95-99], although their precise role in GvHD is unclear. NK cells 
are classified as large granular lymphocytes (LGL) and like CD8+ CTL, can be 
directly cytotoxic [100]. However, in contrast to specific CTL-mediated 
cytotoxicity, the susceptibility of target cells to NK cell-mediated lysis is inversely
fI
proportional to their expression of class I MHC antigens [101]. Increased NK cell 
activity is observed early during several models of GvHD [7, 49, 95-98] and 
involves both donor and host NK cell populations [95, 102, 103]. NK cell 
depleted donor populations induce a less severe acute GvHD [102, 104, 105] and 
depletion of NK cells in recipient mice by in vivo injection of anti-ASGM-1 
antiserum [105, 106] also reduces lethal disease. NK cells are found in areas of 
epithelial cell damage [102, 107-109] and therefore may contribute to disease by 
cytotoxicity. NK cells are thought to mediate rejection of certain parental bone 
marrow grafts by Fi hybrid mice (hybrid resistance) [110, 111]. However NK 
cells may also contribute to acute GvHD by releasing pathogenic cytokines such as 
IFN-y. This possibility is consistent with current ideas that, by providing an early 
source of IFN-y, NK cells are an important component of innate defence against
pathogens, by activating phagocytic cells [112-114] and promoting Thl cell 
differentiation [115-117], NK cells are recruited and activated by IL-12 [118- 
121], a proinflammatory cytokine released by m(j)s and other APC [76, 122,123].
'
IL-12 therefore provides a link between innate resistance and T cell-dependent 
responses. The role of NK cells in polarising GvHD has not been examined 
previously, nor has the relationship between IL-12 and NK cells been explored.
IMMUNOPATHOGENESIS OF CHRONIC GvHD
DBA/2 => BDFi mice develop a chronic GvHD, characterised by 
persistent immune stimulation of mainly host B lymphocytes. This leads to 
increased levels of serum IgG and IgE [37-39, 48] and production of 
autoantibodies against nuclear antigens, double-stranded DNA (ds-DNA), 
erythrocytes and thymocytes [21, 23, 38, 39]. Unlike the acute GvHD, tissue 
destruction and early death are not features of the chronic disease. However, after 
several months, DBA/2 => BDFi mice develop immune complex-mediated 
glomerulonephritis (ICGN), as evidenced by proteinuria, ascites and deposits of
immune-complexes in renal glomeruli and usually die from kidney failure, or 
lymphoma [21,36-39].
Chronic GvHD appears to be mediated entirely by CD4+ T cells [26,30], 
which are activated by allogeneic class II MHC antigens expressed on host B cells 
and then release cytokines which activate the B cells to proliferate and produce 
autoantobodies [39, 124]. No expansion of donor CD8+ T cells is observed and 
anti-host CTL activity is not detectable [27, 28, 31]. As a result, host 
lymphohaemopoietic cells are not eliminated and instead of repopulation by the 
donor cells, mixed chimerism develops [21, 23]. Chronic GvHD can also be 
induced by the injection of purified B6 CD4+ T cells [30, 125], while depletion of 
CD8*- T cells prevents the ability of B6 cells to induce acute GvHD and promotes 
development of chronic GvHD [30,31]. Similarly, chronic GvHD is induced by 
B6 cells when the host expresses an isolated MHC class II disparity [25, 26, 29]. 
Previous studies suggest that the key-factor in chronic GvHD is the continued 
stimulation of host reactive donor CD4+ T cells by host MHC class II-expressing 
B cells [39, 124, 126, 127] and that this occurs because host B cells are not 
eliminated by the inflammatory processes which underlie acute GvHD [24, 27,
31]. Potentially autoreactive B cells exist even in normal mice [21] and when
adequate Th cell help is provided (in this case by alloreactive donor CD4+ T cells), 
these can be triggered to secrete high affinity autoantibodies [21,39,124].
Recent work has suggested that chronic GvHD may be associated with a 
Th2-type cytokine phenotype [42, 46-48, 128]. This is consistent with the fact 
that Th2 cytokines drive B cell responses [53] and recent studies have shown 
elevated levels of mRNA for IL-4 and IL-10, but not for IFN-y, in unstimulated 
cultures of chronic GvHD spleen cells [42, 46, 47]. Furthermore, the majority of
I
antibodies produced during chronic GvHD are of the IgGi and IgE subclasses 
[48], both of which are highly dependent on IL-4 production [129] and are
therefore preferentially associated with Th2 responses. Anti-IL-4 treatment in vivo
8
131], it would appear that a low pCTL frequency does not in itself prevent the 
development of acute GvHD. Furthermore, these experiments show that chronic
"1I
has also been shown to prevent the elevated serum immunoglobulin and 
proteinuria associated with the disease, in addition to reducing mortality [48, 128].
The reasons why the same class I and class II MHC antigens cause 
different pathological outcomes depending on the donor cell origin are unclear.
Using limiting dilution analysis, it has been shown that DBA/2J mice have a nine­
fold lower anti-BDFj precursor CTL (pCTL) frequency than B6 mice [31] and 
thus are unable to generate a comparable CD8+-mediated cytotoxic attack on BDFi 
recipients. However, when spleen cells from congenic DBA/2HaSmm mice are 
used to induce GvHD in BDFi mice, instead of the DBA/2J cells normally used in 
this model, a classic acute GvHD with anti-host CTL activity and 
immunosuppression develops [130]. As DBA/2HaSmm mice are also H-2^ and 
have a similarily low anti-H-2*  ^pCTL frequency as that of DBA/2J mice [130,
a
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GvHD does not simply result from injecting H-2^ donor cells into BDFi mice and 
cells from other H-2^ strains, including C57B1 congenic B 10.D2 mice elicit acute 
GvHD normally [21]. Thus, the inherent differences in the T cell responses of B6 
and DBA/2 mice responsible for modulating GvHD remain unidentified.
Taken together, it appears that Thl cytokine production, together with 
CD8+ donor T cell engraftment provokes acute GvHD, while a preferential Th2 
cytokine response and a lack of donor CD8+ T cell engraftment, leads to chronic 
GvHD. Determining why these different T cell responses were elicited by B6 and 
DBA/2 donor cells was the main focus of my work and it is important to 
understand what factors are responsible for polarising the specific immune 
response in other systems.
I
Thl and Th2 CELL DIFFERENTIATION
The cytokine profile produced by activated CD4+ T helper (Th) cells 
determines the specialised effector function of the cell [53,132]. Thl cells secrete
I
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cytokines which provide help for cell mediated immune responses and are 
functionally defined as cells which produce IFN-y, while Th2 cells secrete 
cytokines which induce antibody production by B cells and are defined on the 
basis of their ability to produce IL-4, IL-5, IL-6, IL-10 and IL-13 [53]. The 
reason(s) why a naive or precursor CD4+ T cell (pTh) becomes polarised to 
differentiate into a Thl or a Th2-type cell are not fully understood and are the 
focus of many current studies. Recent use of TcR transgenic (TcR Tg) mice, in 
which the majority of CD# T cells express a TcR specific for known antigen/class 
II MHC molecule complexes, has strongly suggested that a single precursor cell 
may differentiate to either a Thl or Th2 phenotype, depending on the conditions 
present during its initial contact with specific antigen [76, 78, 133-135]. These 
studies have also been instrumental in showing that many factors can play a role in 
aquisition of T helper cell phenotype, including the type of APC involved [132,
136] antigen dose [137, 138] and genetic background [139, 140]. However, the 
most potent influence on Th phenotype acquisition appears to be exerted by 
cytokines themselves [76-78, 133-135, 141]. The majority of studies agree that 
differentiation towards a Th2 response is critically dependent on the presence of 
IL-4 during priming [134, 135, 141] and that mast cells, basophils and/or CD4+
NK1.1+ cells may be important IL-4-producing cell types during the early non­
specific immune response [116, 142-146]. In addition, much interest has focused 
on the role of the recently described AFC-derived cytokine, IL-12, in determining 
the outcome of CD4+ T cell-mediated immune responses [76-78,147].
INTERLEUKIN-12
IL-12 (originally known as Natural Killer Cell Stimulatory Factor 
(NKSF)) is a heterodimeric cytokine consisting of a 35kD and a 40kD chain 
[123]. It is produced by phagocytic cells, particularly m<j)s, in response to 
microbial constitutents [76, 122], or when CD40 on the m(|) surface is ligated by 
CD40 ligand (CD40L) on activated T cells [148, 149]. Originally cloned from
'" 3 3 :
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EBV-transformed B cell lines, IL-12 was first functionally described as a potent
1 1
inducer of IFN-y in T and NK cells and an enhancer of cytotoxic activity in CD8+ 
T cells and NK cells [118, 120, 150, 151]. It is now known that IL-12 acts at 
several different levels during T cell-mediated immune responses, as illustrated in 
Figure 1.2.
Early during the response, APC-derived IL-12 stimulates NK and T cells 
to produce IFN-y. Both resting and activated NK cells produce IFN-y in response 
to IL-12 [121, 123], alone, or in synergy with IL-1 and TNF-a [119, 152]. This 
early, T cell-independent pathway of IFN-y production may therefore be extremely 
important in determining the outcome of the specific adaptive response [112-114,
117, 152, 153]. IL-12 also induces IFN-y production by CD4+ and CD8+ T cells 
[92, 120, 121, 151], but maximal production of IFN-y by T cells also requires 
TcR/CD3 engagement and costimulatory signals delivered via the CD28 molecule 
on the T cell surface by B7 on APC [154,155]. In addition to eliciting IFN-y from 
NK cells and T cells, IL-12 also enhances their cytotoxic responses [118, 120, 
121]. IL-12 augments both NK cell-mediated and CTL-mediated cytotoxicity and 
promotes the expansion of activated NK and CD8+ T cells [123, 156, 157].
B cells and m<j)s can both produce IL-12 [76-78, 120, 122, 152, 158, 
159], but m(|)S appear to be the major producers of IL-12 under physiological 
conditions, as LPS induces similar levels of IL-12 in normal and B cell deficient 
SCID mice [152]. Although stimulation with bacteria or bacterial products (e.g. 
LPS), or signalling via the CD40 antigen can activate m (|)S to release IL-12, m(|)s 
also usually require priming with IFN-y for optimal IL-12 production [148, 160]. 
Very recently, it has been suggested that dendritic cells (DCs) can also produce IL- 
12, albeit at much lower levels than are produced by activated M<|>s [123]. The 
signals required for IL-12 production by DCs are not yet fully characterised, 
however the ability of DCs to produce IL-12 while acting as APCs may be 
important in influencing Th cell differentiation.
IL-12 is critically required for the differentiation of pTh into effector Thl 
cells [76-78, 159]. Hsieh et al. [76] were the first to demonstrate this by showing 
that the addition of heat killed Listeria monocytogenes (HKLM) to unprimed 
cultures of TcR Tg T cells augmented their subsequent IFN-y production. This 
effect was only observed if m(|)S were present in the original culture and was found 
even if the m<j)s were not recognised by T cells in a cognate fashion. This was 
prevented by the addition of anti-IL-12 mAb to the cultures. IL-12 appears to act 
directly on pTh to promote Thl differentiation, as it also enhances priming for 
IFN-y in an APC-indendent system [78], but it may also increase Thl responses 
by inhibiting priming for IL-4 production, thereby preventing Th2 cell 
differentiation.
Whether IFN-y is necessary for Thl responses induced by IL-12 is, as 
yet, unresolved [77, 78, 159, 161]. Studies in some systems, suggest that in the 
presence of neutralising anti-IFN-y antibodies, IL-12 can still promote 
differentiation of pTh towards a Thl phenotype [77, 78]. However, it is thought 
that the ability of IL-12 to inhibit Th2 differentiation is mediated by IFN-y. This 
hypothesis is supported by a number of in vivo studies [162-164], and is 
particularly well illustrated in mice treated in vivo with anti-IgD antibody to induce 
a Th2 response [163]. In such mice, recombinant IL-12 reduced IL-4 mRNA 
levels in an IFN-y dependent manner, while augmenting IFN-y production in an 
IFN-y independent fashion.
Taken together, it appears that IL-12 provides an important link between 
the early innate immune response, mediated by phagocytes and NK cells, and the 
subsequent cell-mediated response, dominated by Thl cells and CTL. It would 
therefore seem likely that IL-12 was responsible for polarising the T cell response 
during BDFi GvHD. This had not been examined before and was the principal 
aim of my thesis.
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AIMS OF THIS STUDY
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Distinct pathological syndromes are elicited by the injection of B6 or 
DBA/2 parental cells into unirradiated BDFi recipient mice, although the factors 
responsible for this polarisation are poorly defined. Dissecting the cellular and 
molecular interactions involved in the two disease processes would lead to a better 
understanding of GvHD and other immunologically-mediated diseases and is 
essential for the development of specific therapies following BMT. The primary 
aim of this study was to examine whether differing patterns of cytokine production 
were associated with acute and chronic GvHD and to examine what factors may be 
responsible for this polarisation. Therefore, in the experiments described in 
Chapter 3 ,1 firstly characterised the kinetics of acute and chronic GvHD using in 
vitro and in vivo indices of disease progression and subsequently examined a time 
course of cytokine production during the early period of the two diseases.
The second important aim of my research was to assess the role played by
13
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the early non-specific immune response in determining the outcome of parental cell
.injection and the role of IL-12 was assessed in Chapters 4-7. From the results of
these chapters, it was clear that IL-12 was instrumental in directing the specific 
response during GvHD and several findings suggested that the role of IL-12 was 
to induce the production of IFN-y. In Chapter 8 ,1 therefore examined directly the 
role of IFN-y in acute GvHD, both in unmanipulated B6 => BDFi mice and in 
DBA/2 =>BDFi mice given IL-12, using the parameters which I had characterised 
in previous chapters.
Finally, it was of interest to determine the cellular source of the cytokines 
produced during acute and chronic GvHD. In Chapter 9 ,1 therefore explored how 
CD4+ and CD8+ T cells contributed to cytokine production in acute and chronic 
GvHD. In addition, since NK cells are important for the pathogenesis of GvHD 
and are implicated as an important early source of IFN-y in other T-dependent
3:
models of infection, I carried out a detailed study of their involvement in the IL-12 
mediated acute form of GvHD. This is described in Chapter 10.
3
I
s
14
ACUTE
C57BU6 Spleen cells
(C57BL/6xDBA/2)F^
BDFi
CHRONIC
(C57BL76xDBA/2)Fi
DBA/2 Spleen cells
BDFi
Lymphoid hyperplasia 
NK cell activity 
Tissue destruction 
Anti-host CTL 
Immunosuppression 
Weight loss 
Death
Persistent lymphoid
hyperplasia 
B cell activation 
Hypergammaglobulinaemia 
Autoantibody production 
Proteinuria 
Ascites
Immune complex
glomerulonephritis
Fig. 1.1. The Spectrum of Pathological Alterations Associated with 
Acute and Chronic GvHD.
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Fig. 1.2. The Role of IL-12 in Cell-mediated Immune Responses.
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CHAPTER 2
MATERIALS AND METHODS
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Animals
Female C57B1/6J (H-2b), DBA/2J (H-2<i) and (C57B1/6J x DBA/2) Fi 
(BDFi) (H-2l*^d) mice were obtained from Harlan Olac Ltd (Bicester, Oxon). 
Animals were specified pathogen-free (SPF) and were maintained under standard
animal house conditions either in the Joint Animal Facility, or the Central Research 
Facility at the University of Glasgow. Mice were normally used at 6-8 weeks of 
age.
Collection of Blood Samples
Under light anaesthesis using 5% Halothane BP (Rhone Merieux Ltd., 
Harlow, Essex), a maximum of 200pl of blood was removed from the retro- 
orbital plexus using heparinised capilliary tubes (Hawksley & Sons LtD., 
Lancing, Sussex). Serum was separated by centrifuging capillary tubes for 10 
mins at 2000 rpm and stored at -20°C until use.
Histopathological Analysis of Kidney Sections
Histopathological analysis was carried out by Dr. Robin Reid (Dept. 
Pathology, Western Infirmary, Glasgow). Mice were sacrificed by cervical 
dislocation and kidneys removed by dissection. Kidneys were then fixed in 10% 
formalin solution and embedded in paraffin wax before 4pm sections were cut and 
stained with either Haematoxylin and Eosin (H and E) or Periodic-Acid Schiff 
(PAS) reagents. Sections were analysed by light microscopy (Nikon Labophot x 
40 objective).
Electron Microscopy of Kidney Sections
Electron microscopy was performed by Mrs Jane Hare (Dept of 
Pathology, Western Infirmaiy, Glasgow). Kidneys were removed as above and 
fixed in 5% paraformaldehyde solution. Sections were then negatively stained 
with 3% phosphotungstic acid (pH6.6) and analysed on a Philips CM 10 
transmission electron microscope (TEM).
Preparation of Lymphoid Cells
Mice were sacrificed by asphyxiation in CO2. Spleens and thymi were 
removed immediately and placed in a petri dish containing 10ml RPMI 1640 
medium (Gibco BRL. Paisley, Scotland). Single-cell suspensions were prepared 
by gently rubbing the tissues through a stainless steel mesh with the plunger of a 
5ml syringe (Becton Dickinson, Cowley, Oxford) and the resultant suspension 
passed through Nitex mesh (Cadisch & Sons, London) to remove clumps and 
debris. Cells were then washed twice in RPMI by centrifuging for 7 mins at 450g 
and resuspending the cell pellet in 10ml fresh RPMI between washes. Viable cells 
were counted by phase contrast microscopy (Nikon Labophot x 40 objective) 
using an Improved Neubauer haemocytometer (Weber Scientific International 
Ltd., Teddington, Middlesex). The final cell pellets were resuspended to a 
concentration of 5 x 10  ^cells/ml in RPMI.
Induction of GvHR
The GvHR was induced by intravenous (i.v.) injection of 10^ viable 
C57B1/6J or DBA/2J donor spleen cells, in a volume of 0.2-0.4 ml RPMI, into the 
tail vein of BDFi recipients. Control mice received 0.2ml of RPMI only.
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Relative Spleen Weight of GvHD Mouse
Mean Relative Spleen Weight of Control Mice
A Spleen Index of greater than 1.3 was considered to be indicative of significant 
GvHD in all experiments [3].
X 10-^M 2-mercaptoethanol (2-ME, Sigma-Aldrich Company Ltd., Poole, Dorset) 
(complete RPMI). The cells were plated in quadruplicate in 96 well flat-bottomed 
microtitre plates (Costar, Northumbria Biologicals, Cramlington, 
Northumberland) at 2 x 10  ^cells/ well in a total volume of 200pl complete RPMI 
medium, either alone, or with lOpg/ml of either Concanavalin A (Con A) or
19
Assessment of Systemic GvHR
The intensity of the systemic GvHR in BDFi mice was assessed by 
regular weighing of mice to gauge weight loss, noting the onset of mortality and 
determining splenomegaly in individual animals.
Calculation of Splenomegaly
BDFi mice were sacrificed, their spleens removed and weighed and their 
body weight noted. The relative spleen weight was expressed in mg/lOg body 
weight and the Spleen Index calculated for each GvHD mouse using the formula
Measurement of Proliferative Responses In Vitro
Spleen cell suspensions of spleens pooled from GvHD or control mice 
were prepared in RPMI as described above. After washing twice in RPMI by 
centrifuging for 7 min at 450g, viable cells were counted and the cell pellet was 
resuspended at a final concentration of 10  ^cells/ml in RPMI medium containing 
10% heat-inactivated foetal calf serum (FCS), lOOU/ml penicillin, lOOpg/ml
streptomycin, L25pg/ml fungizone and 2mM 1-glutamine, (all Gibco BRL) and 5
20
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Lipopolysaccharide derived from Salmonella Enteritidis (LPS; both Sigma- 
Aldrich). Plates were sealed with ICN Titertek non-toxic platesealers (ICN 
Biomedicals, Flow Laboratories, Irvine, Scotland) and placed in a humidified 
3 7 ^  incubator with a 5% CO2 atmosphere. Either immediately, or after various 
culture periods, individual wells were pulsed with IpCi %-thymidine (West of 
Scotland Radionucleotide Dispensary, Western Infirmary, Glasgow) for 4 hours 
(spontaneous 'ex~vivo* proliferation) or 24 hours before being harvested onto 
glass fibre filters using a 1295 Betaplate 96 well harvester. DNA-^H-thymidine 
incorporation was assessed by liquid scintillation using a 1205 Betaplate 
scintillation counter (all LKB Wallac, Turku, Finland).
Induction and Measurement of Cytokine Production in vitro
Single spleen cell suspensions were resuspended at a final concentration of 
4 X ICP cells/ml and cultured in 1ml aliquots in 24 well tissue culture plates
I
(Costar) in complete RPMI. Cells were cultured in medium alone (to assess 
spontaneous production of cytokines) or with lOpg/ml Con A or LPS. 
Supernatants were harvested after 1-4 days of culture, centrifuged in a 
Microcentaur Microfuge (Scotlab) at 13000 rpm for 5 minutes to remove cellular 
debris and stored at -20®C until assayed.
Production of IL-2, IFN-y, IL-4, IL-5 and IL-10 were quantified using 
sandwich Enzyme-Linked Immunosorbent Assays (ELISA). 96-well ELISA 
plates (Immunlon 4, Dynatech Laboratories Ltd., Billingshurst, West Sussex) 
were coated with 50pl per well of monoclonal anti-cytokine capture antibody 
(mAb) at the predetermined optimal concentration (Table 1) in carbonate buffer 
(Appendix 1) and then incubated overnight in a sealed container at 4®C. The 
contents of the wells were emptied and the plates washed twice by filling the wells 
with phosphate buffered saline (PBS; Appendix 1) containing 0.05% Tween 20 
(BDH, Poole, Dorset) (PBS/Tween), leaving to stand for 1 min and emptying the 
contents again. Non-specific protein binding sites were blocked by incubation
.i
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with 200^1 of PBS containing 10% FCS (PBS/FCS) for Ihr at 31^C. After 
blocking, the plates were washed twice with PBS/Tween and culture supernatants 
or standard recombinant murine cytokines at predetermined concentrations (Table
2) were added to individual wells in a volume of 50pi. Standard recombinant 
cytokines were then serially diluted to provide the range of concentrations shown
-in Table 2 and the plates were incubated at 37®C for 3hrs. Plates were then 
washed 4 times with PBS/Tween and 50pl of biotinylated anti-cytokine detecting
'antibody, diluted in PBS/10% FCS, was added at the concentrations shown in 
Table 1. After incubation for Ihr at 37®C, the plates were washed 6 times with 
PBS/Tween and lOOpl of extravidin-peroxidase, (Sigma), prediluted to 2pg/ml in 
PBS/10% FCS, was added to each well. Following a final incubation for Ihr at 
3 7 ^ , the plates were washed 8 times with PBS/Tween, before lOOpl 3,3'5,5- 
tetramethylbenzidine (TMB) peroxidase substrate (Dynatech) was added to each 
well. The plates were then read at 630nm using an MR5000 automatic microplate 
reader (Dynatech) using Mikrofit version 4.5 software (Mikrotek Laborsysteme
'S.-GmbH) and the cytokine concentration in each test supernatant calculated with 
reference to a standard curve constructed using serial dilutions of recombinant 
cytokines.
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IL-12 p75 Heterodimer Specific ELISA
Production of IL-12 was also quantified using a sandwich ELISA. 96-well 
ELISA plates (Immunlon 4, Dynatech) were coated with lOOpl per well of 
monoclonal anti-mouse p75 antibody (kindly provided by Dr. M. K. Gately,
Hoffmann-La Roche, Nutley, NJ) diluted to 5pg/ml in IL-12 coating buffer 
(Appendix 1) and then incubated overnight in a sealed container at 4^C. The plates 
were then washed three times with PBS/Tween before being blocked by the 
addition of 200pl per well of PBS containing 3% bovine serum albumin (BSA;
PBS/BSA) for Ihr at 37^0. After blocking, the plates were washed three times
with PBS/Tween and culture supernatants were added to individual wells in a
2 1
volume of 100pl. Recombinant murine IL-12, diluted to 20ng/ml in IL-12 assay 
buffer (Appendix 1), was also added to individual wells in a volume of lOOpl and 
serially diluted to construct a standard curve of IL-12 concentrations from 20ng/ml 
- 15.6pg/ml. After incubation for 3hrs at room temperature, the plates were 
washed 4 times with PBS/Tween and 100pi of horseradish peroxidase conjugated 
(HRPO) rat anti-mouse p40 detecting mAb (Dr. M. K. Gately) was added at 
500ng/ml diluted in IL-12 assay buffer for 2hr at room temperature. The plates 
were washed a further 5 times before lOOpl TMB peroxidase substrate was added 
to each well. The plates were then read as before using an MR5000 automatic 
microplate reader (Dynatech) and the IL-12 concentration in each test supernatant 
calculated with reference to the standard curve constructed using serial dilutions of 
recombinant IL-12.
Maintenance of Cell Lines in vitro
EL4 cells [derived from a thymoma of C57B1/6 origin (H-2^)], P815 cells 
[derived from a methylcholanthene-induced mastocytoma of DBA/2 origin (H-2d)] 
and YAC-1 cells (derived from a thymoma of A strain origin) were maintained in 
RPMI containing 10% heat-inactivated FCS, lOOU/ml penicillin, lOOpg/ml 
streptomycin, 1.25pg/ml fungizone and 2mM 1-glutamine in a humidified 37% 
incubator with a 5% CO2 atmosphere. These cell lines were subcultured every 2-3 
days, by adding l-2ml of cell suspension (approximately 10  ^ cells) to 10ml of 
fresh medium and were always subcultured 2 days before use, to ensure that the 
majority of cells would be in the log phase of growth.
Measurement of Specific and Non-Specific Cytotoxicity
EL4 and P815 target cells were used to detect anti-H-2^ and anti-H2‘* 
allospecific CTL activity respectively, while YAC-1 cells were used to detect NK 
cell activity. Aliquots of 2.5 x 10  ^ target cells were labelled with ^^Cr by 
incubation in 1ml RPMI 1640/5% newborn calf serum (NCS, Gibco BRL)
2 2
% Specific Cytotoxicity (Experimental cpm - Spontaneous cpm)
100%
(Maximum cpm - Spontaneous cpm)
containing either 200pg/ml anti-CD4 mAb (YTS 191.1) or anti-CD8a mAb (YTS 
169.4) (both kindly provided by Dr. Eleanor Bolton, Dept. Surgery, University of 
Glasgow) and incubated for 60 min on ice. After two washes in RPMI/5% FCS
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containing 2 MBq Na2^%r0 4  (West of Scotland Radionucleotide Dispensary) for 
50 min at 37^C. They were then washed 5 times in RPMI/5% NCS by
centrifuging at 450g for 7 minutes and the number of viable cells counted before 
resuspending at a final concentration of 2 x 10^cells/ml. lOOpl of single cell 
suspensions of effector cells, resuspended at a final concentration of 2 x 10^ 
cells/ml in RPMI/5% NCS were added in quadruplicate to lOOpl aliquots of ^^Cr- 
labelled target cells in V-bottomed microtitre plates (Costar), giving final effector
cell : target cell (E :T) ratios of 100:1,50:1,25:1 and 12.5:1. After 4hrs incubation
■in a humidified 37% incubator with a 5% CO2 atmosphere, lOOpl of supernatant
was removed from each well to assess ^^Cr release in a 1282 Compugamma 
counter (LKB Wallac). The cytotoxic activity was then calculated by the following 
formula:
In all assays, maximum release was obtained by adding lOOpl 10% Triton-X 100
(Sigma) to wells containing 2 x 10  ^^%r labelled target cells. In CTL assays.
spontaneous release was calculated using spleen cells from control mice, while in 
NK cell assays, thymocytes from control mice were used.
ÿ;
Depletion of T Cell Subsets in vitro
CD4+ and CD8+ T cell subsets were depleted in vitro by complement- 
mediated lysis. Spleen cells were resuspended at 10'^  cells/ml in RPMI/5% FCS
ft
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by centrifuging for 7 min at 450g, the cells were resuspended at 5 x 10  ^cells/ml in 
RPMI/5% FCS containing 10% (v/v) rabbit complement (Low-Tox M, Cedarlane 
Laboratories Ltd., Hornby, Ontario, Canada) and incubated for 60 min in a 37% 
humidified incubator with a 5% CO2 atmosphere. The cells were then washed 
twice in RPMI, counted and resuspended at 4 x 10  ^cells/ml in complete RPMI. 
Control cells were incubated in RPMI/5% FCS containing 10% rabbit complement 
alone.
The efficacy of the depleting antibodies was assessed by flow cytometry 
(as described below) and the percentage of residual CD4+ or CD8+ cells remaining 
after depletion was consistently < 0.2%, as shown in Fig. 9.1.
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Depletion of NK Cells In Vivo
NK cells were depleted in vivo by the i.v. injection of 30pl polyclonal 
anti-asialo-GM-1 rabbit antiserum (anti-ASGM-1; Wako Chemicals, Germany) 
diluted in 200pl PBS. Control mice received 0.2mls of normal rabbit serum 
(provided by CRF animal facility). The effect of anti-ASGM-1 treatment on
:splenic NK cell activity in GvHD and control mice is shown in Fig. 10.2.
Phenotypic Analysis of Lymphocytes by Flow Cytometry
Aliquots of 10^ spleen cells were resuspended in 50pl staining buffer (SB; 
Appendix 1) containing the appropriate concentration of primary antibody (Table
3). The samples were incubated for 30-40min on ice in the dark and then washed 
twice in SB for 7min at 450g. For two colour analysis, biotinylated anti-H-2D‘^ 
and anti-H-2 Db MHC Class I primary antibodies were then detected by incubating 
the cells in 50pl SB containing either 1/100 fluoroscein isothiocyanate-streptavidin 
(FITC-SAV) or 1/50 phycoerythrin-streptavidin (PE-SAV) (both from Vector 
Laboratories, Peterborough) for 30-40min on ice in the dark. The cells were then 
washed twice in SB and erythrocytes lysed by incubating the cells in 0.5ml of cold 
"Facslyse Solution" (Becton Dickinson) pre-diluted 1/10 in distilled water for 10
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minutes at room temperature. The cells were again washed twice in SB and 
resuspended in 0.5ml "Facsflow" solution (Becton Dickinson) before being 
analysed using a FACscan IV flow cytometer (Becton Dickinson) with a 488nm 
argon laser. Lymphocytes were gated on the basis of their forward and side light 
scatter properties and the data analysed using Lysis II software (Becton 
Dickinson). In all experiments, negative control samples were cells incubated with 
FITC-SAV or PE-SAV in the absence of primary antibody.
Measurement of Total Serum Immunoglobulin Levels
i) Total IgG Levels
Serum levels of total IgG were measured by radial-immunodiffusion (RID) 
using agarose gel RID kits, according to the manufacturers’ instructions (Bind A 
RID NL RN272, The Binding Site, Birmingham). Test serum samples were 
diluted 1/10 and 5pl of each sample was applied to individual wells in the agarose 
gel (which contains antibodies to mouse IgG). On each RID plate, 3 wells were 
also filled with 5pl of one of three standard samples containing known 
concentrations of IgG. The plates were then resealed, wrapped in damp tissue 
paper and incubated at 4®C for 72 hrs to allow diffusion of IgG through the 
agarose gel. After incubation, the lids were removed and the diameter of the 
precipitin ring formed for each sample was measued using a pocket focusing 
magnifier with measuring scale (Philip Harris Scientific, Clydebank, Scotland). A 
linear calibration curve was constructed by plotting the square of the diameter of 
the precipitin rings formed by the three standard samples against their specific 
protein concentration and the concentration of IgG in each test sample was then 
read off the calibration curve.
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ii) Total IgE Levels
Serum IgE levels were measured using sandwich ELISA techniques. 50pl 
purified rat IgG anti-mouse IgE monoclonal antibody (Clone R35-72, 
Pharmingen) was added to the wells of flat bottomed microtiter plates (Coming
Easy Wash, Bibby Sterilin Ltd., Newport, Gwent) at Ipg/ml in carbonate buffer.
The plates were incubated overnight at 4®C and then washed twice with 
PBS/Tween before blocking by incubation with 100 pi per well PBS/15% FCS 
for 2 hours at room temperature. lOOpl of each serum sample was added in 
duplicate to individual wells, either neat or diluted 1/50 in PBS/15% FCS.
Purified murine IgE standard (Clone IgE-3, Pharmingen) diluted to a starting 
concentration of 200ng/ml in PBS/15% FCS was added to additional wells in 
lOOpl and serial dilutions made to construct a standard curve. The samples and 
standards were incubated on the plates overnight at 4^C, after which the plates 
were washed 4 times in PBS/Tween before addition of 50pi per well of 
biotinylated rat anti-mouse IgE detecting antibody (Clone R35-92, Pharmingen) at
4pg/ml in PBS/15% FCS. After incubation for 1 hour at 31^C, the plates were
■washed 6  times in PBS/Tween and lOOpl streptavidin peroxidase (Sigma), diluted 
1/1000 in PBS/15% FCS was added to each well. Following a final incubation for 
1 hour at room temperature, the plates were washed 8  times in PBS/Tween prior
.to addition of lOOpl/well TMB peroxidase substrate (Dynatech). The plates were 
then read at 630nm using an MR5000 automatic microplate reader (Dynatech).
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ill) Measurement of Antl-Double-Stranded DNA Antibodies
Serum levels of anti-double stranded DNA (ds DNA) antibodies were 
assessed using sandwich ELISAs. Flat-bottomed microtitre plates (Immulon 2, 
Dynatech) were coated with lOOpl per well of poly-l-lysine (Sigma) diluted to
50pg/ml in borate buffered saline (BBS; Appendix 1) for Ihr at 37^C, then 
overnight at 4%. The plates were washed three times with BBS containing 0.05% 
Tween 20 (BBS/Tween) and then coated with 50pl per well of ds DNA at
lOpg/ml for Ihr at 37°C. After a further three washes in BBS/Tween, non­
specific protein binding sites were blocked by the addition of lOOpl per well of 
BBS containing 1% BSA, (BSA/BBS) for Ihr at room temperature. Following 
blocking, the plates were washed twice in BBS/Tween and 50pl of test serum 
samples diluted 1/100, 1/500 and 1/1000 in BSA/BBS containing 0.05% Tween 
20 (BSA/BBS/Tween) were then added to individual wells for 2hr at room 
temperature. After four more washes with BBS/Tween, 50pl of alkaline 
phosphatase conjugated anti-mouse IgG (Sigma) diluted 1/10000 in 
BSA/BBS/Tween was added to the wells for 2hr at room temperature. Finally, the 
plates were washed 6  times in BBS/Tween before the addition of lOOpl per well 
of p-nitrophenyl phosphate-disodium substrate (Dynatech) in 1% Diethanolamine 
solution (BDH) and 0.01% MgC12. The colour was allowed to develop for 30-
volume of 0.2ml PBS containing 1% homologous mouse serum. Control mice 
received 0.2ml PBS containing 1% homologous mouse serum.
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60min and then the plates were read at 405nm using an MR5000 automatic 
microplate reader (Dynatech).
Neutralisation of IL-12 In Vivo
Endogenous IL-12 was neutralised by the i.p. injection of 0.5mg purified 
goat anti-mouse IL-12 polyclonal IgG (provided by Dr. Maurice K. Gately, 
Hoffmann-La Roche Inc., Nutley, New Jersey, USA), diluted in 0.2ml PBS. 
Control mice received 0.5mg of purified normal goat IgG (Sigma; Reagent Grade) 
diluted in PBS.
Administration of Exogenous IL-12 In Vivo
IL-12 was administered by the i.p. injection of lOOng purified recombinant 
murine IL-12 (rm IL-12; Dr Maurice K. Gately, Hoffmann-La Roche) in a total
rîtft
Neutralisation of IFN-y In Vivo
Endogenous IFN-y was neutralised by the i.p. injection of 0.5mg purified 
hamster anti-mouse IFN-y IgG mAb H22 (provided by Dr. Adrienne Morgan,
Celltech Ltd., Slough, Berkshire). Control mice received 0.5 mg of isotype 
matched hamster control antibody (also provided by Dr. Adrienne Morgan).
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Statistics
Unless otherwise stated, results were expressed as means -f/- standard 
deviations (SD) and were compared by Student's t-test. i
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TABLE 2.1
Monoclonal Antibodies used in Cytokine Sandwich ELISAs
i) Purified Capture Antibodies
Specificity Clone Isotype Concentration
(pg/ml)
IL-2 JES6-1A12 RAT IgG2a 2
IFN-y R4-6A2 RAT IgGl 2
IL-10 JES5-2A5 RAT IgGl 2
IL-4 BVD4-1D11 RAT IgG2b 2
IL-5 TRFK5 RAT IgGl 4
ii) Biotinylated Detecting Antibodies
Specificity Clone Isotype Concentration
(pg/ml)
IL-2 JES6-5H4 RAT IgG2b 1
IFN-y XMG1.2 RAT IgGl 1
IL-10 SXC-1 RATIgM 2
IL-4 BVD6-24G2 RAT IgGl 1
IL-5 TRFK4 RAT IgG2a 4
The optimal concentration of capture and detecting antibodies for use in cytokine 
ELISAs was determined by chequerboard titrations.
All of the above monoclonal antibodies were purchased from Pharmingen, San 
Diego, U.S.A.
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TABLE 2.2
Recombinant Murine Cytokine Standards used in Sandwich ELISAs
Cytokine Concentration Range Source
IL-2 200U/ml - L56U/ml Pharmingen
IFN-y 40ng/ml - 1.25ng/ml Pharmingen
IL-10 40ng/ml - 1.25ng/ml Genzyme (West Mailing, 
Kent)
IL-4 200U/ml - 1.56U/ml Genzyme
IL-5 200U/ml - 1.56U/ml Pharmingen
3 0
TABLE 2.3 
Antibodies used in Flow Cytometric Analysis
5
i) Monoclonal Antibodies
Specificity Clone Isotype Source Dilution
PE-anti-CD4 GK1.5 RatIgG2b Becton 1:16
Dickinson
FITC-anti- 53-6.7 Rat IgG2a Becton 1:16
CD8a Dickinson
Bio-anti- KH95 Balb/c Pharmingen 1:12
H-2Db IgG2b,K
Bio-anti- 34-2-12 C3H Pharmingen 1:50
H-2Dd IgG2a, K
ii) Polyclonal Antibodies
Specificity
Dilution
Bio-anti-mouse Ig
Nature & Source
Rabbit F(ab’)2 fragments 1:25
Dako Ltd., High Wycombe, Bucks
:
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KEY:
Bio Antibodies conjugated to biotin.
PE Antibodies conjugated to phycoerythrin.
FITC Antibodies conjugated to fluorescein isothiocyanate.
"■'I
ft
?J:
f
31
.
Reagents and Solutions
Complete RPMI
Carbonate Buffer
O.IM NaHCOs in deionised, distilled water (dd H^O)
Phosphate Buffered Saline (PBS)
80g NaCl
11 .6 g Na2HP04 
2g KH2PO4 
2gKCL
dissolved in 10 litres of dd H2O
32
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APPENDIX 1 :
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RPMI medium containing-:
ft'ft10% heat-inactivated foetal calf serum (FCS) 
lOOU/ml penicillin 
lOOpg/ml streptomycin 
1.25pg/ml fungizone 
2mM 1-glutamine 
5 X 10-^M 2-mercaptoethanol
Cell Culture Medium (for P815, EL4, YAC-1 cell lines)
RPMI medium containing-:
10% heat-inactivated foetal calf serum (FCS) 
lOOU/ml penicillin 
lOOpg/ml streptomycin
1.25pg/ml fungizone 
2mM 1-glutamine
PBS/Tween
PBS containing 0.05% (v/v) Tween-20
Facs Staining Buffer
PBS containing:
2% (v/v) FCS
0.05% (w/v) sodium azide
Borate Buffered Saline (BBS)
6 .2 g H3BO4 
19g NaB40?
9gNaCl
dissolved in 1 litre of dd H2O
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IL-12 ELISA Coating Buffer 
IMNaHCOs
IM Na2C0  ^in dd H2O and Ph adjusted to 9.6
IL-12 ELISA Assay Buffer
1% w/v BSA 
0.5M NaCl 
0.02M Na2HP04 
0.05% (v/v) Tween-20 
0 .0 1 % (w/v) thimerosal 
dissolved in dd H2O and Ph adjusted to 6.5
BBS/Tween
BBS containing 0.05% (v/v) Tween-20
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CHAPTER 3
KINETIC STUDY OF SYSTEMIC ACUTE AND CHRONIC GvHD
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Introduction
Previous studies have indicated that differential activation of CD4+ T 
helper cell subsets may underlie the distinct diseases which occur in BDFi mice 
injected with either C57B1/6 or DBA/2 parental spleen cells, by demonstrating that 
a Thl-type cytokine profile was apparent during acute GvHD while Th2-type 
cytokines were produced preferentially during chronic GvHD [42, 46, 47]. 
However, these studies examined cytokine production over a limited time course 
and did not attempt to determine when T cell polarisation occurred, or address the 
underlying mechanism.
The main aim of my project was to examine the factor(s) involved in the 
polarisation of Th cell responses in acute and chronic GvHD and, in particular, to 
assess the role played by the early non-specific immune response in determining 
the subsequent pattern of the two diseases. My initial series of experiments were 
therefore designed to determine at what point the cytokine response becomes 
skewed towards a preferential Thl or Th2 phenotype by characterising the kinetics 
of acute and chronic GvHD in BDFi mice, using in vivo and in vitro indices of 
disease progression in parallel with measurements of cytokine production. For this 
study, I therefore mainly concentrated on events occurring during the first 3 weeks 
of disease.
Experimental Protocol
The GvHR was induced by i.v. injection of 10® viable C57B1/6 or DBA/2 
parental spleen cells into BDFi recipients. The intensity of the systemic GvHR in 
vivo was monitored by assessing body weight, splenomegaly and mortality. The 
effect of GvHD on the immune system was determined by counting the total
" î
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lymphocytes in the spleen and by measuring the proportions of splenic CD4+ and 
CD8+ T lymphocytes by FACS analysis.
■'■I,Immune function was determined by measuring the proliferative capacity 
of spleen cells from GvHD mice either 'ex-vivo\ or in response to stimulation 
with T or B cell mitogens. IFN-y, IL-2, IL-10, IL-5 and IL-4 production was 
measured by culturing spleen cells from GvHD mice either in medium alone or 
with Con A. I chose to measure these particular cytokines because they are 
characteristically associated with either Thl (IFN-y and IL-2) or Th2 (IL-4, IL-5 
and IL-10) responses. Levels of total serum IgG and anti-ds DNA antibodies were 
measured on days 10, 20 and 30 of the GvHD.
Samples of kidney were taken from GvHD mice on day 48 (which was 
when chronic GvHD showed evidence of oedema and proteinuria) and examined 
for the presence of immune complex deposition by both light and electron 
microscopy.
i) Weight Loss and Mortality
Consistent with previous studies in our own and other laboratories [7, 21, 
23, 24, 27, 55, 98], BDFi mice injected with 10® B6  parental spleen cells 
developed an acute GvHD, with progressive weight loss from day 16 of the 
GvHD, which continued until the study was terminated on day 20 (Fig 3.1). 
Mortality was also apparent on day 16, with two deaths (Fig 3.1). A further three 
deaths occurred on day 18 and one on day 2 0 , by which time an overall mortality 
rate of 80 % was observed (Fig. 3.1). In contrast, BDFi mice injected with 10® 
DBA/2 parental spleen cells showed no significant weight loss and none of these 
mice died during this phase of the disease (Fig. 3.1).
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ii) Splenomegaly and Lymphoid Populations 
a) Acute GvHD
B6  => BDFi mice exhibited significant splenomegaly by day 1 of the acute 
GvHD (Fig 3.2). This increased sharply, peaked on day 10, then returned 
towards control values, until no significant splenomegaly was observed in 
surviving mice on day 18 (Fig 3.2). A similar biphasic pattern of hyperplasia 
followed by lymphoid involution was evident when the total lymphocyte number 
in the spleens of these mice was assessed. By day 2, spleen cell numbers were 
already almost double that in control mice (Fig 3.3a and 3.3c). There was then a 
steady increase until day 10, when lymphocyte numbers began to return to control 
levels and by day 18 these were markedly reduced compared with control mice 
(Fig. 3.3a and 3.3c).
Phenotypic analysis of these spleen cell populations showed that on days 2 
and 7, the proportions of CD4+ and CD8 + T cells in B6  => BDFi spleens were 
not different from those observed in control spleens (Table 3.1). Thus, there were 
dramatic increases in the absolute numbers of both populations in acute GvHD 
mice compared with controls (Fig. 3.3a and 3.3c). By day 10 and thereafter, the 
proportions of CD4+ and CD8 + splenic T cells in B6  => BDFi mice were 
strikingly different from those in control mice (Table 3.1). On days 10 and 14, 
there was a large increase in the percentage of T cells in the spleens of mice with 
acute GvHD compared with controls (60-70 % vs 25-30 %). This consisted 
mainly of CD8 + T cells, with B6  => BDFi spleens containing up to 5 times as 
many CD8 + T cells as controls. However, the percentage of CD4+ T cells in the 
spleens of mice with acute GvHD was also higher than controls at all times up to 
the end of the study on day 18 (Table 3.1).
ib) Chronic GvHD
Splenomegaly also developed in BDFi mice with chronic GvHD, initially 
following a similar initial pattern to that observed in mice with acute GvHD (Fig.
3.2). However, by day 7 and thereafter, the splenomegaly was less intense in 
chronic GvHD and it persisted at this level for the remainder of the study. In 
parallel, spleen lymphocyte numbers increased in DBA/2 => BDFi mice during the 
first 10 days in a manner similar to that observed in B6  => BDFi mice (Fig. 3.3b).
However, after day 10, lymphocyte numbers continued to increase in mice with 
chronic GvHD, in contrast to the markedly reduced lymphocyte numbers evident 
in mice with acute GvHD after this time (Fig. 3.3a and 3.3b).
FACS analysis also revealed that the dramatic differences in the 
proportions of CD4+ and CD8 + T cells in the spleens of B6  => BDFi mice were 
not apparent in DBA/2 => BDFi mice (Table 3.1). Although the proportions of 
CD4+ and CD8+ T cells remained essentially the same as those in control mice 
throughout the GvHD (Table 3.1), the absolute numbers of splenic T cells did 
increase (Fig. 3.3b).
iii) Immune Function
I next examined how the effects of the different GvHD models in vivo 
correlated with parameters of immune function. Previous work had indicated that 
the B6  => BDFi GvHD is associated with suppressed T and B cell function in 
vitro and in vivo [24, 27, 71, 73, 165], whereas DBA/2 => BDFi GvHD is 
characterised by B cell hyperreactivity [23,36-39]. I therefore assessed the ability 
of spleen cells from GvHD mice to proliferate, either spontaneously 'ex-vivo' or 
in response to mitogenic stimulation in vitro, using Con A and LPS to stimulate 
proliferation of T cells and B cells respectively. :ft
ftI
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a) Spontaneous Ex-Vivo Proliferative Responses
Spleen cells from B6  => BDFi mice showed significantly increased 
spontaneous proliferation by day 2 after induction of GvHD (Fig 3.4). This 
peaked on day 10 and had returned to control levels by day 18. In contrast, the 
spontaneous proliferation of spleen cells from DBA/2 => BDFi mice was only
:
modestly enhanced throughout the first 10 days after donor cell transfer, but 
continued to increase progressively thereafter (Fig 3.4). Thus, the changes in
,splenomegaly and spleen cell numbers in the two diseases are parallelled by 
alterations in the inherent proliferative capacity of lymphocytes.
b) Proliferative Responses to Con A Stimulation
Spleen cells from B6  => BDFi mice initially also showed significantly
.increased responsiveness to stimulation with Con A in vitro compared with control 
spleen cells (Fig 3.5). However, by day 7, these responses were significantly 
lower than those of controls and were almost negligible from day 10 onwards. In 
contrast, the Con A responses of DBA/2 => BDFi spleen cells were usually 
similar to those of control spleen cells (Fig 3.5), although a significant increase 
was observed on day 10. 1
c) Proliferative Responses to LPS Stimulation
Spleen cells from both B6  => BDFi and DBA/2 => BDFi mice initially
exhibited similarly enhanced responses to LPS compared with control cells. This 
was evident throughout the first 10 days after donor cell transfer in both models of 
GvHD (Fig. 3.6). However, the LPS response of B6  => BDFi spleen cells was 
subsequently suppressed, with complete ablation evident by day 14. This was in 
contrast to cells from DBA/2 => BDFi mice, which continued to show significant 
hyperresponsiveness to LPS throughout the chronic disease (Fig. 3.6).
Thus, both forms of GvHD are characterised by an initial period of B cell 
hyperresponsiveness, but this disappears in acute GvHD and persists in chronic
i. a
GvHD. To explore this further, I went on to examine a number of in vivo indices 
of B cell function.
iv) In Vivo Assessment of B cell Activity in Acute and Chronic 
GvHD
a) IgG Production
On day 10, significantly increased levels of total IgG were detected in the 
serum of mice with acute GvHD compared with controls (Fig, 3.7). However, by 
day 20 and thereafter, serum IgG levels were undetectable in these mice, 
consistent with their abrogated LPS responses observed at earlier time points in 
vitro (Fig3.6). In contrast, mice with chronic GvHD showed strikingly high IgG 
levels on both days 20 and 30, further supporting the persistent B cell stimulation 
throughout this disease (Fig. 3.7).
'I
b) Anti-ds DNA Antibodies
B6  => BDFi and DBA/2 => BDFi mice both displayed high levels of anti- 
ds DNA serum antibodies on day 10, with particularly high levels apparent in mice 
with acute GvHD (Fig 3.8). However, by day 20 and thereafter, no anti-ds DNA 
antibodies were detected in the serum of mice with acute GvHD, despite their 
continued presence in mice with chronic GvHD. No anti-ds DNA antibodies were 
found in control mice at any time.
I
c) Renal Immunopathology
To assess possible pathological consequences of the B cell hyperreactivity,
I examined kidney sections for the presence of ICGN in mice surviving 7 weeks 
into GvHD, since this was when mice with chronic GvHD started to show clinical 
signs of kidney damage, such as oedema and proteinuria. At no time did mice
Ifrom any other group exhibit physical evidence of kidney dysfunction and in
3 9
'I
particular, the small number of B6  => BDFi mice which survived past day 21 of
the acute GvHD remained visibly healthy.
Kidney sections from DBA/2 ^  BDFi mice showed widespread renal
4 0
damage both by LM and EM at this time. By LM, the glomerular basement 
membrane appeared thickened, there was glomerular hypercellularity and evidence 
of focal protein casts (Fig. 3.9a). By EM, endothelial swelling was evident, 
resulting in loss of filtration space and there was ablation of the normal podocyte 
architecture (Fig. 3.10a). Numerous sub-epithelial electron-dense deposits were 
observed in most glomeruli and together these features were consistent with the 
presence of severe ICGN. In parallel with the severe kidney damage evident by 
microscopy, mice at this stage of chronic GvHD began to show progressive 
oedema and started to die on day 50 (33% mortality), with 77% mortality 
occurring by day 100 (Fig 3.11). In contrast, sections of kidney from B6  => 
BDFI mice on day 48 of the acute GvHD showed no significant changes either by 
light microscopy (LM) or electron microscopy (EM) (Figs. 3.9b & 3.10b) and 
resembled kidneys from control mice (Figs. 3.9c & 3.10c).
Thus, the brief B cell hyperplasia observed in B6  ==> BDFI mice does not 
lead to autoimmune pathology, but the persistently high levels of serum IgG and
anti-ds DNA antibodies observed in mice with chronic GvHD provoke ICGN, as 
described previously [36-39].
v) Cytokine Production During Acute and Chronic GvHD
Although both forms of GvHD are clearly associated with expansion of T 
cell numbers, the results above showed that persistent B cell responses were 
apparent in chronic, but not acute GvHD. In addition, previous work has 
suggested that activation of different CD4+ T helper cell subsets may cause the
'distinct outcomes of the GvHD in BDFi recipient mice [42, 46]. I therefore 
compared the pattern of cytokines produced by lymphocytes from mice with acute
or chronic GvHD in vitrOy both spontaneously and in response to Con A 
stimulation.
IFN-y
High levels of IFN-y were produced spontaneously by B6  => BDFi 
splenocytes throughout the first 10 days of the acute GvHD (Fig. 3.12a). This 
was observed as early as day 2 , peaked on day 10 and was undetectable after day 
14. This was in direct contrast to cells from DBA/2 => BDFi mice, which 
spontaneously secreted similar low levels of IFN-y to control cells at all time 
points examined (Fig. 3.12a).
B6  => BDFi spleen cells also exhibited enhanced IFN-y production in 
response to Con A stimulation in vitro (Fig. 3.12b). Once again, elevated levels 
were apparent on day 2  and peaked on day 10, before falling below control levels 
at the later time points. In contrast to the lack of spontaneous IFN-y production by 
DBA/2 => BDFi spleen cells. Con A induced the production of similar or 
significantly higher levels of IFN-y by these cells compared with control cells at all 
times after day 2 of this study (Fig. 3.12b). Although these levels were never as 
high as those observed during the course of the acute GvHD, they remained 
elevated throughout the course of this study.
IL-2
IL-2 was not produced spontaneously by cells from any group (data not 
shown).
B6  => BDFi spleen cells produced significantly higher levels of IL-2 in 
response to Con A than control cells on day 2 (Fig. 3.13), but at all times 
thereafter, IL-2 levels were significantly lower than those produced by control 
cells and were negligible after day 10. In contrast, spleen cells from DBA/2 =>
BDFi mice produced similar levels of IL-2 in response to Con A stimulation to
I
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control cells on day 2 (Fig. 3.13) and significantly higher levels of IL-2 than 
control cells at all time points thereafter (Fig. 3.13).
IL-4
IL-5
Spontaneously produced IL-5 was not detected in any group during this 
study (data not shown).
B6  => BDFi cells produced significantly enhanced levels of IL-5 in 
réponse to Con A on both days 2 and 4 after donor cell transfer, compaied with 
control cells (Fig. 3.14). However, the levels in acute GvHD mice then fell below 
the level of detection after day 10. In contrast, DBA/2 => BDFi spleen cells 
produced strikingly high levels of IL-5 in response to Con A throughout the time 
course examined (Fig. 3.14). These levels were consistently several fold greater 
than those produced by either control cells or B6  => BDFi cells after day 4 of the 
GvHD.
■■1
No IL-4 production was detected by cells from any group at any of the 
time points examined (data not shown). It was unclear whether this reflected the 
fact that the levels of IL-4 produced were below the level of detection of this 
assay, or if IL-4 was produced transiently and then rapidly utilised by cells in 
culture.
IL-IO
As with IL-5, IL-IO was not detected in supernatants from unstimulated 
cells of any group (data not shown).
From days 2-10 of the acute GvHD, B6  => BDFi spleen cells produced 
similar levels of IL-IO to control cells (Fig 3.15), but at later time points, IL-IO 
production fell to below control levels. DBA/2 => BDFi cells secreted elevated
42
levels of IL-IO at all time points examined, with significant increases compared to 
both control cells and B6  => BDFi cells after day 4 (Fig. 3.15).
Summary and Conclusions
43
Thus, acute GvHD is associated with spontaneous production of IFN-y 
early in the disease, accompanied by very high levels of inducible IFN-y and 
transient priming of IL-2 and IL-5 production. However, the production of all
"S'cytokines subsequently ceased as lymphoid atrophy developed. In contrast,
-DBA/2 => BDFi cells produced no IFN-y spontaneously and displayed Con A 
induced IFN-y production which was similar to, or only slightly above control 
levels. Conversely, cells from these mice produced increased levels of IL-2, IL-5 
and IL-IO.
The results of this kinetic study show that the first 10 days of both acute
-i:
■i.
and chronic GvHD are characterised by an initial period of immune activation. In 
both diseases, this was manifest by splenomegaly, high levels of spontaneous 'ex~ 
vivo' proliferation and increased spleen cell numbers and both groups of mice 
showed heightened responsiveness to stimulation with B and T cell mitogens. 
However, the transfer of B6  donor cells provoked a more aggressive systemic 
GvHD than transfer of DBA/2 donor cells, since a much greater level of 
immunostimulation occurred early in acute GvHD. Furthermore, while the early 
period of immune activation in acute GvHD was rapidly replaced by involution, 
characterised by splenic atrophy, loss of T and B cell function, weight loss and 
death, mice with chronic GvHD continued to display evidence of immune 
activation throughout the study.
The pattern of early hyperplasia followed by immunosuppression in acute 
GvHD was also evidenced when I examined B cell responses in vivo. 
Accordingly, although enhanced levels of total IgG and anti-ds DNA antibodies
were found early during acute GvHD, these were both absent at the later time
4 4
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points and did not provoke renal immunopathology. This was again in contrast to 
my findings in chronic GvHD, where elevated IgG and anti-ds DNA antibodies 
were always observed and these mice developed lethal ICGN.
Phenotypic analysis of the T cell populations in the spleens of GvHD mice 
also revealed dramatic differences between the acute and chronic forms of disease. 
Thus, while DBA/2 => BDFi mice maintained normal proportions of splenic
CD4+ and CD8+ T lymphocytes, expansion of CD8 + T cells and, to a lesser
Iextent, CD4+ T cells was observed in B6  => BDFi mice from day 10 until the end 
of the study, thereby correlating with the onset of the destructive phase of acute 
GvHD.
Finally, my results confirmed that there is a dichotomy in the cytokines
■ Èproduced by cells from mice with acute and chronic GvHD. Thus, while acute 
GvHD was associated with early spontaneous production of IFN-y, cells from 
chronic GvHD mice did not secrete IFN-y spontaneously, but produced 
persistently high levels of IL-IO and IL-5 and IL-2, in response to stimulation 
with Con A.
Together, these results support the view that acute GvHD in B6  => BDFi 
mice is a biphasic disease, in which Thl cytokines and generalised, intense
-Ilymphoid hyperreactivity evolve into a destructive disease characterised by death %
I
and immunosuppression. Chronic GvHD, on the other hand, is an initially milder, t i
but ultimately more persistent disorder, which appears to involve a mainly Th2- Imediated immune response. These findings highlight both the quantitative and 
qualitative differences between the two forms of GvHD and therefore form the 
basis for the remainder of my thesis. In the following chapters, I went on to use 
the parameters characterised here to examine the different cell types involved in the 
polarisation of the alloimmune response and how their cytokine products affect its 
outcome.
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Fig. 3.1. Weight loss and mortality during acute and chronic 
GvHD. BDFi mice given 10  ^ B6  spleen cells i.v. show progressive and 
significant weight loss and death from day 16 of the acute GvHD, while BDFi 
mice given DBA/2 cells i.v. show a similar increase in weight to control mice and 
do not die during this early period. Results show the mean body weight ± 1 SD 
for 9 mice per group.
p < 0.05; ** p<  0.005 vs controls and chronic GvHD mice; f -  Death).
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Fig. 3.2. Splenomegaly during acute and chronic GvHD.
BDFi mice given 10  ^ B6  or DBA/2 spleen cells i.v. develop significant 
splenomegaly from day 2 of the GvHD. Results show the mean spleen index of 3 
GvHD mice per group ± ISD, calculated with reference to the mean spleen 
weights of 3 control mice.
(* p < 0.05 vs chronic GvHD; ** p < 0.001 vs chronic GvHD).
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Fig. 3.3. Splenic lymphocyte numbers in mice with GvHD.
The data show the mean total lymphocyte number and the mean absolute number 
of CD4+ and CD8 + lymphocytes in the spleens of BDFi mice given either 10  ^B6  
(Fig. 3.3a) or DBA/2 (Fig. 3.3b) spleen cells i.v. The number of splenic 
lymphocytes in control mice is also shown for comparison (Fig. 3.3c). The results 
are from pooled samples and are representative of the findings of 3 similar 
experiments.
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Fig. 3.4. Spontaneous 'ex-vivo' proliferation by lymphocytes from 
mice with acute and chronic GvHD.
The results show the spontaneous proliferative capacity of splenocytes from BDFi 
mice given either 10  ^B6  or DBA/2 spleen cells i.v. The results are expressed as 
the mean uptake of 3H-TdR ± 1 SD after 4 hours in quadruplicate cultures, using 
spleen cells pooled from 3 mice per group. (* p < 0.05; ** p < 0.01 (acute GvHD 
vs controls); t  p < 0.05 (chronic GvHD vs controls)).
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Fig, 3.5. Con A induced proliferation by lymphocytes from mice 
with acute and chronic GvHD.
The results show the proliferative capacity of splenocytes from BDFi mice given 
10  ^B6  or DBA/2 spleen cells i.v. in response to mitogenic stimulation with Con 
A, Data are expressed as the mean uptake of 3H-TdR ± 1 SD after 48 hours in 
quadruplicate cultures, in the presence of lOpg/ml Con A using spleen cells 
pooled from 3-4 mice per group. (* p < 0.05 ** p < 0.01 (acute GvHD vs 
controls); |  P < 0.05 (chronic GvHD vs controls).
I
:
afI
i
4 9
I4
4t
4
I
.4.î|:'
-g
■i
3H TdR Incorporation 
(cpm/well)
15000 -I
Acute GvHD 
Chronic GvHD 
C on tro l
10000  -
5000 -
200 4 8 12 16
DAY OF GVHD
Fig. 3.6. LPS induced proliferation by lymphocytes from mice with 
acute and chronic GvHD.
The results show the proliferative capacity of splenocytes from BDFI mice given 
108 B6  or DBA/2 spleen cells i.v. in response to mitogenic stimulation with LPS. 
Data are expressed as the mean uptake of 3H-TdR ± 1 SD after 24 hours in 
quadruplicate cultures in the presence of lOpg/ml LPS, using spleen cells pooled 
from 3-4 mice per group. (* p < 0.001 (acute GvHD vs controls); f p < 0.001 
(chronic GvHD vs controls).
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Fig. 3.7. Total serum IgG levels in GvHD mice.
Results show the mean total IgG levels ± ISD in the serum of BDFi mice given 
1Q8 B6  or DBA/2 spleen cells i.v., as determined by RID. The IgG levels of 5-6 
mice per group were assessed at each time point. (* p<  0.001  vs controls).
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Fig. 3.8. Anti-ds DNA antibodies in the serum of GvHD mice.
The results show the mean level of anti-ds DNA specific IgG antibodies present in 
the serum of BDFi mice given 10  ^B6  or DBA/2 spleen cells i.v., as determined 
by ELISA. The anti-ds DNA antibody levels of 6  mice per group were assessed at 
each time point and expressed as the mean OD value for positive sera at 1:50 ± 
ISD for each group at 630nm. (* p < 0.05 vs chronic GvHD).
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Fig. 3.9. Assessment of renal immunopathology in GvHD mice by 
light microscopy.
Histopathological analysis of kidneys from BDFi mice given 10* B6 or DBA/2 
spleen cells on day 48 of GvHD.
9a. Representative chronic GvHD kidney section. The glomerular basement 
membrane was significantly thickened and glomeruli appeared hypercellular 
(arrowed). Numerous protein casts were observed in the kidney tubules of these 
mice (t) (H&E x 40).
9b. Representative acute GvHD kidney section showing normal glomerular 
morphology (arrowed), with no thickening of the glomerular basement membrane. 
The tubules did not contain protein casts (H&E x40).
9c. Representative control kidney section (H&E x 40).
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Fig. 3.10. Assessment of renal immunopathology in GvHD mice by 
electron microscopy.
Histopathological analysis of kidneys from BDFi mice given 10* B6 or DBA/2 
spleen cells on day 48 of GvHD.
10a. Representative chronic GvHD kidney section. Numerous sub-epithelial 
electron-dense deposits were observed in most glomeruli (arrowed), indicating the 
presence of immune complexes. Endothelial swelling was evident and the normal 
podocyte architecture was destroyed (x 14850)
10b. Representative acute GvHD kidney section showing normal glomerular 
morphology. No electron-dense immune complex deposits were observed and the 
endothelium (arrowed) and podocyte architecture (p) appeared normal (x 11700) 
10c. Representative control kidney section (x 14875)
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Fig. 3.11. Mice with chronic GvHD die late in disease.
BDFi mice given 10* DBA/2 spleen cells develop progressive oedema and start to 
die on day 50 from ICGN. The results show the percentage survival in a group of 
9 chronic GvHD mice and are representative of the findings of 3 similar 
experiments.
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Fig 3.12, IFN-y production during acute and chronic GvHD.
Splenocytes from BDFi mice given 10  ^B6 or DBA/2 spleen cells were cultured in 
medium (Fig. 3.12a) or in the presence of lO^g/ml Con A (Fig. 3.12b) for 48 
hours, before the supernatants were removed and assayed for the presence of 
IFN-y by ELISA. Results shown are means ± 1 SD of triplicate samples. (* p < 
0.05 ** p < 0.001 (acute GvHD vs controls); f p < 0.01 (chronic GvHD vs 
controls)).
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Fig. 3.13. IL-2 production during acute and chronic GvHD.
Splenocytes from BDFi mice given 10® B6 or DBA/2 spleen cells were cultured in 
the presence of lOpg/ml Con A for 24 hours, before the supernatants were 
removed and assayed for the presence of IL-2 by ELISA. Results shown are 
means ± 1 SD of triplicate samples. p < 0.05; ** p < 0.001 (acute GvHD vs 
controls); f p < 0.001 (chronic GvHD vs controls)).
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Fig. 3.14. IL-5 production during acute and chronic GvHD.
Splenocytes from BDFi mice given 10  ^B6 or DBA/2 spleen cells were cultured in 
the presence of 10p,g/ml Con A for 96 hours, before the supernatants were 
removed and assayed for the presence of IL-5 by ELISA. Results shown are 
means ± 1 SD of triplicate samples. (* p < 0.005; ** p < 0.001 (acute GvHD vs 
chronic GvHD and controls); t  P < 0.05; t t  P < 0.001 (chronic GvHD vs acute 
GvHD and controls)).
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Fig. 3.15. IL-IO production during acute and chronic GvHD.
Splenocytes from BDFj mice given 10* B6 or DBA/2 spleen cells were cultured in 
the presence of lOpg/ml Con A for 48 hours, before the supernatants were 
removed and assayed for the presence of IL-5 by ELISA. Results shown are 
means ± 1 SD of triplicate samples. (* p < 0.05 ** p < 0.01 (acute GvHD vs 
chronic GvHD and controls); t  p < 0.001 (chronic GvHD vs acute GvHD and 
controls)).
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Table 3.1
Splenic T lymphocyte Populations in Mice with 
Acute and Chronic GvHD
Day of GvHD B6 => BDFi DBA/2 => BDFi Control
(Acute GvHD) (Chronic GvHD)
2 12.4 12.7 12.4
9.7 9.6 10.5
7 14.1 12.3 17.6
11.8 7.3 11.4
10 21.8 14.7 17.9
39.1 11.9 10.5
14 26.6 13.6 15.7
45.8 7.9 8.8
18 23.2 13.9 14.2
50.0 7.5 7.2
Table 3.1 Percentages of splenic CD4+ and CD8+ T lymphocytes in 
GvHD mice.
The results show the proportions of splenic CD4+ and CD8  ^T cells in BDFi mice 
given 10  ^B6 or DBA/2 spleen cells i.v., assessed by flow cytometrical analysis 
and expressed as a percentage of the total gated splenic lymphocyte population. 
The upper number indicates the percentage of CD4+ lymphocytes and the lower 
number indicates the percentage of CD8+ cells.
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CHAPTERS 4-7 
ROLE OF ENDOGENOUS IL-12 IN GvHD 
General Introduction
The study of cytokine production during acute and chronic GvHD in BDFi 
mice detailed in Chapter 3 showed a clear dichotomy in the cytokine responses of 
mice with the different forms of disease. Thus, the Thl cytokine IFN-y was 
produced spontaneously by cells from mice with acute GvHD, while high levels 
of IL-5 and IL-IO could only be induced by mitogenic stimulation of cells from 
mice with chronic GvHD. In agreement with previous studies [42, 46], these 
findings suggest that differential activation of CD4+ T helper subsets may underlie 
the distinct diseases and also indicated that this polarisation of the specific 
response occurred early after transfer of the different donor cells.
In other models of T cell mediated immunity, the differentiation of Thl and 
Th2 cells from naive CD4+ T cells appears to be influenced by the early 
production of cytokines by cells of the innate immune system [115, 116]. Thus 
the presence of IL-4 during the initial period of immune stimulation promotes the 
development of a Th2 type response [133-135, 141], while IL-12 and IFN-y, 
produced by macrophages and NK cells respectively, initiate Thl cell 
differentiation [76-78, 159, 161]. Studies reported as I was performing my work 
showed that the autoimmune consequences of chronic GvHD in BDFi mice can be 
prevented by administration of rm IL-12 [166], suggesting that this non-specific 
cytokine may have an important influence on the nature of GvHD which develops 
in these animals. I therefore decided to examine the role of IL-12 in determining 
the outcome of the GvHD in BDFi mice, by investigating the effect of 
administering or neutralising IL-12 on the in vivo and in vitro parameters of acute 
and chronic GvHD characterised in Chapter 3. In addition, since IL-12 is an 
important growth factor for NK cells and specific CTL [118, 120, 121, 150] and
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disease during the early proliferative phase and at the onset of the destructive late 
phase.
i s
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both cell types are thought to be involved in the pathogenesis of acute, but not 
chronic GvHD [30, 31, 49, 96], I also assessed the role of IL-12 in regulating 
specific and non-specific cytotoxic responses during GvHD.
The role of IL-12 in acute and chronic GvHD is described in the next four 
chapters. In the current chapter, I will show the effect of a single dose of "'ÎÎneutralising anti-IL-12 antibody on the early phase of both forms of GvHD, while 
in Chapter 5 ,1 conducted a more detailed study on the effect of repeated anti-IL-12 
administration on the acute form of disease only. Chapter 6 then examines the 
long-term effects of neutralising IL-12 during acute or chronic GvHD and finally.
Chapter 7 focuses on the effect of exogenous rm IL-12 on acute and chronic 
GvHD.
1) Effect of a Single Dose of Anti-IL-12 Antibody on Acute and 
Chronic GvHD
My initial experiments examined the effect of a single injection of 
neutralising anti-IL-12 antibody given 1 day prior to induction of acute or chronic 
GvHD. I chose to administer the antibody at this time because it is well established 
that the cytokine environment in which T cell priming occurs, strongly influences 
the nature of the subsequent specific immune response [76, 78, 132-135, 159].
Furthermore, the results of Chapter 3 indicated that polarisation of the GvHD 
occurred very rapidly after the transfer of parental spleen cells, suggesting that a 
single neutralisation of IL-12 early in the disease might be sufficient to alter the
subsequent course of disease. For this series of experiments, I concentrated on 
days 2 and 10 of GvHD, since these time points give a good indication of the
I
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Experimental Protocol
The GvHR was induced by i.v. injection of 10* viable B6 or DBA/2 
parental spleen cells into BDFi recipients as before. Endogenous IL-12 was 
neutralised in vivo by i.p. injection of 0.5mg goat IgG anti-mouse IL-12 antibody 
given 1 day before induction of GvHR. Control animals received 0.5 mg of 
normal goat IgG. The intensity of the systemic GvHD was assessed by measuring 
splenomegaly. Lymphocyte proliferation and cytokine production were determined 
as descibed in Chapter 3. Levels of splenic NK cell-mediated cytotoxicity were 
measured in GvHD mice on day 2 using YAC-1 cells as targets. I
■IResults
i) Splenomegaly
As before, B6 => BDFi mice exhibited significant splenomegaly on day 2 
of the acute GvHD (Fig. 4.1a) which continued to increase up to day 10 (Fig.
4.1b). Anti-IL-12 treatment reduced the early splenomegaly on day 2 of the acute 
disease (Fig. 4.1a), but by day 10, the splenomegaly in anti-IL-12 treated B6 
BDFi mice was similar to that in unmanipulated B6 => BDFi animals (Fig. 4. lb).
DBA/2 => BDFi mice also displayed significant splenomegaly on both day 
2 and day 10 of the chronic disease (Figs. 4.1a & b), but as I found earlier, the 
splenomegaly in these mice was less marked than in B6 => BDFi mice at both 
time points. Anti-IL-12 treatment did not affect the splenomegaly evident in 
chronic GvHD mice on either day 2 or day 10 (Figs. 4. la  & b).
?
ii) NK cell activity
A characteristic early feature of several models of GvHD is enhanced NK 
cell-mediated cytotoxicity [7, 49, 95-98]. Since IL-12 was originally described as
-
a growth factor for NK cells [118, 120, 121, 150], I decided to examine whether 
neutralising IL-12 in vivo affected NK cell activity early during the GvHD in
BDFi mice. B6 => BDFi mice showed enhanced splenic NK cell activity on day 2
of the acute GvHD compared with control mice (Fig. 4.2). This was reduced to
below control levels by a single dose of anti-IL-12 antibody (Fig. 4.2).
In contrast, mice with chronic GvHD showed similar levels of NK cell
mediated cytotoxicity to control mice and anti-IL-12 treatment did not affect these
levels in either DBA/2 => BDFI or control mice (Fig. 4.2).
It should be noted that in this chapter, I only examined the effect of anti-
IL-12 on NK cell levels on day 2, since previous work had suggested that NK
cell-mediated cytotoxicity was primarily a very early feature of the disease [49].
When I subsequently examined a more detailed time course study of NK cell
activity during both diseases, I found that after day 4, mice with chronic GvHD
also showed enhanced NK cell activity (detailed in Chapter 9).
I
iii) Immune function
I next went on to examine the effect of anti-IL-12 on immune function in ■■
both acute and chronic GvHD, by assessing its effect on the ability of cells from 
B6 => BDFI and DBA/2 => BDFi mice to proliferate spontaneously, or in 
réponse to stimulation with either Con A or LPS in vitro.
a) Spontaneous 'ex-vivo* proliferation
As before, on both days 2 and 10, splenocytes from B6 => BDFi mice 
showed enhanced spontaneous 'ex-vivo' proliferation compared with control 
splenocytes (Figs. 4.3a & b). Anti-IL-12 treatment caused a significant reduction 
in these levels on both days 2 and 10 (Figs. 4.3a & b), although on day 10, the 
spontaneous proliferative capacity of splenocytes from anti-IL-12 treated B6 => 
BDFi mice remained higher than that of control cells.
In contrast, splenocytes from DBA/2 => BDFi mice showed a similar 
ability to proliferate 'ex-vivo' to cells from control mice on day 2 of chronic 
GvHD (Fig. 4.3a), but by day 10 their proliferation was significantly higher than
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control levels (Fig. 4.3b). Anti-IL-12 treatment did not affect the levels of 
spontaneous 'ex-vivo' proliferation of chronic GvHD spleen cells on day 2 (Fig. 
4.3a), but on day 10, spleen cells from anti-IL-12 treated DBA/2 => BDFi mice 
had significantly increased spontaneous'ex-v/vo' proliferation (Fig. 4.3b).
Anti-IL-12 antibody did not affect the ability of control cells to proliferate 
'ex-vivo' on either day 2 or day 10 (Figs. 4.3a & b).
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b) Proliferative Responses to Con A Stimulation
As demonstrated in Chapter 3, on day 2 of GvHD, spleen cells from B6 
=> BDFi mice showed significantly increased responsiveness to stimulation with 
Con A in vitro compared with control spleen cells (Fig. 4.4a). By day 10, the 
Con A induced reponses of B6 => BDFi mice were essentially the same as those 
of control mice (Fig. 4.4b). Anti-IL-12 treament of B6 => BDFi mice significantly 
reduced their heightened responsiveness to Con A on day 2 of acute GvHD (Fig.
4.4a), but this effect had disappeared by day 10, when the responses of ■■
unmanipulated and anti-IL-12 treated B6 => BDFi mice were similar (Fig. 4.4b).
DBA/2 => BDFi spleen cells showed very similar Con A induced 
responses to control spleen cells on day 2 (Fig. 4.4a), but by day 10, these were 
significantly increased above control levels (Fig. 4.4b). Anti-IL-12 treatment did 
not significantly affect the Con A responses of chronic GvHD mice on either day 2 
(Fig. 4.4a) or day 10 (Fig. 4,4b) and similarity did not affect the Con A responses 
of control mice at either time point (Figs. 4.4a & 4.4b).
c) Proliferative Responses to LPS Stimulation
On day 2, spleen cells from B6 => BDFi mice showed significantly 
increased responsiveness to stimulation with LPS in vitro compared with control 
spleen cells (Fig. 4.5a). By day 10, the responses of these mice to LPS 
stimulation were significantly lower than those of control mice (Fig. 4.5b). Anti- 
IL-12 treatment caused a significant reduction in the enhanced LPS responses of
'N  ' A
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acute GvHD mice on day 2 (Fig. 4.5a), but by day 10, the responses of anti-IL-12 
treated B6 => BDFi mice were identical to those of unmodified B6 => BDFi mice 
(Fig. 4.5b).
In contrast, DBA/2 => BDFi spleen cells showed similar LPS responses to 
control cells on day 2 (Fig. 4.5a), but significantly increased responses by day 10 
(Fig. 4.5b) and these were unaffected by anti-IL-12 treatment. Similarly, anti-IL- 
12 did not affect the LPS responses of control mice at either time point (Figs. 4.5a 
&b).
iv) Cytokine Production
Given the critical role of IL-12 in T helper cell phenotype development 
[76-78, 161], I then examined the effect of anti-IL-12 treatment on the cytokines 
produced by cells from mice with either acute or chronic GvHD.
IFN-y
In this study, IFN-y was not produced spontaneously by cells from any
■group (data not shown).
On both days 2 and 10, spleen cells from B6 => BDFi mice produced 
significantly more IFN-y in response to Con A stimulation than control cells (Figs.
4.6a & b). This increase was abolished on day 2 by treatment with anti-IL-12 
antibody (Fig. 4.6a), but by day 10, similarly high levels of IFN-y were produced 
by cells from both anti-IL-12 treated and unmanipulated B6 => BDFi mice (Fig.
4.6b).
.Spleen cells from DBA/2 => BDFi mice produced significantly lower 
levels of IFN-y in response to Con A stimulation than control spleen cells on both 
days 2 and 10 (Figs. 4.6a & b). Anti-IL-12 treatment did not affect these levels at 
either time point (Figs. 4.6a & b). Anti-IL-12 treatment of control mice did not 
affect the ability of spleen cells from these mice to produce IFN-y on day 2 or 10 
(Fig. 4.6a & b).
1IL-2
I-IL-2 was not produced spontaneously by cells from any group at any time 
during this study (data not shown).
On day 2, spleen cells from B6 => BDFi mice produced similar levels of 
IL-2 in response to Con A to control cells (Fig. 4,7a). By day 10, however, IL-2 
production by cells from B6 => BDFi mice was dramatically reduced and levels 
were severalfold lower than those produced by control cells (Fig. 4.7b). Anti-ILr 
12 treatment caused a significant reduction in the levels of IL-2 produced by 
spleen cells from B6 => BDFi mice on day 2 (Fig. 4.7a) and completely ablated 
IL-2 production in acute GvHD mice by day 10 (Fig. 4.7b).
IL-2 production by DBA/2 => BDFi spleen cells was significantly lower 
than that of control spleen cells on both days 2 and 10 (Figs. 4.7a & b). This was 
in contrast to the enhanced levels of IL-2 which these cells produced in the study 
described in Chapter 3 and may reflect altered consumption of IL-2 in vitro. Anti- 
IL-12 did not affect these levels (Figs. 4.7a & b). Similarly, anti-IL-12 treatment 
of control mice did not affect the ability of spleen cells from these mice to produce 
IL-2 on either day 2 or day 10 of this study (Figs. 4.7a & b).
IL-10
IL-10 was not produced spontaneously by cells from any group at any 
time during this study (data not shown).
On both days 2 and 10, spleen cells from B6 => BDFi mice produced 
significantly lower levels of IL-10 in response to Con A stimulation than control 
cells (Figs. 4.8a & b). Anti-IL-12 treatment restored IL-10 production to control 
levels on day 2 (Fig. 4,8a), but by day 10, spleen cells from anti-IL-12 treated and 
untreated B6 => BDFi mice produced similarly low levels of IL-10 (Fig. 4.8b).
i
Spleen cells from DBA/2 => BDFi mice produced significantly higher 
levels of IL-10 in response to Con A stimulation compared with controls on days 
2 and 10 and this was unaffected by anti-IL-12 treatment (Figs, 4,8a & b). Spleen
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cells from control mice given anti-IL-12 produced similar levels of IL-10 to 
unmodified controls on days 2 and 10 (Fig. 4.8a & b).
IL-5
IL-5 was not produced spontaneously by cells from any group at any time 
during this study (data not shown). Con A induced IL-5 production was not 
detected in cultures of cells from any group on day 2 (data not shown) and spleen 
cells from anti-IL-12 treated and unmanipulated B6 => BDFi mice did not produce 
detectable Con A induced IL-5 on day 10 (Fig. 4.9),
In contrast, on day 10, spleen cells from DBA/2 => BDFi mice produced 
significantly higher levels of Con A stimulated IL-5 than control cells (Fig. 4.9). 
Again, the levels of IL-5 produced by both control spleen cells or cells from 
DBA/2 => BDFi mice were not significantly affected by anti-IL-12 treatment.
IL-4
IL-4 production by cells from all groups was below the level of detection 
at all time points during this study (data not shown).
Summary
This study showed that a single dose of anti-IL-12 antibody abrogated 
many of the early proliferative features of acute GvHD, including splenomegaly,
!■enhanced spontaneous and mitogen induced proliferation, elevated NK cell activity 
and increased IFN-y and IL-2 production. In parallel, anti-IL-12 increased the 
levels of IL-10. Despite these effects on the early phase of the acute disease, a 
single injection of anti-IL-12 was unable to prevent acute GvHD completely and 
by day 10, anti-IL-12 treated B6 => BDFi mice showed the same degree of 
splenomegaly and reduced responses to Con A and LPS stimulation as 
unmanipulated B6 => BDFi mice. They also exhibited the characteristic Th 1-type
cytokine pattern associated with the acute disease. This dose of anti-IL-12 was 
therefore sufficient to delay, but not to abrogate onset of acute GvHD.
In contrast anti-IL-12 treatment had no effect on the chronic form of 
GvHD. Anti-IL-12 treated DBA/2 => BDFi mice had identical splenomegaly, NK 
cell activity, and levels of mitogen induced proliferation to unmanipulated DBA/2 
=> BDFi mice on both days 2 and 10, although on day 10, the anti-IL-12 treated 
group had markedly higher levels of spontaneous 'ex-vivo' proliferation than 
unmanipulated DBA/2 => BDFi mice, perhaps indicating a subtle regulatory role 
for IL-12 at this stage in the chronic GvHD. The cytokine profile of mice with 
chronic GvHD was also unaffected by anti-IL-12 treatment and cells from both 
unmanipulated and anti-IL-12 treated DBA/2 => BDFi mice produced significantly 
lower levels of IFN-y and increased levels of IL-10 and IL-5 as cells from control 
mice.
Conclusions
These results suggest that endogenous IL-12 may be involved in the 
development of acute, but not chronic GvHD. However, the effects of anti-IL-12 
were transient. I therefore decided to extend these initial studies by neutralising 
endogenous IL-12 in B6 => BDFi mice for a longer period to determine whether 
this would have a more dramatic effect on the development of acute GvHD.
«
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Fig. 4.1. Effects of anti-IL-12 treatment on splenomegaly during 
acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 antibody on 
splenomegaly in BDFi mice given 10  ^B6 or DBA/2 spleen cells i.v. Results 
shown are the mean spleen indices of 3 GvHD mice per group ± ISD relative to 
the mean spleen weights of 3 control mice on days 2 (Fig. 4.1a) and 10 (Fig. 
4.1b) of GvHD. (* p < 0.001 vs controls). Ab = Anti-IL-12 treated.
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Fig. 4.2. Effects of anti-IL-12 treatment on NK cell activity during 
acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 antibody on splenic NK 
cell activity in BDFi mice given 10  ^B6 (Fig. 4.2a) or DBA/2 (Fig. 4.2b) spleen 
cells i.v. The results shown are the % cytotoxicity against YAC-1 target cells from 
quadruplicate assays measured at effector : target (E:T) ratios from 100:1 to 
12.5; 1, using spleen cells pooled from 3 mice per group on day 2 of GvHD. Ab = 
Anti-IL-12 treated.
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Fig. 4.3. Effects of anti-IL-12 treatment on spontaneous 'ex-vivo' 
proliferation during acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 antibody on the 
spontaneous proliferative capacity of splenocytes from BDFi mice given 10  ^B6 
or DBA/2 spleen cells i.v. The results are expressed as the mean uptake of 3H- 
TdR ± 1 SD after 4 hours in quadruplicate cultures, using spleen cells pooled from 
3 mice per group on days 2 (Fig. 4.3a) and 10 (Fig. 4.3b) of the GvHD. (* p < 
0.001 vs controls; t  P < 0.01 vs unmodified acute GvHD; § p < 0.001 vs 
unmodified chronic GvHD). Ab = Anti-IL-12 treated.
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Fig, 4.4. Effects of anti-IL-12 treatment on Con A i n d u c e d  
proliferation during acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 antibody on the 
proliferative capacity of splenocytes from BDFi mice given 10® B6 or DBA/2 
spleen cells i.v. in response to mitogenic stimulation with 10p,g/ml Con A. The 
data are expressed as the mean uptake of 3H-TdR ± 1 SD after 48 hours in 
quadruplicate cultures, using spleen cells pooled from 3-4 mice per group on days 
2 (Fig. 4.4a) and 10 (Fig. 4.4b) of the GvHD. (* p < 0.01 vs controls; t  p < 0.01 
vs unmodified acute GvHD). Ab = Anti-IL-12 treated
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Fig. 4.5. Effects of anti-IL-12 treatment on LPS induced 
proliferation during acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 antibody on the 
proliferative capacity of splenocytes from BDFi mice given 10® B6 or DBA/2 
spleen cells i.v. in response to mitogenic stimulation with lOpg/ml LPS. Data are 
expressed as the mean uptake of 3H-TdR ± 1 SD after 24 hours in quadruplicate 
cultures, using spleen cells pooled from 3-4 mice per group on days 2 (Fig. 4.5a) 
and 10 (Fig. 4.5b) of the GvHD. (* p <  0.05 **p<  0.001 vs controls; f p < 0.01 
vs unmodified acute GvHD). Ab = Anti-IL-12 treated.
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Fig. 4.6. Effects of anti-IL-12 treatment on IFN-y product ion  
during acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 on IFN-y production by 
splenocytes from BDFi mice given B6 or DBA/2 spleen cells i.v. Splenocytes 
from B6 => BDFi and DBA/2 => BDFi mice were cultured with lOpg/ml Con A 
for 48 hours and the supernatants assayed for the presence of IFN-y by ELISA. 
The results shown are the means ± SD of triplicate samples on days 2 (Fig. 4.6a) 
and 10 (Fig. 4.6b) of the GvHD. (* p < 0.001 vs controls; t  P < 0.001 vs 
unmodified acute GvFQD).
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Fig. 4.7. Effects of anti-IL-12 treatment on IL-2 production during 
acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 on IL-2 production by 
splenocytes from BDFi mice given B6 or DBA/2 spleen cells i.v. Splenocytes 
from B6 => BDFi and DBA/2 => BDFi mice were cultured with lOpg/ml Con A 
for 24 hours and the supernatants assayed for the presence of IL-2 by ELISA. The 
results shown are the means ± SD of triplicate samples on days 2 (Fig. 4.7a) and 
10 (Fig. 4.7b) of the GvHD. (* p < 0.001 vs controls; f p < 0.001 vs unmodified 
acute GvHD). Ab = Anti-IL-12 treated.
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Fig. 4.8. Effects of anti-IL-12 treatment on IL-10 production during 
acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 on IL-10 production by 
splenocytes from BDFi mice given B6 or DBA/2 spleen cells i.v. Splenocytes 
from B6 => BDFi and DBA/2 => BDFi mice were cultured with lOpg/ml Con A 
for 48 hours and the supernatants assayed for the presence of IL-10 by ELISA. 
The results shown are the means ± SD of triplicate samples on days 2 (Fig. 4.8a) 
and 10 (Fig. 4.8b) of the GvHD. (* p < 0.01 vs controls; f p < 0.001 vs 
unmodified acute GvHD). Ab = Anti-IL-12 treated.
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Fig. 4.9. Effects of anti-IL-12 treatment on IL-5 production during 
acute and chronic GvHD.
The results show the effect of a single dose of anti-IL-12 on IL-5 production by 
splenocytes from BDFi mice given B6 or DBA/2 spleen cells i.v. Splenocytes 
from B6 => BDFi and DBA/2 => BDFi mice were cultured with lOpg/ml Con A 
for 96 hours, and the supernatants assayed for the presence of IL-5 by ELISA. 
The results shown are the means ± SD of triplicate samples on day day 10 of the 
GvHD. (* p < 0.05 vs unmodified controls).
Ab = Anti-IL-12 treated.
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CHAPTER 5
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ROLE OF ENDOGENOUS IL-12 IN GvHD
I '
Effects of Repeated Anti-IL-12 Administration on Acute GvHD 
Introduction
In Chapter 4 ,1 demonstrated that early production of IL-12 is important 
for the development of acute, but not chronic GvHD. My results also showed that 
while neutralising IL-12 during the afferent phase of acute GvHD abrogated many 
of the early features of the disease, it was unable to prevent its onset. In this 
chapter, I wanted to examine whether neutralising IL-12 in B6 => BDFi mice for a 
longer period could inhibit development of acute GvHD. In addition to assessing 
the effects of repeated antibody treatment on the disease on days 2 and 10 as 
before, I also examined a later time point in the disease to determine whether 
repeated doses of anti-IL-12 antibody affected parameters associated with the more 
established disease, such as immunosuppression, weight loss and mortality.
Because the supplies of neutralising anti-IL-12 antibody were limiting and 
because anti-IL-12 treatment had little effect on the chronic form of GvHD, I 
restricted this more detailed study to the acute form of the GvHD. The long-term 
effects of neutralising endogenous IL-12 on the autoimmune consequences of 
chronic GvHD are detailed in Chapter 6.
:ir
Experimental protocol
The protocol used in this chapter was similar to that in Chapter 4, except 
that neutralising anti-IL-12 antibody was given on days - 1 , 2 , 5  and 8. In 
addition, the effect of the antibody on acute GvHD was examined up to day 20 
and CTL activity was measured in the spleens of GvHD mice on day 10 using 
P815(H-2d) target cells.
I
Results
i) Weight loss and mortality
As expected, BDFi mice injected with B6 parental cells developed an acute
■GvHD with progressive weight loss beginning on day 12 and continuing until the 
end of this study on day 20 (Fig. 5.1). Additionally, two of these mice died on 
day 17 and a further two on day 19. In contrast, B6 => BDFi mice given repeated 
doses of anti-IL-12 antibody during the first 8 days of acute GvHD showed no 
significant weight loss or mortality (Fig. 5.1).
day 20, the spleen weights of these mice were several fold greater than those of 
unmodified acute GvHD mice (Fig. 5.2).
Hi) Immune function
8 0
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ii) Splenomegaly
In parallel, unmanipulated B6 => BDFi mice with acute GvHD developed 
significant splenomegaly by day 2, which peaked on day 10 before returning 
towards control values (Fig. 5.2). Treatment with anti-IL-12 antibody 
significantly reduced the degree of splenomegaly on day 2, but, as in Chapter 4, 
on day 10 these mice had similar splenomegaly to that observed in unmodified 
mice with acute GvHD (Fig. 5.2). However, while the spleen weights of 
unmodified B6 => BDFi mice returned towards control levels by day 20, the 
splenomegaly in anti-IL-12 treated B6 => BDFi animals was prolonged and on
a) Spontaneous 'ex-vivo' proliferation
Spleen cells from unmanipulated B6 => BDFi mice showed enhanced 
levels of spontaneous 'ex~vivo' proliferation compared with control cells. This 
was apparent by day 2, peaked at day 10, but was markedly reduced by day 20 
(Fig. 5.3). Treatment with anti-IL-12 antibody did not alter the enhanced
?I
I
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spontaneous proliferation seen on days 2 and 10, but on day 20, the proliferative 
capacity of spleen cells from anti-IL-12 treated B6 =#> BDFi mice remained 
significantly higher than both untreated acute GvHD and control levels (Fig. 5.3). 
In Chapter 4 ,1 observed that cells from B6 => BDFi mice given a single injection 
of anti-IL-12 showed significantly reduced spontaneous proliferation on both days 
2 and 10 compared with cells from unmodified B6 BDFi mice. The reason
why antibody treatment did not similarly affect proliferation in this study was 
unclear, although different batches of anti-IL-12 antibody were used in the two f
studies.
Anti-IL-12 did not significantly affect the spontaneous proliferative 
capacity of control cells at any time (Fig. 5.3).
li:
b) Proliferative responses to Con A stimulation
In this experiment, I used Con A responsiveness as a measure of the 
immunosuppression which occurs in the established phase of the acute disease. As ■
anticipated, on day 20, splenocytes from B6 => BDFi mice showed significantly 
reduced responses to Con A stimulation compared with cells from control mice 
(Fig. 5.4). This defect was prevented by treatment with anti-IL-12, as spleen cells 
from anti-IL-12 treated B6 => BDFi mice had Con A responses identical to those 
in anti-IL-12 treated controls (Fig. 5.4).
■
Anti-IL-12 caused a significant reduction in the responses of control cells 
to Con A stimulation (Fig. 5.4).
c) Proliferative responses to LPS stimulation
LPS induced proliferation was also assessed on day 20, in order to 
determine whether anti-IL-12 altered the B cell suppression observed late during 
acute GvHD. As expected, splenocytes from unmodified B6 => BDFi mice 
showed significantly reduced proliferative responses to LPS stimulation compared 
with cells from control mice (Fig. 5.5). The LPS responses of spleen cells from
anti-IL-12 treated B6 ==> BDFi mice were significantly higher than those of
iv) Cytokine Production
I then went on to compare the cytokine profiles of cells from 
immanipulated and anti-IL-12 treated B6 => BDFi mice.
IFN-y
spontaneous IFN-y production (Fig. 5.6).
unmodified B6 BDFi mice (Fig. 5.5). However, they were still significantly 
reduced compared with the responses of control cells (Fig. 5.5). Splenocytes from
control mice given anti-IL-12 antibody exhibited proliferative responses to LPS 
similar to those of spleen cells from unmodified control mice (Fig. 5.5).
Spontaneous
On days 2 and 20, IFN-y was not produced spontaneously by cells from 
any group (data not shown). On day 10, however, spleen cells from
unmanipulated B6 => BDFi mice produced high levels of IFN-y spontaneously 
(Fig. 5.6). Treatment with anti-IL-12 caused a significant reduction in this
Con A
As before, on both days 2 and 10, cells from unmodified B6 => BDFi 
mice produced significantly enhanced amounts of IFN-y in response to Con A 
compared with control cells (Fig. 5.7a and b). By day 20, however, cells from
these mice produced similar levels of IFN-y to control cells (Fig. 5.7c). Repeated 
treatment with anti-IL-12 significantly reduced the levels of IFN-y produced by 
cells from B6 => BDFi mice on both days 2 and 10 (Fig. 5.7a and b). This was in 
contrast to the effect of a single dose of anti-IL-12, which reduced IFN-y levels on 
day 2, but not day 10 (see Chapter 4). Furthermore, on day 20, cells from anti-IL-
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12 treated B6 => BDFi mice showed similar Con A stimulated IFN-y production 
to cells from unmodified B6 => BDFi and control mice (Fig. 5.7c).
Anti-IL-12 had no effect on Con A stimulated IFN-y production by control 
spleen cells at any time during this study (Figs. 5.7a-c).
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IL-2
IL-2 was not produced spontaneously by cells from any group at any time 
during this study (data not shown).
On day 2, spleen cells from B6 => BDFi mice produced levels of IL-2 in 
response to Con A which were similar to those produced by control cells (Fig. 
5.8a), However by day 10, IL-2 production by cells from GvHD mice was 
dramatically reduced, with levels severalfold lower than those produced by control 
cells (Fig. 5.8b) and on day 20, there was no IL-2 production at all (Fig. 5.8c).
$
This paralleled the loss of Con A proliferative responses by these cells (Fig. 5.4).
In contrast, cells from anti-IL-12 treated B6 => BDFi mice produced significantly 
lower levels of IL-2 than cells from unmodified B6 => BDFi mice on day 2 (Fig.
5.8a) and by day 10, similarly reduced IL-2 production by cells from unmodified 
and anti-IL-12 treated B6 => BDFi mice was apparent when compared with 
control cells (Fig. 5.8b). Thus, the effects of repeated anti-IL-12 administration 
were similar to those of a single injection of the antibody (see Chapter 4).
However, on day 20, cells from anti-IL-12 treated B6 => BDFi mice retained the 
capacity to produce IL-2 in response to Con A stimulation, albeit at significantly 
lower levels than control cells (Fig. 5.8c).
Repeated administration of anti-IL-12 antibody to control mice resulted in 
significantly reduced IL-2 production at all time points examined (Figs. 5.8a-c), 
consistent with the lower Con A induced proliferative responses of cells from anti- 
IL-12 treated control mice compared with unmanipulated controls (Fig. 5.4).
Reduced Con A induced IL-2 levels were a common feature of anti-IL-12 treated
3 4
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GvHD and control mice, suggesting that IL-12 may play a regulatory role in IL-2 
production.
:
IL-10
IL-10 was not produced spontaneously by cells from any group at any 
time during this study (data not shown). Similarly, on day 20, Con A stimulated 
IL-10 levels were also below the level of detection for all groups. Since IL-10 
production in response to Con A was readily detectable on days 2 and 10 (see 
below), the reason for its absence on day 20 was not clear.
On both days 2 and 10, spleen cells from B6 => BDFi mice produced 
significantly lower levels of IL-10 in response to Con A stimulation compared
with control cells (Figs. 5.9a & b). Repeated anti-IL-12 treatment resulted in a ■significant increase in the levels of Con A induced IL-10 production by B6 =>
BDFi spleen cells on both days 2 and 10 (Figs. 5.9a & b). This was in contrast to 
the effect of a single administration of anti-IL-12, which had no effect on IL-10 
production by B6 => BDFi cells after day 2 (see Chapter 4).
:
Spleen cells from control mice given repeated injections of anti-IL-12 
produced similar levels of IL-10 to cells from unmodified control mice at both time 
points examined (Figs. 5.9a & b).
IL-5
IL-5 production by cells from all groups was below the level of detection 
at all time points during this study (data not shown). Since IL-5 was detected in 
the previous studies detailed in Chapters 3 and 4, its absence in this study 
highlights the potential variability of cytokine production between experiments.
IL-4
IL-4 production by cells from all groups was below the level of detection
at all time points during this study (data not shown).
8 4
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v) Non-Specific and Specific Cell-Mediated Cytotoxicity
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a) NK cell activity
As before, B6 => BDFi mice showed enhanced splenic NK cell activity on -If
day 2 of the acute GvHD compared with control mice (Fig. 5.10). As I found in 
Chapter 4, this increased NK cell activity was reduced to below control levels by
anti-IL-12 antibody treatment (Fig. 5.10).
b) CTL activity
Since IL-12 is also involved in facilitating specific CTL-mediated 
responses [118, 120, 121, 150], I next examined whether anti-IL-12 treatment 
also reduced the donor anti-host cytotoxicity which occurs later during acute 
GvHD.
On day 10 of acute GvHD, spleen cells from unmodified B6 => BDFi 
mice showed high levels of anti-host CTL activity (Fig. 5.11). Despite the 
dramatic effect of anti-IL-12 on early NK cell activation and its ability to 
ameliorate the associated weight loss and mortality, anti-IL-12 did not prevent the 
generation of anti-host CTL (Fig. 5.11).
Summary
These results indicate that neutralising endogenous IL-12 during the first 8 
days of acute GvHD ameliorated the disease and prevented the 
immunosuppression, weight loss and mortality which occur in established acute 
GvHD. Thus repeated neutralisation of IL-12 extended the effects of a single 
injection of anti-IL-12 antibody and also converted the characteristic Thl-type 
cytokine profile associated with acute GvHD into a more Th2 dominated response, 
as evidenced by reduced IFN-y production and increased levels of the Th2 
cytokine, IL-10. In contrast, the single dose of anti-IL-12 only altered cytokine 
production on day 2. Despite its dramatic effect on weight loss and mortality,
■'il'
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however, anti-IL-12 treatment did not reduce the high levels of anti-host 
cytotoxicity in the spleens of B6 =*- BDFi mice.
Conclusions
Thus, many features of early acute GvHD such as IFN-y production and
NK cell activation are dependent on IL-12, as are the immunosuppression, weight 
loss and mortality which occur in the established disease. Initiation of acute GvHD 
is critically dependent on IL-12, supporting the view that this is a Thl-mediated 
disease. In the next chapter, I went on to examine the long-term consequences of 
neutralising IL-12.
I
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DAY OF GvHD
Fig. 5.1. Effects of anti-IL-12 treatment on weight ioss and 
mortality during acute GvHD,
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on weight loss and mortality in BDFi mice given 10  ^B6 
spleen cells i.v. The results shown are the mean body weights ± 1 SD for 6 mice 
per group. (* p < 0.05 vs controls; § p < 0.05 vs unmodified acute GvHD; t  
Death).
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D Acute GvHD 
■  Acute GvHD + Antî-IL-12 
E3 Control + Antî-IL-12
t  t
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DAY OF GvHD
Fig. 5.2. Effects of anti-IL-12 treatment on splenomegaly during 
acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on splenomegaly in BDFi mice given 10® B6 spleen cells 
i.v. The results shown are the mean spleen indices of 3 GvHD mice per group ± 1 
SD relative to the mean spleen weights of 3 control mice. (* p<  0.001 vs controls; 
t  p < 0.05 f t  P < 0.001 vs unmodified acute GvHD).
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Fig. 5.3. Effects of anti-IL-12 treatment on spontaneous ^ex-vivo^ 
proliferation during acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on the spontaneous proliferative capacity of splenocytes from 
BDFj mice given 10® B6 spleen cells i.v. The results are expressed as the mean 
uptake of 3H-TdR ± 1 SD after 4 hours in quadruplicate cultures using spleen 
cells pooled from 3 mice per group. (* p < 0.001 vs controls; t  P < 0.001 vs 
unmodified acute GvHD).
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Acute Acute + Anti-IL-12 Control Control + Anti-IL-12
Fig. 5.4. Effects of anti-IL-12 treatment on Con A i n d u c e d  
proliferation during acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on the proliferative capacity of splenocytes from BDFi mice 
given 10® B6 spleen cells i.v. in response to mitogenic stimulation with lOpg/ml 
Con A. The data are expressed as the mean uptake of 3H-TdR ± 1 SD after 48 
hours in quadruplicate cultures, using spleen cells pooled from 3-4 mice per group 
on day 20 of the disease. (* p < 0.005 ** p < 0.001 vs controls; t  P < 0,005 vs 
unmodified acute GvHD),
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Fig. 5.5. Effects of anti-IL-12 treatment on LPS induced 
proliferation during acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on the proliferative capacity of splenocytes from BDFi mice 
given 10  ^B6 spleen cells i.v. in response to mitogenic stimulation with 10p,g/ml 
LPS. The data are expressed as the mean uptake of 3H-TdR ± 1 SD after 24 hours 
in quadruplicate cultures, using spleen cells pooled from 3-4 mice per group on 
day 20 of the disease. (* p < 0.001 vs controls; t  P < 0.05 vs unmodified acute 
GvHD).
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Fig. 5.6. Effects of anti-IL-12 treatment on spontaneous IFN-y 
production during acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on spontaneous IFN-y production by splenocytes from BDFi 
mice given 10  ^B6 spleen cells i.v. Splenocytes from B6 => BDFi mice were 
cultured in medium for 48 hours and the supernatants assayed for the presence of 
IFN-y by ELISA. The results shown are the means ± SD of triplicate samples on
day 10 of the GvHD. (t p < 0.001 vs unmodified acute GvHD).
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Fig. 5.7. Effects of anti-IL-12 treatment on Con A induced IFN-y 
production during acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on Con A induced IFN-y production by cells from BDFi 
mice given 10  ^B6 spleen cells i.v. Splenocytes from B6 => BDFi mice were 
cultured with lOpg/ml Con A for 48 hours and the supernatants assayed for the 
presence of IFN-y by ELISA. The results shown are the means ± SD of triplicate 
samples on days 2 (Fig. 5.7a), 10 (Fig. 5.7b) or 20 (Fig. 5.7c) of the GvHD. (* 
p < 0.05 p < 0.001 vs controls; t  P < 0.001 vs unmodified acute GvHD).
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Fig. 5.8. Effects of anti-IL-12 treatm ent on IL-2 production during 
acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on Con A induced IL-2 production by cells from BDFi mice 
given W  B6 spleen cells i.v. Splenocytes from B6 => BDFi mice were cultured 
with lOpg/ml Con A for 24 hours and the supernatants assayed for the presence of 
IL-2 by ELISA. The results shown are the means ± SD of triplicate samples on 
days 2 (Fig. 5.7a), 10 (Fig. 5.7b) and 20 (Fig. 5.7c) of the GvHD. (* p <  0.005 
** p < 0.001 vs unmodified controls; t  P < 0.001 vs unmodified acute GvHD).
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Fig. 5.9. Effects of anti-IL-12 treatment on IL-10 production during 
acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on Con A induced IL-10 production by splenocytes from 
BDFi mice given 10  ^B6 spleen cells i.v. Splenocytes from B6 => BDFi were 
cultured with lOpg/ml Con A for 48 hours and the supernatants assayed for the 
presence of IL-10 by ELISA. The results shown are the means ± SD of triplicate 
samples on days 2 (Fig. 5.9a) and 10 (Fig. 5.9b) of the GvHD. (* p < 0.01 **
0.001 vs controls; f p < 0.001 vs unmodified acute GvHD).
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Fig. 5.10. Effects of anti-IL-12 treatment on NK cell activity during 
acute GvHD.
The results show the effect of a neutralising endogenous IL-12 during the first 8 
days of acute GvHD on splenic NK cell activity in BDFi mice given 10  ^B6 i.v. 
The results shown are the % cytotoxicity against YAC-1 target cells from 
quadruplicate assays measured at effector : target (E:T) ratios from 100:1 to 
12.5:1, using spleen cells pooled from 3 mice per group on day 2 of the GvHD.
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Fig. 5.11. Effects of IL-12 depletion on specific CTL activity 
during acute GvHD.
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on splenic CTL activity in BDFi mice given 10  ^B6 i.v. The 
results shown are the % cytotoxicity against P815 target cells from quadruplicate 
assays measured at effector : target (E:T) ratios from 100:1 to 12.5:1, using spleen 
cells pooled from 3 mice per group on day 10 of the GvHD.
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CHAPTER 6
ROLE OF ENDOGENOUS IL-12 IN GvHD
.,;:ï
Long-Term Effects of IL-12 Neutralisation 
on Acute and Chronic GvHD
98
Introduction:
In Chapters 4 & 5, I showed the importance of the cytokine IL-12 in 
mediating acute GvHD in BDFi mice, by demonstrating that in vivo 
administration of neutralising anti-IL-12 antibody inhibited the Thl cytokine 
production, immunosuppression, weight loss and mortality which occur during
■Î
if
the first 3 weeks of the disease. A number of important issues were raised by 
these earlier studies. Firstly, they did not address the critical question of whether 
neutralising IL-12 early in GvHD conferred long-term protection from acute 
disease, or simply delayed its onset. Secondly, I did not establish whether IL-12 
depletion impaired the development of donor haemopoietic chimerism. If so, host 
cells might remain to allow continued stimulation of donor T cells. Finally, if 
neutralising IL-12 promotes the development of a Th2 cytokine response to 
alloantigen, this may eventually result in the development of a chronic GvHD, 
comparable to that observed in DBA/2 => BDFi animals. In this chapter, I have 
addressed these issues in an extended time course of acute GvHD. To determine 
whether anti-IL-12 treated B6 => BDFi mice go on to develop chronic GvHD, I 
examined whether long-term survivors exhibit any of the features of the chronic 
disease, such as high levels of Th2 cytokine production, B cell hyperplasia 
enhanced serum immunoglobulin and anti-ds DMA antibody levels, and antibody- 
mediated kidney pathology. In addition, I investigated whether DBA/2 => BDFi
mice given anti-IL-12 antibody developed raised serum immunoglobulin and anti-
ds DNA antibody levels earlier than unmodified DBA/2 => BDFi mice and if the 
antibody treatment increased long-term mortality in chronic GvHD.
Experimental Protocol
The GvHR was induced by i.v. injection of 10^ viable B6 or DBA/2 
parental spleen cells into BDFi recipients, as usual. IL-12 was neutralised in vivo 
as described in Chapter 5.
The numbers of donor and host derived CD4+ and CD8+ T cells in the 
spleen were assessed by flow cytometry using mAbs directed against polymorphic 
determinants expressed by either H-2D^ or H-2D*). Lymphocytes expressing high 
levels of both H-2D^ and H-2 D^ were identified as host lymphocytes, while cells 
which lacked expression of H-2D^ Class 1 MHC were designated B6 donor- 
derived cells.
Immune function was determined on day 70 by assessing the ability of 
GvHD splenocytes to proliferate in response to Con A or LPS stimulation in vitro 
. Cytokine production was also measured at this time. Levels of total serum IgG 
were measured throughout the GvHD using radial immunodiffusion, while serum 
IgE and anti-ds-DNA antibody levels were both determined by ELISA.
Kidneys were harvested from GvHD mice on days 50, 70 and 130 and 
examined blind for evidence of immune complex deposition and glomerular 
damage by both light and electron microscopy.
1. Long-Term Effects of Anti-IL-12 Treatment on Acute GvHD
Results
i) Survival
Unmodified B6 => BDFi mice with acute GvHD showed the expected 
early mortality, with the first death occurring on day 16 and 78% mortality in this
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group by day 23 (Fig. 6.1). Only two out of the 8 mice in the anti-IL-12 treated 
B6 => BDF group died (one on day 19 and one on day 28 - 25% mortality). No 
further deaths were observed in either group after day 28 until the study was 
terminated on day 130. Thus, early treatment with anti-IL-12 confers long-term 
protection from mortality.
Iii) Effect of anti-IL-12 treatment on donor cell engraftment
As expected, unmodified B6 => BDFi mice showed progressive 
repopulation by donor-derived CD4+^  T cells (Fig. 6.2 and Table 6.1). This was 
already marked by day 9 (Fig. 6.2), had increased significantly by day 17 and was 
virtually complete in the small number of mice which survived until day 70 (Table
6.1). Engraftment of donor CD8+ T cells occurred more slowly than that of donor 
CD4+ cells and on day 9, only 4.7% of the CD8+ T cells in the spleen of B6 =>
BDFi mice were of donor origin (Fig. 6.2). The percentage of donor-derived 
CD8+ T cells in these mice increased dramatically between days 9-17 (Table 6.1), 
although no further increase was observed thereafter and in mice surviving on day ■70, repopulation of the CD8+ T cell compartment was still incomplete (Table 6.1).
Insufficient mice were available thereafter to establish if complete repopulation by
idonor CDS*' T cells occurred.Anti-IL-12 treated B6 => BDFi mice showed equivalent engraftment of 
donor CD4+ T cells to that seen in unmodified B6 BDFi mice on days 9 (Fig.
6.2) and 17 (Table 6.1). However, on day 70, the percentage of CD4+ 
lymphocytes in anti-IL-12 treated B6 =>BDFi mice was markedly lower than that 
observed in unmodified B6 => BDFi mice (Table 6.1), suggesting that 
repopulation of the CD4'*' compartment occurred more slowly in anti-IL-12 treated 
mice. However, complete CD4+T cell chimerism was observed in anti-IL-12 
treated mice by day 130 (Table 6.1). Engraftment of donor CD8+ T cells occurred 
at a similar rate in untreated and anti-IL-12 treated B6 => BDFi mice (Fig. 6.2 and 
Table 6.1), but the larger numbers of surviving mice allowed me to establish that
i
On day 70, the LPS induced responses of splenocytes from both anti-IL- 
12 treated B6 => BDFi mice and unmodified DBA/2 => BDFi mice were 
significantly enhanced compared to those of control cells (Fig. 6.4). Similarily
1 0 1
by day 130, complete repopulation by donor derived CD8+ cells had occurred in 
anti-IL-12 treated mice (Table 6.1).
Thus, the long-term survival observed in anti-IL-12 treated B6 => BDFi 
mice is accompanied by complete repopulation of their CD4+ and CD8+ T cell 
compartments by engrafted donor B6 cells.
I
iii) Immune function
In Chapter 5, I demonstrated that anti-IL-12 prevented the T cell 
immunosuppression observed on day 20 of acute GvHD, although it had a less 
dramatic effect on the B cell suppression observed at this time. To establish 
whether anti-IL-12 treated mice retain immunocompetence in the long-term, I 
examined the ability of their spleen cells to proliferate in response to Con A or 
LPS stimulation on day 7 0 .1 also assessed whether these mice developed the B 
cell hyperreactivity associated with chronic GvHD by comparing the responses of
anti-IL-12 treated B6 => BDFi mice to those of DBA/2 => BDFi mice with 
chronic GvHD.
The high mortality rate of unmanipulated B6 => BDFi mice precluded 
analysis of their functional responses at this point.
a) Proliferative responses to Con A stimulation
On day 70, spleen cells from anti-IL-12 treated B6 =>BDFi mice showed 
Con A responses identical to those of spleen cells from both control and DBA/2 => 
BDFi mice (Fig. 6,3). Anti-IL-12 treatment did not affect the Con A responses of 
control mice in the long-term (Fig. 6.3).
b) Proliferative responses to LPS stimulation
enhanced responses to LPS were found in control mice treated with anti-IL-12 
(Fig. 6.4).
Administration of anti-IL-12 therefore appears to provide long-term preservation 
of T cell responses in B6 => BDFi mice, but induces a state of hyper­
responsiveness to the B cell mitogen, LPS, in both acute GvHD and control 
animals. These features are similar to those observed in DBA/2 => BDFi mice 
with chronic GvHD.
iv) Cytokine production
In Chapter 5, I showed that IL-12 depletion reduced the high levels of 
IFN-y produced during the early period of acute GvHD and this was associated 
with increased IL-10 production. I now examined whether antibody treatment 
polarised the cytokine response of long-term survivors of the acute GvHD 
towards a permanent Th2 phenotype, similar to that observed in DBA/2 => BDFi 
mice with the chronic disease. Again, the high mortality rate of unmanipulated B6 
=> BDFi mice precluded analysis of their cytokine phenotype at this point.
IFN-y
IFN-y was not produced spontaneously by cells from any group on day 70 
(data not shown).
On day 70, spleen cells from anti-IL-12 treated B6 => BDFi survivors 
produced significantly lower levels of IFN-y in response to Con A than cells from 
control animals (Fig. 6.5). The levels of IFN-y produced by Con A stimulated 
cells from DBA/2 => BDFi mice were below the level of detection for this assay 
(Fig. 6.5). Anti-IL-12 did not affect the ability of control spleen cells to produced 
IFN-y in response to Con A.
1 0 2
12 treated control mice (Fig. 6.6).
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IL-2
IL-2 was not produced spontaneously by cells from any group on day 70
(data not shown).
Similar levels of IL-2 were produced by Con A stimulated cells from anti- 
IL-12 treated B6 =»- BDFi, DBA/2 => BDFi and both unmanipulated and anti-IL-
IL-10
IL-10 was not produced spontaneously by cells from any group on day 70 
(data not shown).
Cells from anti-IL-12 treated B6 => BDFi mice produced significantly 
enhanced levels of IL-10 in response to Con A, in comparison with both controls 
and DBA/2 => BDFi mice (Fig. 6.7). Control mice given anti-IL-12 also showed 
significantly enhanced IL-10 production compared to unmanipulated controls (Fig.
6.7).
IL-S
IL-5 was not produced spontaneously by cells from any group on day 70 
(data not shown).
Cells from anti-IL-12 treated B6 ==> BDFi mice produced significantly 
enhanced amounts of IL-5 in response to Con A compared with both controls 
(which did not produce any detectable IL-5) and with cells from DBA/2 => BDFi 
mice (Fig. 6.8). Control mice given anti-IL-12 also showed significantly enhanced 
Con A stimulated IL-5 production compared with unmanipulated controls (Fig.
6 .8).
IL-4
IL-4 production by cells from all groups was below the level of detection 
at all time points during this study (data not shown).
v) Serum Immunoglobulin Levels
As IL-12 depleted B6 => BDFi mice exhibited a polarised Th2 cytokine 
profile and heightened LPS proliferative responses, I next assessed whether these 
mice also had the B cell hyperreactivity characteristic of chronic GvHD. The high 
mortality rate in B6 => BDFi mice prevented analysis of their immunoglobulin 
levels after day 30. Mice with chronic GvHD also started to die from ICGN from 
day 50 onwards and insufficient numbers of these mice remained to analyse on
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a) IgG
DBA/2 B D Fi mice with chronic GvHD developed hyper-
gammaglobulinaemia, with strikingly higher than normal levels of total serum IgG 
on days 20 and 30 of the disease (Fig. 6.9). Serum IgG levels in these mice 
declined thereafter, probably due to hypoproteinanaemia resulting from severe 
ICGN [36, 37, 39, 167]. In contrast, unmodified B6 => BDFi mice with acute 
GvHD had no detectable serum IgG on days 20 and 30, reflecting their profound 
immunosuppression (Fig. 6.9). Anti-IL-12 treated B6 => BDFi mice maintained 
normal levels of serum IgG until day 130, when levels became significantly 
elevated compared with those of controls (Fig. 6.9). However, these did not reach
the strikingly high levels seen at the peak of chronic GvHD. Treatment of control
;mice with anti-IL-12 also resulted in a transient increase in the levels of IgG on 
days 20 to 70 (Fig. 6.9), consistent with their enhanced LPS response in vitro and 
the increased production of Th2 type cytokines. However, by day 130, IgG levels 
in these mice were identical to those in untreated control mice.
b) IgE
As anticipated, DBA/2 => BDFi mice with chronic GvHD also displayed 
very high levels of total serum IgE compared with control mice. This was evident
on days 20 to 70 of the disease (Fig. 6.10). In contrast, untreated mice with acute
GvHD had no detectable serum IgE when examined on days 20 or 30 of the 
disease (Fig. 6.10). Anti-IL-12 treated B6 => BDFi mice had negligible levels of 
IgE on day 20, but levels gradually recovered and on day 70 and thereafter, their 
serum IgE levels were significantly elevated compared with control mice (Fig.
1
6.10). Again, these levels did not reach the same magnitude as those observed 
during the course of chronic GvHD.
e) Anti-ds DNA Antibodies
The increased levels of serum IgG and IgE present in mice with chronic 
GvHD was accompanied by high levels of anti-ds DNA antibodies (Table 6.2).
These antibodies were not observed in the serum of anti-IL-12 treated B6 =>
BDFi mice on days 20 and 30, but on day 70 and thereafter, anti-ds DNA 
antibody levels were similar to those seen in mice with chronic GvHD (Table 6.2).
Some of the unmodified and anti-IL-12 treated BDFi mice also had anti-ds DNA 
antibodies in their serum at later time points, which has previously been described 
in ageing mice [30].
Thus, in anti-IL-12 treated B6 ==> BDFi long-term survivors, there was
■some evidence of B cell hyperreactivity in vivo, but this was minor in comparison 
with that observed in DBA/2 => BDFi mice with chronic GvHD.
vi) Antibody Mediated Immunopathology
Finally, it was important to determine whether the B cell hyperplasia 
evident in anti-IL-12 treated B6 => BDFi long-term survivors was accompanied 
by the antibody-dependent immunopathology characteristically seen in DBA/2 =>
■-ii-
BDFi mice. I therefore examined for evidence of ICGN at different time points 
using both light and electron microscopy.
As I found previously, in the kidneys of all DBA/2 => BDFi mice 
examined, a severe and progressive ICGN was readily detectable by 50 days and 
was still present in surviving mice on day 70 (Figs. 6.11A & B). Light
>
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microscopy revealed extensive glomerular damage and many of the renal tubules 
contained protein casts. There was thickening of basement membranes, mesangial 
prominence and hyperplasia of the epithelium of Bowman's capsule (Fig. 6.11 A). 
Electron microscopy confirmed the presence of subepithelial immune complex 
deposits and focal endothelial swelling (Fig. 6.1 IB).
In contrast, kidneys from anti-IL-12 treated B6 => BDFi mice displayed 
no evidence of ICGN at any time point examined (Fig. 6.11C & D). The 
glomeruli appeared healthy and although occasional mesangial hyperplasia was 
evident, there was no thickening of the glomerular basement membrane or 
detectable immune complex deposits. However, there was evidence of a mild to 
moderate infiltration by chronic inflammatory cells which was perivascular in 
distribution, but was not associated with tissue injury (Fig.6.11C). The 
significance of this is unclear, but has been previously described in long-term 
survivors of unmodified acute GvHD [33].
2) Long-term effects of Anti-IL-12 on Chronic GvHD
In the final part of this chapter, I went on to assess the role of endogenous 
IL-12 in chronic GvHD by examining whether neutralising IL-12 during the 
initiation of the chronic GvHD affected the mortality and enhanced serum 
immunoglobulin production. The unmodified DBA/2 => BDFi GvHD data are the 
same as those shown in the first part of this chapter.
Results
i) Survival
As described in Chapter 3, DBA/2 => BDFi mice developed severe 
oedema which became evident in the majority of mice from day 40 onwards. Mice 
started to die on day 50 and by day 72, 67% mortality was observed (Fig. 6.12). 
Anti-IL-12 treated DBA/2 => BDFi mice also began to develop oedema die by day
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ii) Serum Immunoglobulin levels
50 (Fig. 6.12) and the overall mortality in this group was eventually even higher 
than in the unmodified DBA/2 => BDFi group, with 100% mortality observed by 
day 80 (Fig. 6.12).
■ 'S '
a) IgG
As before, unmodified DBA/2 => BDFi mice with chronic GvHD showed 
strikingly higher than normal levels of total serum IgG on days 20 and 30 of the 
disease, and again, these declined by day 70 (Fig. 6.13). Anti-IL-12 treated 
DBA/2 => BDFi mice exhibited similarly high serum IgG levels to unmodified 
DBA/2 => BDFi animals on day 20 (Fig.6.13). However, these IgG levels 
appeared to decline more rapidly than in unmodified mice, consistent with more 
pronounced proteinuria and they were significantly lower than in unmodified mice 
by day 30. In addition, by day 70, IgG levels in anti-IL-12 treated DBA/2 
BDFi mice were similar to, or lower than, those of controls (Fig. 6.13).
Treatment of control mice with anti-IL-12 resulted in mildly increased 
levels of IgG on days 20 to 70, but by day 130, IgG levels in these mice were 
identical to those in untreated control mice (Fig. 6.13).
b)IgE
DBA/2 BDFi mice with chronic GvHD again displayed significantly 
higher serum IgE levels compared with control mice on days 20 to 70 of the 
disease (Fig. 6.14). Anti-IL-12 treatment of DBA/2 => BDFi mice resulted in a 
further significant increase in IgE levels on days 20 and 30, but on day 70, the 
levels of IgE in the serum of antibody treated DBA/2 => BDFi mice were similar 
to those in unmodified DBA/2 => BDFi mice (Fig. 6.14).
Anti-IL-12 did not affect the levels of IgE in the serum of control mice 
(Fig. 6.14).
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c) Anti-ds DNA Antibodies
The high levels of anti-ds DNA antibodies present in the serum of DBA/2 
=> BDFi mice on days 20 to 70 of the chronic GvHD were unaffected by anti-ILr 
12 treatment (Fig. 6.15). Both unmodified and anti-IL-12 treated control mice did 
not display detectable levels of anti-ds DNA antibodies on days 20 or 30, but by 
day 70, one mouse from each of these groups showed a high titer of these 
antibodies (Fig. 6.15).
iii) Antibody-Mediated Pathology
Kidneys were harvested from both unmanipulated and anti-IL-12 treated 
DBA/2 => BDFi mice on day 70 and examined for ICGN by electron microscopy. 
The kidneys of both groups of mice showed characteristic glomerular damage at 
both time points, which, as before was evidenced by thickening of the glomerular 
basement membrane and immune complex deposition (Figs. 6.16 A & B). The
severity of the kidney damage was not obviously different between the untreated 
and anti-IL-12 treated groups.
Summary and Conclusions
In this chapter I have shown that neutralising endogenous IL-12 for a brief 
period during the initiation of acute GvHD in B6 => BDFi mice not only confers 
long-term protection from the disease but also permits full repopulation with donor 
B6 lymphocytes. The cytokine response of surviving mice was permanently 
polarised towards a Th2 phenotype similar to that observed in DBA/2 => BDFi 
mice and long-term survivors showed B cell hyperplasia, as evidenced by 
heightened responses to the B cell mitogen LPS in vitro. However, compared with 
DBA/2 => BDFi mice, anti-IL-12 treated B6 BDFi animals displayed only 
mildly increased serum IgG and IgE levels and moderate levels of anti-ds DNA 
antibodies. Furthermore, detailed examination of the kidneys from anti-IL-12 
treated B6 => BDFi mice by both light and electron microscopy did not reveal any
■S
repeated.
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evidence of the ICGN apparent in mice with chronic GvHD. In parallel, anti-IL-12 
treated mice did not develop oedema or die. These results therefore confirm the 
critical role of early IL-12 production in acute GvHD.
Consistent with its ability to polarise acute GvHD towards a Th2 
phenotype, neutralising IL-12 appeared to slightly exacerbate chronic GvHD in 
DBA/2 ^  BDFi mice. Although antibody treated DBA/2 => BDFi mice 
developed oedema and started to die at exactly the same time as unmodified DBA/2 
=> BDFi mice, the overall mortality rate was slightly higher in the antibody treated 
group than in the unmodified group. In parallel, IgE levels were significantly 
higher in anti-IL-12 treated DBA/2 => BDFi mice and serum IgG levels declined
I
more rapidly in antibody treated animals, perhaps suggesting a more rapid onset of 
hypoproteinaemia. However these differences were relatively subtle and only 
small numbers of mice were analysed. In addition, anti-ds DNA antibody levels 
were similar in both groups of mice. Thus, although IL-12 may play a subtle 
regulatory role in the development of the chronic GvHD, these results need
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Fig. 6.1. Effect of neutralising IL-12 on long-term survival during  
acute GvHD,
The results show the effect of neutralising endogenous IL-12 during the first 8 
days of acute GvHD on long-term survival in BDFi mice given 10  ^B6 spleen 
cells i.v. The data show the percentage of surviving mice in each group 
throughout the acute disease.
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Fig. 6.2. Effect of neutralising IL-12 on donor cell chimerism in 
acute GvHD.
Donor cell chimerism was assessed throughout the GvHD by flow cytometry. The 
level of H-2fX and H-2D*) expression on gated control CD4+ and CD8+ splenic 
lymphocytes was determined and the percentage of H-2D^ and H-2D^ negative 
cells defined by Ml. These control histograms (shown in red) were then used to 
calculate the percentage of H-2D  ^negative (donor derived) cells in GvHD mice, as 
illustrated on page 112. All histograms shown were obtained on day 9 of the 
GvHD, while the percentage of donor-derived cells at later time points are given in 
Table 6.1.
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Fig. 6.2. Effect of neutralising IL-12 on donor cell chim erism  in 
acute GvHD. The percentage of donor-derived cells is defined by region Ml.
112
3H TdR Incorporation
(cpm/weil)
150000
100000  -
50000 “
’
■lit
Î
■
Acute + Anti-IL-12 Chronic Control Control + Anti-IL-12
f
I
I
.#■Ii.:
Fig. 6.3. Effect of neutralising IL-12 on T cell function in long­
term survivors of acute GvHD.
The data show the proliferative responses of spleen cells after stimulation with 
10p,g/ml Con A on day 70 of acute or chronic GvHD and are expressed as the 
mean uptake of 3H-TdR ± 1 SD after 48 hours in quadruplicate cultures, using 
spleen cells pooled from 3-4 mice per group.
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Fig. 6.4. Effect of neutralising IL-12 on B cell function in lon g ­
term survivors of acute GvHD.
The data show the proliferative responses of spleen cells after stimulation with 
lOfAg/ml LPS on day 70 of acute or chronic GvHD and are expressed as the mean 
uptake of 3H-TdR ± 1 SD after 24 hours in quadruplicate cultures, using spleen 
cells pooled from 3-4 mice per group. (* p < 0.001 vs controls).
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Fig. 6.5. Effect of neutralising IL-12 on IFN-y production in long­
term survivors of acute GvHD.
The results show IFN-y production by spleen cells from mice on day 70 of acute 
or chronic GvHD after stimulation with lOpg/ml Con A for 48 hours and are the 
means ± SD of triplicate samples. (* p < 0.001 vs controls).
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Fig. 6.6. Effect of neutralising IL-12 on IL-2 production in long­
term survivors of acute GvHD.
The results show IL-2 production by spleen cells from mice on day 70 of acute or 
chronic GvHD after stimulation with lOpg/ml Con A for 24 hours and are the 
means ± SD of triplicate samples.
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Fig. 6.7. Effect of neutralising IL-12 on IL-10 production in long­
term survivors of acute GvHD,
The results show IL-10 production by spleen cells from mice on day 70 of acute 
or chronic GvHD after stimulation with lOpg/ml Con A for 48 hours and are the 
means ± SD of triplicate samples. (* p < 0.01 ** p < 0.001 vs controls).
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Fig. 6.8. Effect of neutralising IL-12 on IL-5 production in long­
term survivors of acute GvHD.
The results show IL-5 production by spleen cells from mice on day 70 of acute or 
chronic GvHD after stimulation with lOpg/ml Con A for 96 hours and are the 
means ± SD of triplicate samples, (t p < 0.001 vs chronic GvHD).
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Fig, 6.9. Effect of neutralising IL-12 on total serum IgG levels in 
long-term survivors of acute GvHD.
The results shown are the levels of total serum IgG in 4-6 mice with acute or 
chronic GvHD and are expressed as the mean ± SD. 
p<  0.05 ** p < 0.001 vs controls). ND = Not done.
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Fig. 6.10. Effect of neutralising IL-12 on total serum IgE levels in 
long-term survivors of acute GvHD.
The results shown are the levels of total serum IgE in 4-6 mice with acute or 
chronic GvHD and are expressed as the mean O.D. at 405 nm ± SD.
(* p < 0.01 ** p < 0.001 vs controls). ND = Not done.
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Fig. 6.11. Renal Immunopathology in GvHD.
Light (A, C, E) and electron (B, D, F) microscopic appearances of kidneys on day 
70 of GvHD. (A, C, E : H &E X 400 ; B, F : X 11500 ; D : x 4000).
A, B. Mice with chronic GvHD have severe ICGN, characterised by thickening 
of the glomerular basement membrane and tubular casts (A) and subepithelial 
immune complex deposition (arrowed in B). C, D. Anti-IL-12 treated B6 => 
BDFi mice had normal kidney architecture apart from perivascular infiltration of 
mononuclear cells (C) and mild mesangial cell prominence (D). E, F. Controls.
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Fig. 6.12. Effect of neutralising IL-12 on long-term mortality in 
chronic GvHD.
Cumulative mortality in mice with chronic GvHD and treated with anti-IL-12 for 
the first 8 days of disease.
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Fig. 6.13. Effect of neutralising IL-12 on total serum IgG levels in 
chronic GvHD.
The results shown are the levels of total serum IgG in 4-6 mice with chronic 
GvHD and are expressed as the mean ± SD.
(* p < 0.05 p < 0.001 vs controls t  p < 0.01 vs unmodified chronic GvHD).
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Fig. 6.14. Effect of neutralising IL-12 on total serum IgE levels in 
chronic GvHD.
The results shown are the levels of total serum IgE in 4-6 mice with chronic 
GvHD and are expressed as the mean O.D. at 405 nm ± SD.
(* p < 0.001 vs controls; t  P < 0.05 vs unmodified chronic GvHD).
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Fig. 6.15. Effect of neutralising IL-12 on anti-ds DNA antibody 
levels in chronic GvHD,
The results shown are the levels of anti-ds DNA antibodies in the serum of 6 mice 
with chronic GvHD and are expressed as the mean OD value ± ISD at 630nm at a 
1:50 dilution.
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$Fig. 6.16. Renal Immunopathology in GvHD.
Electron microscopic appearances of kidneys on day 50 of GvHD. 
Kidneys from unmodified (A) and anti-IL-12 treated (B) mice with chronic GvHD 
show a similar degree of kidney damage, characterised by thickening of the 
glomerular basement membrane and subepithelial immune complex deposition (x 
11500).
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Table 6.1.
Effect of Neutralising IL-12 on Donor Cell Chimerism
in Acute GvHD.
Table 6.1. Effect of Anti-IL-12 Treatment on Donor Cell Chimerism 
in Acute GvHD.
The levels of donor-derived CD4+ and CD8^ splenic lymphocytes were 
determined in GvHD mice throughout the disease, as described in Fig. 6.2. Cells 
expressing H-2D% but not H-2D^ were designated as being of donor origin.
ND = not done.
% Donor-Derived Lymphocytes
Day of GvHD Unmodified 
B6 => BDFi
Anti-IL-12Treated
B6 => BDFi
CD4 CD8 CD4 CD8
9 19.9 4.7 21.4 8.0
17 69.9 73.2 54.3 69.9
70 95.8 63.2 30.0 71.4
130 ND ND 100 100
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Table 6.2.
Effect of Neutralising IL-12 on Anti-ds DNA Antibody Levels in
GvHD
Experimental
Group
Day 20 Day 30 Day 70 Day 130
Unmodified 0/6 0/4 ND ND
B6 => BDFi
Anti-IL-12 treated 0/6 0/6 6/6 4/4
B6 => BDFi (0.1 ± 0.02) (0.145 ± 0.05)
DBA/2 => BDFi 6/6 6/6 5/5 ND
(0.16 ± 0.04) (0.19 ±0.07) (0.09 ± 0.002)
Control 0/6 0/6 1/6 1/4
(0.081) (0.085)
Control + Anti-IL-12 0/6 0/6 1/6 2/4
(0.12) (0.09)
The data show the number of mice/group with detectable anti-ds DNA antibody 
levels, while the results in parenthesis are the mean OD readings for the positive 
sera at a dilution of 1:50 ± ISD for each group. ND = Not done.
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CHAPTER 7
ROLE OF ENDOGENOUS IL-12 IN GvHD
Modulation of Acute and Chronic GvHD by 
Administration of Exogenous IL-12
■p.
Taken together, the results detailed Chapters 4-6 indicate a role for 
endogenous IL-12 in acute, but not chronic GvHD in BDFi mice. To explore 
further the influence of IL-12 in acute vs chronic GvHD, I next examined whether
,
giving exogenous rm IL-12 to DBA/2 => BDFi mice could convert the chronic 
form of GvHD into an acute disease. In parallel, I also examined the effects of 
exogenous IL-12 on acute GvHD and tested the hypothesis that the different 
outcomes of the two diseases were due to differences in the production of 
endogenous IL-12 during GvHD.
Experimental Protocol
.Exogenous IL-12 was administered by i.p. injection of lOOng rm IL-12 
from day -1 to 3 and 6 to 10 of GvHD. Control mice received PBS containing 1% 
syngeneic mouse serum. The effects on GvHD were assessed as before, with EL- 
4 cells used as targets for measuring anti-host CTL activity in the spleens of 
DBA/2 BDFi mice.
IL-12 production was measured by culturing spleen cells from GvHD mice 
in medium alone, or in the presence of lOpg/ml LPS. The supernatants were then
4‘harvested at 24,48,72 and 96 hours and levels of IL-12 assessed by ELISA. The 
results shown are for peak IL-12 production, which occuned at 48 hours.
Results
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i) Weight loss and mortality
As described in Chapter 3, BDFj mice with chronic GvHD showed no 
evidence of weight loss or mortality for the duration of this study (Fig. 7.1).
However, DBA/2 => BDFi mice injected with lOOng of rm IL-12 for 10 
consecutive days developed an acute GvHD-like syndrome, with weight loss 
evident by day 12, 50% mortality by day 14 (Fig. 7.1) and 100% mortality by day 
15 (data not shown). Due to this high mortality rate, the study was terminated at 
this point. Rm IL-12 also exacerbated the systemic consequences of acute GvHD, 
with weight loss and mortality appearing in the IL-12 treated group, but not in the 
unmodified B6 => BDFi mice by the time the experiment was terminated (Fig.
7.1). Rm IL-12 did not provoke weight loss or mortality in control animals (Fig.
7.1).
s
ii) Splenomegaly
On day 1, mice with chronic GvHD had not yet developed significant
I.splenomegaly (Fig. 7.2a). By day 10, the spleens of mice from this group were 
significantly enlarged compared with controls, but the splenomegaly was less than 
that found in mice with the acute form of the disease (Fig. 7.2b). IL-12 treatment 
significantly increased the degree of spleen enlargement in mice with chronic 
GvHD at both days 1 and 10, reaching levels similar to those observed in mice
•
with acute GvHD (Figs. 7.2a & b). IL-12 also significantly enhanced the 
splenomegaly seen in mice with acute GvHD on both days 1 and 10 (Figs. 7.2a & 
b) and had provoked significant splenomegaly in control animals by day 10, 
perhaps reflecting the increased extrameduallary haematopoiesis observed in 
previous sudies of IL-12 treated mice [121].
I
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iii) Lymphocyte Function
a) Spontaneous 'ex-vivo' proliferation
Splenocytes from unmodified DBA/2 => BDFi mice showed significantly 
enhanced spontaneous proliferation compared with control cells on both days 1 
(Fig. 7.3a) and 10 (Fig. 7.3b) of GvHD, although this was less marked than that 
found in acute GvHD at either time point. Treatment with im IL-12 had no effect 
on the proliferation of chronic GvHD spleen cells on day 1 (Fig. 7.3a), but by day 
10, the rm IL-12 treated chronic GvHD spleen cells showed a marked increase in 
their spontaneous proliferative capacity which resembled that observed in mice 
with acute GvHD (Fig. 7.3b).
Treatment with rm IL-12 had no effect on the enhanced spontaneous 
proliferation of acute GvHD spleen cells on day 1 (Fig. 7.3a), but by day 10, the 
proliferative capacity of splenocytes from rm IL-12 treated acute GvHD mice was 
significantly reduced compared with untreated mice with acute GvHD (Fig. 7.3b). 
Rm IL-12 injected control animals exhibited significantly enhanced spontaneous 
proliferative responses on both day 1 (Fig. 7.3a) and day 10 (Fig. 7.3b).
b) Proliferative responses to Con A stimulation
To determine whether DBA/2 => BDFi mice given exogenous IL-12 
developed immunosuppression similar to that usually found in B6 => BDFi mice 
with acute GvHD, I assessed Con A responses on day 15, as this was when 
significant weight loss and mortality were evident in DBA/2 => BDFi mice given 
exogenous IL-12.
At this time, spleen cells from unmodified DBA/2 => BDFi mice showed 
Con A responses similar to those of control cells (Fig. 7.4). Conversely, the 
responses of cells from DBA/2 => BDFi mice given IL-12 were markedly 
suppressed at this time, with responses similar to those found in unmodified B6 
=> BDFi mice with acute GvHD (Fig. 7.4). Exogenous IL-12 actually slightly
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increased the low Con A responses of acute GvHD cells on day 15, although these
c) Proliferative repsonses to LPS stimulation
The low numbers of lymphocytes recovered from the spleeens of IL-12 
treated B6 => BDFi a^d DBA/2 => BDFi mice precluded comparison of their LPS 
responsiveness on day 15.
Spontaneous IFN-y
On days 1 and 10, spleen cells from mice with chronic GvHD produced 
similarily low levels of spontaneous IFN-y to control cells (Fig. 7.5a & b). 
Administration of rm IL-12 to DBA/2 =*> BDFi mice resulted in a large increase in
remained significantly suppressed compared with controls (Fig. 7.4 ).
The Con A responses of splenocytes from control mice were unaffected by 
rm IL-12 treatment (Fig. 7.4).
I'
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Jiv) Cytokine productionI now went on to examine the effect of IL-12 on cytokine production. This 
was carried out only on days 1 and 10 of acute and chronic GvHD, as the low 
numbers of lymphocytes recovered from the spleeens of IL-12 treated B6 => 
BDFi and DBA/2 => BDFi mice precluded analysis at later times.
I
,spontaneous IFN-y production by splenocytes at both time points and these
reached levels equal to, or above those produced by acute GvHD cells (Figs. 7.5a 
& b). IL-12 had little effect on the already high levels of IFN-y produced 
spontaneously by cells from mice with the acute form of GvHD at both time points 
(Figs. 7.5a & b). Although exogenous IL-12 had no effect on IFN-y production 
by control cells on day 1 (Fig. 7.5a), it induced the spontaneous production of 
IFN-y from control spleen cells by day 10 (Fig. 7.5b).
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Con A Induced IFN-y
On day 1, spleen cells from unmodified DBA/2 => BDFi mice produced 
similar levels of IFN-y in response to Con A to control cells (Fig. 7.6a), whereas 
by day 10, IFN-y production by DBA/2 => BDFi cells was significantly lower 
than that of control cells (Fig. 7.6b). IL-12 did not affect Con A induced IFN-y 
production by DBA/2 => BDFi cells on day 1 (Fig. 7.6a), but significantly 
increased that observed on day 10 to levels even greater than the high amounts 
produced by cells from B6 => BDFi mice (Fig. 7.6b). In contrast, IL-12 did not 
significantly increase the already high levels of IFN-y produced by Con A 
stimulated B6 => BDFi spleen cells on either days 1 or 10 (Figs. 7.6a & b). Cells 
from control mice given IL-12 produced similar levels of IFN-y in response to 
Con A to cells from unmodified controls on day 1 (Fig. 7.6a), but by day 10, 
these mice had significantly enhanced levels of IFN-y production compared with 
unmodified controls (Fig. 7.6b),
IL-2
On both days 1 and 10, spleen cells from unmodified mice with chronic 
GvHD produced significantly higher levels of IL-2 in response to Con A than cells 
from control mice (Figs. 7.7a & b). This was in contrast to cells from mice with 
the acute form of the disease, which produced higher levels of IL-2 in response to 
Con A than control cells on day 1, but by day 10 had undetectable IL-2 production 
(Figs. 7.7a), consistent with the suppressed Con A responses of these mice. 
Administration of exogenous IL-12 significantly reduced the capacity of cells from 
mice with chronic GvHD to produce IL-2 in response to Con A on day 1 (Fig. 
7.7a) and by day 10, IL-2 production by IL-12 treated DBA/2 => BDFi mice was 
abolished (Figs. 7.7b). IL-12 also reduced the early enhancement in IL-2 
production by cells from B6 => BDFi mice on day 1 (Fig. 7.7a) and by day 10, 
IL-12 treated B6 => BDF% mice did not produce any detectable IL-2 (Figs. 7.7b).
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at all time points during this study (data not shown).
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Cells from IL-12 treated control mice also produced significantly lower 
levels of IL-2 on day 1 compared with cells from unmodified control mice (Fig.
7.7a). However, on day 10, both unmodified and IL-12 treated control mice 
produced similar levels of IL-2 (Figs. 7.7b).
■i:"
IL-10
IL-10 was not produced spontaneously by cells from any group at any 
time during this study (data not shown). Similarly, on day 1, IL-10 production by 
Con A stimulated cells from all groups was below the level of detection (data not 
shown).
On day 10, cells from mice with chronic GvHD produced significantly 
higher levels of IL-10 in response to Con A than cells from control mice, although 
these levels were lower than those found using chronic GvHD splenocytes in 
earlier experiments (Fig. 7.8). Treatment with exogenous IL-12 resulted in a
■significant reduction in IL-10 production by DBA/2 =» BDFi splenocytes to 
below control levels (Fig. 7.8). However it had no effect on the levels of IL-10 
produced by cells of any other group. I
IL-5
IL-5 production by cells from all groups was below the level of detection 
at all time points during this study (data not shown).
I
IL-4
IL-4 production by cells from all groups was below the level of detection
'Ï
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v) Non-specific and specific cell-mediated cytotoxicity
Finally, I examined whether administration of exogenous IL-12 to DBA/2 
=> BDFi mice could elicit the high levels of NK cell-mediated and specific CTL- 
mediated cytotoxicity usually associated with acute GvHD.
•I
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Ia) NK cell activity %As before, the early phase of acute GvHD in B6 => BDFi mice was 
associated with increased NK cell activity on day 1 (Fig. 7.9a). This increase was 
not evident in mice with chronic GvHD at this time (Fig. 7.9b). Administration of 
IL-12 did not induce enhanced NK cell activity in DBA/2 => BDFi mice, (Fig.
7.9b), although it did slightly increase the levels of NK cell activity observed in 
B6 => BDFi and control mice (Fig. 7.9a).
b) CTL activity
As before, untreated mice with acute GvHD exhibited high levels of anti­
host CTL activity on day 10 (Fig. 7.10a), but little or no anti-host CTL activity 
was found in mice with chronic GvHD at this time (Fig. 7,10b). Administration of 
rm IL-12 induced high levels of CTL activity in mice with the chronic form of the 
disease (Fig. 7.10b), but suppressed those observed in acute GvHD (Fig. 7.10a). 
This may have been because the peak of CTL activity had already passed in the 
highly aggressive GvHD which occurred in IL-12 treated B6 => BDFi mice (Fig. 
7.10a). No lysis of P815 or EL4 cells was induced in control mice by IL-12 
(Figs. 7.10a &b).
v^  IL-12 production during acute and chronic GvHD
In view of evidence that manipulating the levels of endogenous and 
exogenous IL-12 modified the course of GvHD, I examined whether the different 
outcomes of acute and chronic GvHD were reflected by differences in IL-12 
production during the critical early period of disease.
I
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No IL-12 was detected in xmstimulated spleen cell cultures of any group at 
any time (data not shown), while control cells produced consistently low amounts 
in response to LPS throughout the study (Fig. 7.11). However, splenocytes from 
B6 => BDÉ i^ mice produced significantly more IL-12 in response to LPS than 
control splenocytes from day 1 of the GvHD, reaching a peak on day 7 of the 
disease (Fig. 7.11). Splenocytes from DBA/2 => BDFi mice also produced 
significantly higher levels of LPS stimulated IL-12 than controls at all time points 
examined, but these levels remained similar at all times after day 1 and did not rise 
to the same peak observed with B6 =*- BDFi splenocytes (Fig. 7.11).
jï
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Summary and Conclusions
Thus, administration of exogenous IL-12 converts chronic GvHD into a
I'more acute type of disease, with a characteristic biphasic pattern of early 1
hyperplasia followed by late immunosuppression and destruction. In addition to 
increasing the early splenomegaly and spontaneous lymphocyte proliferation 
normally observed in DBA/2 ==> BDFi mice up to levels similar to those found in 
the early period of acute GvHD, exogenous IL-12 also provoked intense 
immunosuppression, anti-host CTL activity, weight loss and mortality, features
not normally associated with this form of disease. Furthermore, administering IL- -
■12 to these mice converted the cytokine profile towards the T hl pattern usually 
seen acute GvHD, with strikingly high levels of IFN-y and reduced IL-10 
production. Finally, my results show that although cells from both B6 => BDFi 
and DBA/2 => BDFi mice produced similarly enhanced IL-12 up to day 2, B6 =>
BDFi splenocytes produced significantly higher IL-12 than DBA/2 =>BDFi cells 
thereafter.
These results confirm the findings of Chapters 4, 5 & 6 by showing that
■V.
IL-12 is critical for the development of acute, but not chronic GvHD. However, 
despite the apparent IL-12 independence of chronic GvHD, enhanced levels of IL-
i
12 were produced by spleen cells from DBA/2 => BDFi mice in response to LPS 
in vitro, albeit at lower levels than those produced by B6 =4* BDFi cells.
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Fig. 7.1. Effects of exogenous IL-12 on weight loss and mortality 
in acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on weight loss 
and mortality in BDFi mice given 10® B6 or DBA/2 spleen cells i.v. and are the 
mean body weight ± 1 SEM for 6 mice per group. The weights of unmodified 
control mice were similar to IL-12 treated controls at all times and are not shown 
for clarity. (* p < 0.05 vs controls; t  Death).
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SPLEEN INDEX3 a
Acute
Acute A cute + IL-12 Chronic Chronic + IL-12 Control + IL-12
A cute + IL-12 Chronic Chronic + IL-12 Control + IL-12
Fig. 7.2. Effects of exogenous IL-12 on splenomegaly during acute 
and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on splenomegaly 
in BDFi mice given 10® B6 or DBA/2 spleen cells i.v. and are the mean spleen 
indices ± 1 SD for 3 mice per group on days 1 (Fig. 7.2a) and 10 (Fig. 7.2b) of 
the GvHD. (^ p < 0.005 vs controls; t  P < 0.05 f t  p < 0.001 vs unmodified acute 
GvHD; § p < 0.001 vs unmodified chronic GvHD).
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Fig. 7.3. Effects of exogenous IL-12 on spontaneous 'ex-vivo^ 
proliferation during acute and chronic GvHD.
T he results show the effect of administering exogenous rm IL-12 on the 
spontaneous proliferative capacity of splenocytes from BDFi mice given 10® B6 
or DBA/2 spleen cells i.v. The results are expressed as the mean uptake of 3H- 
TdR ± 1 SD after 4 hours in quadruplicate cultures using spleen cells pooled from 
3 mice per group on days 1 (Fig. 7.3a) and 10 (Fig. 7,3b) of the GvHD. (^ p < 
0.05 ** p < 0.001 vs controls; t  P < 0.001 vs unmodified acute GvHD; § P < 
0.001 vs unmodified chronic GvHD).
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Fig. 7.4, Effects of exogenous IL-12 on Con A i n d u c e d  
proliferation during acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on the 
proliferative capacity of splenocytes from BDFi mice given 10* B6 or DBA/2 
spleen cells i.v. in response to mitogenic stimulation with lOpg/ml Con A. The 
data are expressed as the mean uptake of 3H-TdR ± 1 SO after 48 hours in 
quadruplicate cultures, using spleen cells pooled from 3-4 mice per group on day 
15 of the GvHD. (* p < 0.001 vs controls; f  p < 0.005 vs unmodified acute 
GvHD; § p < 0.001 vs unmodified chronic GvHD).
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Fig. 7.5. Effects of exogenous IL -1 2  on sp ontaneous IFN-y 
production during acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on spontaneous 
IFN-7 production by splenocytes from BDFi mice given 10* B6 or DBA/2 spleen 
cells i.v. Splenocytes from B6 => BDFi and DBA/2 => BDFi mice were cultured 
in medium for 48 hours and the supernatants assayed for the presence of IFN-y by 
ELISA. The results shown are the means ± SD of triplicate samples on days 1 
(Fig. 7.5a) and 10 (Fig. 7.5b) of the GvHD. (* p < 0.001 vs controls; § p < 
0.001 vs unmodified chronic GvHD).
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Fig. 7.6. Effects of exogenous IL-12 on Con A induced IFN-y 
production during acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on IFN-y 
production by Con A stimulated splenocytes from BDFi mice given B6 or 
DBA/2 spleen cells i.v. Cells from B6 =» BDFi and DBA/2 => BDFi mice were 
cultured with lOpg/ml Con A for 48 hours and the supernatants assayed for the 
presence of IFN-y by ELISA. The results shown are the means ± SD of triplicate 
samples on days 1 (Fig. 7.6a) and 10 (Fig. 7.6b) of the GvHD. (* p < 0.005 vs 
controls; § p < 0.001 vs unmodified chronic GvHD). N.B. Con A induced IFN- 
y production is expressed as OD units at 405nm, since the levels for all groups 
were greater than the highest standard on the standard curve (40ng/ml).
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Fig. 7.7 . Effects of exogenous IL-12 on IL-2 production during 
acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on Con A 
induced IL-2 production by cells from BDFi mice given 10* B6 or DBA/2 spleen 
cells i.v. Splenocytes from B6 => BDFi and DBA/2 => BDFi mice were cultured 
with lOpg/ml Con A for 24 hours and the supernatants were assayed for the 
presence of IL-2 by ELISA. The results shown are the means ± SD of triplicate 
samples on days 1 (Fig. 7.7a) and 10 (Fig. 7.7b) of the GvHD. (* p < 0.05 ** p 
< 0.001 vs controls; f p < 0.001 vs unmodified acute GvHD; § p < 0.001 vs 
unmodified chronic GvHD).
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Fig. 7.8. Effects of exogenous IL-12 administration on I L - 1 0  
production during acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on Con A 
induced IL-10 production by splenocytes from BDFi mice given 10* B6 or 
DBA/2 spleen cells i.v. Splenocytes from B6 => BDFi and DBA/2 => BDFi mice 
were cultured with lOpg/ml Con A for 48 hours and the supernatants assayed for 
the presence of IL-10 by ELISA. The results shown are the means ± SD of 
triplicate samples on day 10 of the GvHD. (* p < 0.001 vs controls; t  p < 0.01 vs 
unmodified acute GvHD; § p < 0.001 vs unmodified chronic GvHD).
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Fig. 7.9. Effect of exogenous IL-12 on NK cell activity during 
acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on splenic NK 
cell activity during acute GvHD in BDFi mice given 10^66 spleen cells i.v. (Fig. 
7.9a) and chronic GvHD in BDFi mice given 10® DBA/2 spleen cells i.v. (Fig. 
7.9b). The results shown are the % cytotoxicity against YAC-1 target cells from 
quadruplicate assays measured at effector : target (E:T) ratios from 100:1 to 
12.5:1, using spleen cells pooled from 3 mice per group on day 1 of the GvHD.
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Fig. 7.10. Effect of exogenous IL-12 on specific CTL activity  
during acute and chronic GvHD.
The results show the effect of administering exogenous rm IL-12 on splenic CTL 
activity during acute and chronic GvHD in BDFi mice given 10® B6 or DBA/2 
spleen cells i.v. The results shown are the % cytotoxicity against EL-4 (H-2^) and 
P815 (H-2^) target cells from quadruplicate assays measured at effector ; target 
(E:T) ratios from 100:1 to 12.5:1, using spleen cells pooled from 3 mice per group 
on day 10 of the GvHD.
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Fig. 7.11. IL-12 production during acute and chronic GvHD.
Splenocytes from BDFi mice given 10® B6 or DBA/2 spleen cells i.v. were 
cultured in the presence of lOpg/ml LPS for 48 hours, before the supernatants 
were removed and assayed for the presence of IL-12 by ELISA. Results shown 
are means ± I SD of triplicate samples. Day 0 represents IL-12 production by 
GvHD splenocytes harvested 4 hours after disease induction. (* p < 0 .0 5 * * p <
0.01 *** p < 0.001 acute GvHD vs controls; t  P < 0.05 f f  p < 0.001 chronic 
GvHD vs controls; § p < 0.001 acute GvHD vs chronic GvHD).
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CHAPTER 8
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THE ROLE OF IFN-y IN IL-12 DEPENDENT ACUTE GvHD.
Introduction JIn Chapters 4-7,1 demonstrated that IL-12 is critical for the development 
of acute GvHD. IL-12 has a variety of potent effects on cells of the 
lymphohaemopoietic system, but its principal immunomodulatory role is to induce 
IFN-y production by CD4+ and CD8+ T cells and NK cells [118, 120, 121, 123,
147, 150, 151]. A number of aspects of my studies suggest that this may be the 
role of IL-12 in acute GvHD. IFN-y production is enhanced very early during the 
acute GvHD and its kinetics follow a similar pattern to those of IL-12.
Furthermore, the beneficial effects of IL-12 depletion in acute GvHD were 
associated with down-regulated production of IFN-y, while the acute GvHD-like 
syndrome which appeared in DBA/2 => BDFi mice given exogenous IL-12 was 
characterised by high levels of IFN-y. That modulation of IFN-y production could 
account for the beneficial effects of anti-IL-12 is suggested by previous studies 
which demonstrated that neutralisation of IFN-y in vivo prevented 
immunopathology in the small intestine of B6 =» BDFi mice [55] and by the 
involvement of IFN-y in GvHD-associated immunosuppression [71-73].
In this chapter, I therefore examined directly the role of IFN-y in acute 
GvHD, both in unmanipulated B6 => BDFi mice and in DBA/2 =4> BDFi mice 
given IL-12, using the parameters which I had characterised in previous chapters.
Experimental Protocol
The GvHR was induced by i.v. injection of 10® viable B6 or DBA/2 
parental spleen cells into BDFi recipients, as before. Endogenous IFN-y was 
neutralised in B6 => BDFi mice in vivo by i.p. injection of 0.5mg H22 mAb
149
(hamster IgG anti-mouse IFN-y), given 1 day before induction of GvHR and
subsequently on days 3 and 7.
To induce acute GvHD in DBA/2 => BDFi mice, animals received lOOng
irof exogenous IL-12 on days -1 to 3 and 6 to 10, as described in Chapter 4. The 
effects of anti-IFN-y on this disease were examined by coadministration of 0.5mg 
H22 anti-IFN-y mAb on days -2, 1, 5 and 8. In all cases, controls received 0.5 
mg of hamster IgG isotype control antibody.
The effect of the antibody on systemic GvHD was monitored by assessing 
body weight, splenomegaly and mortality as before, while lymphocyte 
proliferation, cytokine production, NK and CTL activity were determined as
=> BDFi Mice.
ii) Splenomegaly
Unmodified B6 => BDFi mice showed the characteristic pattern of 
splenomegaly described in Chapter 3. It was evident on day 2, peaked on day 10 
and returned to control levels by day 22 (Fig. 8.2). Anti-IFN-y antibody had no
150
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descibed in Chapters 3-7.
Results
1) Effects of Neutralising IFN-y on Acute GvHD in Unmodified B6
i) Weight Loss and mortality
Unmodified B6 =>BDFi mice displayed significant weight loss from day 
18 of the GvHD, which continued until the study was terminated on day 22 
(Fig.8.1). One of these mice died on day 18 and a further two deaths occurred on 
day 20. (The remaining 3 mice, which had all lost weight, were sacrificed on day 
22 for use in functional studies). In contrast, B6 BDFi mice which received 
anti-IFN-y antibody showed no significant weight loss or mortality (Fig. 8.1).
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effect on the splenomegaly observed on day 2, but significantly reduced the 
splenomegaly observed on day 10 (Fig. 8.2). Interestingly, splenomegaly was 
maintained in anti-IFN-y treated B6 => BDFi mice on day 22 and did not show the 
atrophy usually seen in untreated mice with acute GvHD.
Hi) Immune Function
a) Spontaneous 'ex~vivo' proliferation
Spleen cells from unmodified B6 => BDFi mice showed enhanced levels 
of spontaneous 'ex-vivo' proliferation compared with control cells on days 2 and 
10 of GvHD (Fig. 8.3). This paralleled the splenomegaly, as did the return to 
control levels by day 22.
On day 2, cells from anti-IFN-y treated B6 => BDFi mice showed 
significantly increased levels of spontaneous proliferation compared with cells 
from unmodified B6 => BDFi mice (Fig. 8.3). Although similar levels of 
proliferation were observed in both groups on day 10, the proliferative capacity of 
cells from anti-IFN-y treated mice continued to be greatly increased on day 22, 
when these cells exhibited levels of proliferation several-fold higher than those of 
any other group (Fig. 8.3).
Anti-IFN-y treatment increased the spontaneous'ex-v/vo'proliferative 
capacity of control spleen cells on days 2 and 10, but by day 22, the spontaneous 
proliferative capacity of cells from anti-IFN-y treated and immodified control mice 
were similar (Fig. 8.3).
b) Mitogen induced proliferative responses
To examine the effects of anti-IFN-y treatment on immunosuppression in 
acute GvHD, I examined the responses of spleen cells to Con A and LPS on day 
22 of disease.
As expected, splenocytes from unmodified B6 => BDFi mice showed 
significantly reduced proliferative responses to Con A (Fig. 8.4) and LPS (Fig.
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8.5) compared with controls. Cells from anti-IFN-y treated B6 => BDFi mice 
showed a significantly increased ability to respond to both Con A (Fig. 8.4) and 
LPS (Fig. 8.5) compared with cells from unmodified B6 => BDFi animals, 
although in both cases, these responses were still significantly suppressed 
compared with controls. Anti-IFN-y had no effect on the Con A or LPS responses 
of control mice (Figs. 8.4 & 8.5).
iv) Cytokine Production
IFN-y
Splenocytes from unmodified B6 => BDFi mice produced IFN-y 
spontaneously on both days 2 (Fig. 8.6a) and 10 (Fig. 8.6b) of acute GvHD. 
Neutralisation of IFN-y caused a significant increase in the levels of spontaneous 
IFN-y production in B6 => BDFi mice on day 2, but had no effect on this 
parameter on day 10. No IFN-y could be detected in unstimulated control cell 
cultures on either day 2 or day 10 and anti-IFN-y treatment did not affect this.
IFN-y production in response to Con A followed a slightly different 
pattern. On day 2, the levels produced by cells from unmodified B6 => BDFi mice 
were similar to those produced by control cells (Fig. 8.6a), but by day 10, IFN-y 
production was significantly enhanced above control levels (Fig. 8.6b). Treatment 
with anti-IFN-y in vivo significantly increased the levels of IFN-y produced by 
cells from B6 => BDFi mice in response to Con A in vitro on day 2 (Fig. 8.6a), 
but did not affect those observed on day 10 (Fig. 8.6b). Neutralisation of IFN-y 
significantly increased Con A induced IFN-y production by control cells on both 
days 2 and 10 (Fig. 8.6a and b).
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Splenocytes from both unmodified and anti-IFN-y treated B6 ^  BDFi 
mice produced IL-2 spontaneously on day 2 of GvHD (Fig. 8.7a). This was in 
contrast to my previous experiments and was not found at later times in GvHD.
IL-2 production in response to Con A was normal in unmanipulated acute 
GvHD spleen cells on day 2 (Fig. 8.7a), but was then considerably reduced 
compared with control cells (Figs. 8.7b & c). A similar pattern was seen with anti- 
IFN-y treated cells, with normal IL-2 production on day 2 (Fig. 8.7a) and
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suppression on days 10 (Fig. 8.7b) and 22 (Fig. 8.7c). However, on day 22, the 
antibody treated group produced significantly higher amounts of IL-2 than cells 
from unmodified B6 => BDFi mice (Fig. 8.7c).
Anti-IFN-y treatment significantly increased the levels of IL-2 produced by 
Con A stimulated control cells on days 2 and 10 (Figs. 8.7a and b), but on day 
22, cells from both unmodified and antibody treated control mice produced similar 
levels of IL-2 (Fig. 8.7c).
IL-5
High levels of IL-5 were produced spontaneously by cells from anti-IFN-y 
treated B6 => BDFi mice on day 2 (Fig. 8.8a), but this was transient and was not 
observed at any other time or with cells from any other group.
On day 2, cells from unmodified B6 BDFi mice produced similar levels
of IL-5 in response to Con A as control cells (Fig. 8.8a), while on day 10, IL-5
.production by cells from both unmodified B6 => BDFi and control mice was
below the level of detection (Fig. 8.8b). Anti-IFN-y treatment significantly 
increased the levels of IL-5 produced by cells from both B6 => BDFi and control 
mice on days 2 (Fig. 8.8a) and 10 (Fig. 8.8b).
IL-4 and IL-10
IL-4 and IL-10 production by all groups was below the level of detection 
at all times in this experiment.
v) Non-specific and specific cell-mediated cytotoxicity
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a) NK cell activity
I first attempted to assess whether the enhanced NK cell activity I had
observed early in acute GvHD in previous experiments was IFN-y-dependent.
...However in this experiment, all groups showed little or no NK cell activity in two
separate assays (data not shown). This appeared to be the result of technical 
problems and time did not permit me to repeat the experiment.
b) CTL activity
As before, spleen cells from unmodified B6 => BDFi mice showed high
levels levels of specific anti-host cytotoxicity on day 10 of GvHD and this was 
only very slightly reduced by anti-IFN-y treatment (Fig. 8.9).
These experiments indicate that IFN-y is responsible for many of the
'characteristic features of acute GvHD in unmanipulated B6 => BDFi mice, 
including weight loss, mortality, and T cell immunosuppression. The effects of 
neutralising IFN-y were therefore very similar to those of neutralising IL-12.1 
therefore next investigated the role of IFN-y in the IL-12 induced acute GvHD in 
DBA/2 => BDFi mice.
'ÎI
I
a
2) Effects of Neutralising IFN-y in IL-12 Induced Acute GvHD in 
DBA/2 => BDFi mice.
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i) Weight loss and mortality
As expected, unmodified BDFi mice given DBA/2 spleen cells did not lose 
weight or die during the early period of the GvHD, whereas the mice given 
exogenous IL-12 showed significant weight loss from day 10 of the disease (Fig.
8.10). These mice also started to die from this time onward, with one mouse 
dying on day 10, a further three on day 11 and the last mouse on day 14 (Fig.
8.10). In contrast, DBA/2 => BDFi mice given exogenous IL-12 together with 
anti-IFN-y did not lose weight and none of these mice had died up to the time the 
experiment had to be terminated on day 14 (Fig. 8.10).
Because of the rapid mortality observed in IL-12 treated mice, I was also 
unable to analyse splenomegaly and lymphocyte function after day 10.
ii) Splenomegaly
DBA/2 => BDFi mice showed significant splenomegaly on days 2 and 10 
of the chronic GvHD and, as before, IL-12 significantly increased this 
splenomegaly (Figs. 8.11a & b). On day 2, this increase in splenomegaly was 
reduced by neutralising IFN-y at the same time as administering exogenous IL-12
-(Fig. 8.11a). However, on day 10, mice treated this way had a similar degree of
splenomegaly as IL-12 treated DBA/2 => BDFi animals (Fig. 8.1 la).
Control mice given IL-12 also developed splenomegaly at both time ■Ti
points, but this was not prevented by neutralising IFN-y in vivo (Figs. 8.11a &
b).
'
iii) Immune function
a) Spontaneous 'ex-vivo' proliferation
On day 10, spleen cells from unmodified DBA/2 => BDFi mice showed
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significantly enhanced spontaneous proliferation compared with controls and as 1 
found previously, IL-12 significantly increased spontaneous proliferation (Fig.
8.12). Administration of anti-IFN-y resulted in a further significant increase in the 
spontaneous proliferation by cells from IL-12 treated DBA/2 => BDFi mice (Fig.
8 . 12).
Exogenous IL-12 also increased the spontaneous proliferative capacity of 
control spleen cells, but this was not affected by anti-IFN-y antibody (Fig. 8.12).
-a
b) Proliferative responses to Con A stimulation
T cell function was assessed on day 10 by determining the ability of 
splenocytes to respond to Con A stimulation. I was unable to examine the LPS 
responsiveness due to low cell yields from IL-12 treated mice with GvHD.
Unmodified DBA/2 => BDFi mice showed similar levels of Con A 
induced proliferation to control cells, but cells from IL-12 treated DBA/2 => BDFi 
mice had dramatically suppressed Con A responses (Fig. 8.13). Neutralisation of 
IFN-y had little effect on these responses. IL-12 also significantly reduced the 
responses of control cells to Con A stimulation and this was not influenced by 
anti-IFN-y (Fig. 8.13).
iv) Cytokine production
4;
IFN-y
On day 2, IFN-y was not produced spontaneously by cells from any group 
(data not shown). On day 10, cells from unmodified DBA/2 => BDFi mice also 
had no spontaneous production of IFN-y, but this was provoked by administration
in contrast, anti-IFN-y had no effect on IL-12 induced IFN-y production by
of IL-12 (Fig. 8.14a). Neutralisation of IFN-y significantly reduced, but did not 
totally ablate this spontaneous IFN-y production (Fig. 8.14a). Cells from control 
mice did not spontaneously produce IFN-y on either day 2 or day 10 irrespective 
of whether treated with anti-IFN-y or not (Fig. 8, Ida).
On both days 2 and 10, cells from DBA/2 => BDFi mice produced slightly 
higher levels of IFN-y in response to Con A than control cells (Fig. 8 .14b & c). 
IL-12 treatment resulted in a dramatic increase in the levels of Con A induced IFN- 
y production by cells from DBA/2 => BDFi mice on day 2 (Fig. 8.14b), but did 
not affect those observed on day 10 (Fig. 8.14c), perhaps because cells from IL-
12 treated DBA/2 => BDFi mice were already producing maximal levels of IFN-y 
spontaneously and could not be stimulated further with Con A. Neutralising IFN-y 
in IL-12 treated DBA/2 => BDFi mice did not significantly affect their IFN-y 
production in response to Con A on either day 2 or 10 (Fig. 8.14b &c).
IL-12 treatment significantly increased the levels of Con A stimulated IFN- 
y production by control cells on both days 2 (Fig. 8.14b) and 10 (Fig. 8.14c). 
Neutralising IFN-y significantly reduced, but did not totally inhibit the ability of 
exogenous IL-12 to increase IFN-y production on day 2 (Fig. 8.14b). By day 10,
control cells (Fig. 8.14c).
IL-2
IL-2 was not produced spontaneously by cells from any group on either
:Kday 2 or day 10 (data not shown).
'On day 2, cells from unmodified DBA/2 => BDFi mice produced 
significantly higher levels of IL-2 in response to Con A than controls (Fig. 8.15a), 
but by day 10, GvHD cells had significantly reduced levels of IL-2 compared with 
controls (Fig. 8.15b). As I did not find this in previous experiments and because 
these mice had increased spontaneous 'ex-vivo* proliferative responses (see
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above), it is likely that this apparent reduction in IL-2 production may reflect 
increased IL-2 consumption by the DBA/2 => BDFi cells.
Administration of IL-12 significantly reduced the levels of IL-2 produced 
by DBA/2 => BDFi mice in response to Con A on day 2 (Fig. 8.15a), and 
completely ablated IL-2 production on day 10 (Fig. 8.15b). Neutralising IFN-y 
prevented the IL-12-induced suppression of IL-2 production on day 2 (Fig. 
8.15a), but not on day 10 (Fig. 8.15b).
Cells from IL-12 treated control mice produced significantly higher levels 
of Con A induced IL-2 on day 2 than cells from unmodified controls (Fig. 8.15a). 
In contrast, on day 10, the levels of IL-2 produced by cells from IL-12 treated 
control mice were significantly lower than those produced by cells from 
unmodified control mice (Fig. 8.15b). Cells from control mice which had received 
IL-12 together with anti-IFN-y mAb produced strikingly high levels of IL-2 on 
day 2, which were significantly higher than those in any other group (Fig. 8.15a). 
However, this enhancing effect of anti-IFN-y was not present on day 10 (Fig. 
8.15b).
IL-10
IL-10 was not produced spontaneously by cells from any group (data not 
shown).
Cells from unmodified DBA/2 => BDFi mice produced significantly 
higher levels of Con A induced IL-10 compared with cells from control mice on 
both days 2 (Fig. 8.16a) and 10 (Fig. 8.16b). Administration of IL-12 to DBA/2 
=> BDFi mice significantly reduced IL-10 production on day 2 (Fig. 8.16a) and 
totally inhibited it on day 10 (Fig. 8.16b). Neutralisation of IFN-y prevented the 
ability of IL-12 to reduce IL-10 production by DBA/2 BDFi spleen cells on 
day 2 (Fig. 8.16a) and animals treated in this way actually had IL-10 levels 
significantly higher than unmodified DBA/2 => BDFi mice. However anti-IFN-y
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Thus, as I found previously, exogenous IL-12 converts the pattern of 
cytokines produced by spleen cells from DBA/2 => BDFj mice from a Th2
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had no effect on the ability of IL-12 to inhibit IL-10 production on day 10 (Fig. 
8.16b).
IL-12 did not affect Con A induced IL-10 production by control cells on 
either day 2 (Fig. 8.16aa) or day 10 (Fig. 8.16b). As in GvHD mice, 
neutralisation of IFN-y significantly increased the levels of IL-10 produced by 
Con A stimulated, IL-12 treated control cells on day 2 (Fig. 8.16a), but had no 
significant effect on day 10 (Fig. 8.16b). a
I
IL-S
In this study, high levels of IL-5 were produced spontaneously by cells 
from unmodified DBA/2 => BDFi mice on day 2 (13.84 ± 2.02 U/ml), but not by 
cells from any other group (data not shown). Cells from unmodified DBA/2 =>
BDFi mice also produced significantly higher levels of IL-5 in response to Con A 
than control cells on day 2 (Fig. 8.17a) and similar levels of IL-5 to control cells 
on day 10 (Fig. 8.17b). IL-12 treatment totally inhibited IL-5 production by cells 
from DBA/2 => BDFi mice on both days 2 (Fig. 8.17a) and 10 (Fig. 8.17b).
Concomitant administration of anti-IFN-y mAb restored the ability of cells from
DBA/2 => BDFi mice to produce high levels of IL-5 on day 2 (Fig. 8.17a) and 
partially restored IL-5 levels on day 10 (Fig. 8.17b).
IL-12 significantly increased the levels of IL-5 produced by Con A 
stimulated control cells on day 2 (Fig. 8.17a), but not day 10 (Fig. 8.17b). 
Administration of anti-IFN-y significantly increased IL-5 production by cells from 
IL-12 treated controls on both days 2 and 10.
IL-4
IL-4 production was not detectable in this experiment.
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phenotype to a more Thl-dominated response and induces immunosppression. 
These effects are at least partially dependent on IFN-y.
V ) Non-specific and specific cell-mediated cytotoxicity
a) NK cell activity
As in the experiments described earlier in this chapter, I was unable to 
assess NK cell activity in this study, due to technical problems.
b) CTL activity
As before, there was virtually no anti-host CTL activity detectable in the 
spleens of DBA/2 => BDFi mice on day 10 (Fig. 8.18). In contrast, similar mice 
given exogenous IL-12 showed specific cytotoxicity against EL-4 target cells at all 
effector : target (E:T) ratios examined (Fig. 8.18). DBA/2 => BDFi mice which 
had received both IL-12 and anti-IFN-y mAb showed even higher levels of 
specific cytotoxicity than mice which received IL-12 alone (Fig. 8.18). Thus, the 
CTL activity in this model of acute GvHD is not dependent on endogenous IFN-y 
production.
Effects of Neutralising IFN-y on Long-Term Consequences of 
GvHD in IL-12 Treated DBA/2 => BDFi Mice.
As neutralising IFN-y prevented the development of IL-12 induced lethal 
GvHD in DBA/2 => BDFi mice and restored the levels of Th2 cytokines produced 
by cells from these mice, I thought it was important to determine whether DBA/2 
=> BDFi mice given IL-12 and anti-IFN-y developed classical chronic GvHD. I 
therefore monitored these mice throughout the following three months, to assess 
whether they developed lethal chronic GvHD, hypergammaglobulinaemia and 
anti-ds DNA antibodies. Of course, there were no surviving IL-12 treated DBA/2 
=> BDFi mice for direct comparison.
1 6 0
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As expected, unmodified DBA/2 => BDFi mice developed oedema and 
started to die on day 80 and by day 90, 50% of this group had died (Fig. 8.19). In 
contrast, none of the DBA/2 => BDFi mice given IL-12 and anti-IFN-y mAb I
displayed oedema or died. This confirms the ability of anti-IFN-y to protect 
against the IL-12 induced acute disease and also shows that it does not provoke 
development of clinical chronic GvHD.
As described previously, unmodified DBA/2 ^  BDFi mice displayed high 
levels of total serum IgG on days 30 (Fig. 8.20a) and 60 (Fig. 8.20b) compared 
with controls. DBA/2 => BDFi mice given both IL-12 and anti-IFN-y mAb 
showed mildly elevated serum IgG levels on day 30, but on day 60, the IgG levels 
in the serum of these mice were not significantly different than control levels (Fig.
8.20b). Furthermore, at both time points, the levels were not as high as those 
observed in the serum of unmodified DBA/2 ==> BDFi mice (Fig. 8.20a and b).
Finally, all of the unmodified DBA/2 => BDFi mice had detectable anti-ds 
DNA antibodies in their serum on both days 30 (Fig. 8.21a) and 60 (Fig. 8.21b).
In contrast, anti-ds DNA antibodies were not detectable in the serum of any other 
group (Fig. 8.21a and b).
In conclusion, therefore, anti-lFN-y mAh promoted long-term survival 
from the acute lethal GvHD in DBA/2 => BDFi mice given IL-12, but did not 
provoke the consequences of classical chronic GvHD, such as progressive 
oedema and death and high levels of serum IgG and anti-ds DNA antibodies.
Thus, it would appear that IL-12 induces acute GvHD in DBA/2 => BDFi mice 
mainly by eliciting production of high levels of IFN-y.
Summary
The results of this chapter indicate that IFN-y plays an integral role in acute 
GvHD induced by B6 cells and that found in BDFi mice given IL-12 and DBA/2 
cells. Neutralising IFN-y during the early period of acute GvHD had very similar 
effects on both models of disease. Most importantly, anti-IFN-y prevented GvHD-
■|
associated weight loss and mortality and in the case of the extremely aggressive 
GvHD in IL-12 treated DBA/2 => BDFi mice, promoted long-term survival. 
Antibody treatment reduced the degree of splenomegaly observed in both 
unmodified B6 => BDFi and IL-12 treated DBA/2 => BDFi mice during the 
proliferative phase of the disease. However, anti-IFN-y treated B6 => BDFi mice 
showed prolonged splenomegaly and did not develop the lymphoid atrophy 
exhibited by their untreated counterparts during the final stages of acute GvHD. In 
both disease models, anti-IFN-y antibody also increased the levels of spontaneous 
'ex-vivo* proliferation exhibited by GvHD splenocytes, consistent with the known 
cytostatic properties of IFN-y in vitro. This was particularly obvious during the 
late stage of disease, when although the spontaneous responses of untreated B6 ^  
BDFi mice returned to control levels, those of anti-IFN-y treated similar mice 
remained several fold higher than controls. Once again, this highlights the ability 
of anti-IFN-y treatment to maintain the proliferative features of acute GvHD. 
Despite these beneficial effects, neutralising endogenous IFN-y had no effect on 
the high levels of anti-host CTL activity observed in either B6 => BDFi mice, or 
DBA/2 => BDFi mice given IL-12.
There were some differences between the effects of anti-IFN-y in the two 
models of acute GvHD. Whereas anti-IFN-y treatment was able to significantly 
increase Con A induced proliferative responses in unmodified B6 => BDFi mice, 
it had little effect on the suppressed Con A responses in IL-12 treated DBA/2 => 
BDFi mice. This may reflect the fact that the disease induced in IL-12 treated 
DBA/2 => BDFi mice is more aggressive than that observed in unmodified B6 => 
BDFi animals.
The effect of anti-IFN-y mAb on cytokine production by acute GvHD 
spleen cells was more complex. Anti-IFN-y treatment in vivo had little effect on 
the ability of acute GvHD cells to produce IFN-y in vitro, and, in the case of 
unmanipulated B6 => BDFi mice, actually increased early (day 2) levels. This 
may reflect a compensatory mechanism activated in the absence of biologically
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active IFN-y. The effects of anti-IFN-y mAh on IL-2 production differed slightly 
between the two models. In B6 ==> BDFi mice, anti-IFN-y had no effect on Con A 
stimulated IL-2 on either day 2 or 10, but restored the suppressed IL-2 levels seen 
at later times. In contrast, anti-IFN-y prevented the IL-12 induced reduction in IL- 
2 levels observed in DBA/2 => BDFi mice on day 2, but had no effect on day 10. 
The reason for the different effects of anti-IFN-y mAb in these two models was 
not clear and the effect on end-stage IL-2 levels was not examined in IL-12 treated 
DBA/2 => BDFi mice. Anti-IFN-y had a more pronounced effect on the level of 
Th2 cytokines produced by acute GvHD splenocytes in vitro. In particular, 
neutralising IFN-y dramatically increased Con A induced IL-5 production by cells 
from both acute GvHD groups at all times examined. This suggested that IFN-y 
may directly regulate IL-5 production during acute GvHD. IFN-y may also 
regulate IL-10 production, since anti-IFN-y prevented the IL-12 induced reduction 
in IL-10 levels in DBA/2 => BDFi mice. However, this was only observed on day 
2 and not day 10, possibly because antibody treatment was terminated on day 8 
and biologically active IFN-y will presumably be present by day 10.
Taken together, these results show that the effects of neutralising IFN-y 
during acute GvHD are broadly similar to those observed in anti-IL-12 treated 
mice. Both anti-IFN-y and anti-IL-12 antibodies reduced the early splenomegaly, 
but prolonged the proliferative period of the disease. Both antibody treatments 
reduced T cell suppression and had a less marked effect on B cell immune 
deficiency. In addition, anti-IFN-y and anti-IL-12 shared the ability to prevent 
weight loss and mortality, but did not reduce the high levels of anti-host CTL 
activity associated with the disease. Finally, it is important to note that anti-IFN-y 
shares with anti-IL-12 the ability to convert the pattern of cytokine production in 
acute GvHD mice from a Thl to a Th2 phenotype. In both cases, however, 
acquisition of a Th2 dominated response was insufficient to promote classic 
chronic GvHD with hypergammaglobulinaemia, anti-ds DNA antibodies, oedema 
and death.
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Conclusions
IFN-y is an important effector cytokine in acute GvHD. In particular, IFN- 
y appears to mediate many of the destructive features of the disease, such as
weight loss, mortality and suppression of lymphoid responses. However, it also 
contributes to the inflammatory response which results in splenomegaly and 
regulates Th2 cytokine production. The high levels of IFN-y required to elicit the 
acute GvHD are critically dependent on IL-12 and there are a variety of cell types 
which may be the source of IL-12 induced IFN-y production. This issue is 
explored in more detail in Chapters 9 and 10
I
I
BODY WEIGHT (g)
23 -1
22 -
21 -
* * * *
Acute GvHD
Acute GvHD +Antl-IFN^f 
C ontro l
Control + Anti-IFN*^
0 8 12 16 20 244
DAY OF GvHD
Fig. 8.1. Effects of neutralising IFN-y on acute GvHD in B6 => 
BDFi mice.
Weight loss and mortality in BDFi mice given 10® B6 spleen cells i.v. and treated 
with anti-IFN-y mAb. The results shown are mean body weight ± 1 SD for 6 mice 
per group. (* p < 0.05 ** p < 0.001 vs all other groups; f Death).
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Fig. 8.2. Effects of neutralising IFN-y on splenomegaly in acute 
GvHD in B6 => BDFi mice.
Splenomegaly in BDFi mice given 10  ^B6 spleen cells i.v. and treated with anti- 
IFN-y mAh. The results shown are mean spleen indices ± 1 SD for 3 mice per 
group. (* p < 0.05 ** p < 0.001 vs controls; t  P < 0.001 vs unmodified acute 
GvHD).
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Fig. 8.3. Effects of neutralising IFN-y on spontaneous ^ex-vivo^ 
proliferative responses in B6 => BDFi mice.
Spontaneous proliferative capacity of splenocytes from BDFi mice given 10  ^B6 
spleen cells i.v. and treated with anti-IFN-y mAh. The results shown are the mean 
uptake of3H-TdR ± 1 SD after 4 hours in quadruplicate cultures, using spleen 
cells pooled from 3-4 mice per group. (* p < 0.001 vs controls; t  P < 0.001 vs 
unmodified acute GvHD)
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Fig. 8.4. Effects of neutralising IFN-y on T cell function in B6 => 
BDFi mice.
Proliferative capacity of splenocytes from BDFi mice given 10  ^B6 spleen cells
i.v. and treated with anti-IFN-y mAh. The results shown are the mean uptake of 
3H-TdR ± 1 SD after 48 hours in quadruplicate cultures with 10p,g/ml Con A, 
using spleen cells pooled from 3-4 mice per group on day 22 of GvHD. (* p <
0.001 vs controls; t  P < 0.001 vs unmodified acute GvHD)
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Fig. 8.5. Effects of neutralising IFN-y on B cell function in B6 => 
BDFi mice.
Proliferative capacity of splenocytes from BDFi mice given 10  ^B6 spleen cells
i.v. and treated with anti-IFN-y mAh. The results shown are the mean uptake of 
3H-TdR ± 1 SD after 24 hours in quadruplicate cultures with 10p,g/ml LPS, using 
spleen cells pooled from 3-4 mice per group on day 22 of GvHD. (* p < 0.001 vs 
controls; t  p < 0.001 vs unmodified acute GvHD)
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Fig. 8.6. Effects of neutralising IFN-y on IFN-y production in 
acute GvHD in B6 => BDFi mice.
IFN-y production by splenocytes from BDFi mice given 10  ^B6 spleen cells i.v. 
and treated with anti-IFN-y mAh after culture in medium alone, or with 10p,g/ml 
Con A for 48 hours. The results shown are the means ± ISD of triplicate samples 
on day 2 (Fig. 8.6a) and day 10 (Fig. 8.6b) of GvHD. (* p < 0.05 ** p < 0.001 
vs unmodified controls; t  P < 0.05 vs unmodified acute GvHD).
170
f■;5£
I
Î
' I
i
*
i:
■"1.
■J: 
' ':A
IL-2 
(U/ml) 70 -1
60 -
5 0 -
40
30 H
20
lO H
0
50 -j 
4 0 -  
30 - 
20  -  
10 -  
0
Acute
□  S p o n ta n e o u s  
■  Con A Stim ulated
Acute +Antl-IFN“Y Control Control + Antl-IFN-Y
40 - 
30 - 
20 
10 -I 
0
Acute Acute + Antl-IFN-Y Control Control +Antl-IFN-Y
Acute Acute + Antl-IFN-v Control Control + Antl-IFN-Y
Fig. 8.7. Effects of neutralising IFN-y on IL-2 production i n  acute 
GvHD in B6 =» BDFi mice.
IL-2 production by splenocytes from BDFi mice given 10  ^B6 spleen cells i.v. 
and treated with anti-IFN-y mAb after culture in medium alone, or with lOpg/ml 
Con A for 24 hours. The results shown are the means ± ISD of triplicate samples 
on day 2 (Fig. 8.7a), day 10 (Fig. 8.7b) and day 22 (Fig. 8.7c) of GvHD. (* p <
0.001 vs unmodified controls; t  p < 0.01 vs unmodified acute GvHD).
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Fig. 8.8. Effects of neutralising IFN-y on IL-5 production in acute 
GvHD in B6 => BDFi mice.
IL-5 production by splenocytes from BDFi mice given 10® B6 spleen cells i.v. 
and treated with anti-IFN-y mAb after culture in medium alone, or with 10p,g/ml 
Con A for 120 hours. The results shown are the means ± ISD of triplicate 
samples on day 2 (Fig. 8.8a) and day 10 (Fig. 8.8b) of GvHD. (* p < 0.001 vs 
unmodified controls; t  p < 0.001 vs unmodified acute GvHD)
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Fig. 8.9. Effects of neutralising IFN-y on CTL activity in acute  
GvHD in B6 => BDFi mice.
Splenic CTL activity in BDFi mice given 10^  B6 spleen cells i.v. and treated with 
anti-IFN-y mAb. The results shown are the % cytotoxicity against P815 target 
cells from quadruplicate assays, using spleen cells pooled from 3 mice per group 
on day 10 of GvHD.
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Fig. 8.10. Effects of neutralising IFN-y acute GvHD in DBA/2 
=> BDFi mice given IL-12.
Weight loss and mortality in BDFi mice given 10  ^DBA/2 spleen cells i.v. and 
treated with rm IL-12 and anti-IFN-y mAh. The results shown are mean body 
weight ± 1 SD for 6 mice per group. Control mice given IL-12 ± anti-IFN-y mAb 
did not lose weight or die and are not shown for clarity (* p < 0.01 ** p < 0.001 
vs all other groups; f Death).
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Fig. 8.11. Effects of neutralising IFN-y in acute GvHD in DBA/2 => 
BDFi mice given IL-12.
Splenomegaly in BDFi mice given 10^  DBA/2 spleen cells i.v. and treated with 
rm IL-12 and anti-IFN-y mAh. The results shown are the mean spleen index ± 1 
SD for 3 mice per group on day 2 (Fig. 8.1 la) and day 10 (Fig. 8.1 lb) of GvHD. 
(* p < 0.001 vs unmodified controls; t  P < 0.01 vs unmodified chronic GvHD; § 
p < 0.05 vs chronic + IL-12).
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Fig. 8.12. Effects of neutralising IFN-y on spontaneous 
proliferative responses in DBA/2 => BDFi mice given IL-12,
Spontaneous proliferative capacity of splenocytes from BDFi mice given 10  ^
DBA/2 spleen cells i.v, and treated with rm IL-12 and anti-IFN-y mAh. The 
results shown are the mean uptake of3H-TdR ± 1 SD after 4 hours in 
quadruplicate cultures, using spleen cells pooled from 3-4 mice per group on day 
10 of GvHD. (* p < 0,001 vs unmodified controls; f  P < 0.001 vs unmodified 
chronic GvHD; § p < 0.001 vs chronic + IL-12).
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Fig. 8.13. Effects of neutralising IFN-y on T cell function in DBA/2 
=> BDFi mice given IL-12.
Proliferative capacity of splenocytes from BDFi mice given 10  ^DBA/2 spleen 
cells i.v. and treated with rm IL-12 and anti-IFN-y mAh. The results shown are 
the mean uptake of 3H-TdR ± 1 SD after 48 hours in quadruplicate cultures with 
lOpg/ml Con A, using spleen cells pooled from 3-4 mice per group on day 10 of 
GvHD. (* p < 0.005 ** p < 0.001 vs unmodified controls; t  P < 0.001 vs 
unmodified chronic GvHD; § p < 0.001 vs chronic + IL-12).
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Fig. 8.14. Effects of neutralising IFN-y on IFN-y production in 
DBA/2 => BDFi mice given IL-12.
IFN-y production by splenocytes from BDFi mice given 10  ^DBA/2 spleen cells 
i.v. and treated with rm IL-12 and anti-IFN-y mAb. The results shown are for 
spontaneous IFN-y production on day 10 of GvHD (Fig. 8.14a) and Con A 
induced IFN-y on days 2 (Fig. 8.14b) and 10 (Fig. 8.14c) of GvHD. The results 
are the means ± ISD of triplicate samples. (* p < 0.05 ** p < 0.001 vs 
unmodified controls; t  P < 0.05 vs unmodified chronic GvHD § p < 0.001 vs 
chronic + IL-12 ).
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Fig. 8.15. Effects of neutralising IFN-y on IL-2 production in  
DBA/2 => BDFi mice given IL-12.
IL-2 production by splenocytes from BDFi mice given 10  ^DBA/2 spleen cells 
i.v. and treated with rm IL-12 and anti-IFN-y mAb, after culture with lOfxg/ml 
Con A for 24 hours. The results shown are the means ± ISD of triplicate samples 
on days 2 (Fig. 8.15a) and 10 (Fig. 8.15b) of GvHD. (* p <  0.005 p < 0.001 
vs unmodified controls; t  P < 0.(X)1 vs unmodified chronic GvHD; § p < 0.001 
vs chronic + IL-12; ± p < 0,001 vs control + IL-12).
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Fig. 8.16. Effects of of neutralising IFN-y on IL-10 production in 
DBA/2 => BDFi mice given IL-12.
IL-10 production by splenocytes from BDFi mice given 10  ^DBA/2 spleen cells
i.v. and treated with rm IL-12 and anti-IFN-y mAb, after culture with lOpg/ml 
Con A for 48 hours. Results shown are means ± SD of triplicate samples on days 
2 (Fig. 8.16a) and 10 (Fig. 8.16b) of GvHD. (* p <  0.01 ** p < 0.001 vs 
unmodified controls; t  P < 0.005 vs unmodified chronic GvHD; § p < 0.005 vs 
chronic + IL-12).
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Fig. 8.17. Effects of neutralising IFN-y on IL-5 production in 
DBA/2 => BDFi mice given IL-12.
IL-5 production by splenocytes from BDFi mice given 10® DBA/2 spleen cells 
i.v. and treated with rm IL-12 and anti-IFN-y mAb, after culture with lOpg/ml 
Con A for 120 hours. The results shown are the means ± ISD of triplicate 
samples on days 2 (Fig. 8.16a) and 10 (Fig. 8.16b) of GvHD. (* p < 0.05 p < 
0.001 vs unmodified controls; § p < 0.001 vs chronic + IL-12; ± p < 0.05 vs 
control 4- IL-12).
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Fig. 8.18. Effects of neutralising IFN-y on CTL activity in DBA/2 
=> BDFi mice given IL-12.
Splenic CTL activity in BDFi mice given 10® DBA/2 spleen cells i.v. and treated 
with rm IL-12 and anti-IFN-y mAb. The results shown are the % cytotoxicity 
against P815 target cells from quadruplicate assays, using spleen cells pooled 
from 3 mice per group on day 10 of GvHD.
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Fig. 8.19. Effects of neutralising IFN-y on long-term consequences 
of IL-12 induced acute GvHD.
The results show the percentage of surviving mice in each group throughout the 
disease.
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Fig. 8.20. Effects of neutralising IFN-y on long-term consequences 
of IL-12 induced acute GvHD.
Levels of serum IgG in BDFi mice given 10  ^DBA/2 spleen cells i.v. and treated 
with anti-IFN-y mAb. The results shown are the mean total IgG levels ± ISD of 
5-6 mice per group on days 30 (Fig. 8.20a) and 60 (Fig. 8.20b) of GvHD. (* p < 
0.05 ** p < 0.001 vs unmodified controls; t  P < 0.05 vs unmodified chronic 
GvHD). ND = Not done.
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Fig. 8.21. Effects of neutralising IFN-y on long-term consequences 
of IL-12 induced acute GvHD.
Levels of anti-ds DNA antibodies in BDFi mice given 10^  DBA/2 spleen cells i.v. 
and treated with rm IL-12 and anti-IFN-y mAb. The results shown are the mean 
OD value ± ISD at 630nm of 5-6 mice per group on days 30 (Fig. 8.21a) and 60 
(Fig. 8.21b) of GvHD.
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CHAPTER 9
THE CELLULAR SOURCE OF CYTOKINES DURING GvHD.
CD4+ AND CD8+ T CELLS
Introduction
In Chapters 3-8,1 have shown that acute and chronic GvHD are associated 
with different patterns of cytokine production, with a Thl or Th2 response 
predominating in acute or chronic GvHD respectively. These results suggest that 
the different diseases induced by B6 or DBA/2 donor cells may reflect expansion 
of distinct subsets of CD4+ Th cells in vivo. However, cells other than CD4+ Th 
lymphocytes are capable of producing several of the relevant cytokines and could 
therefore be important for the polarisation of GvHD. Two cell types which 
warrant particular attention are CD8+ T lymphocytes and NK cells.
In Chapter 3 , 1 demonstrated that CD8+ T cells expanded preferentially 
during acute, but not chronic GvHD and become a major component of the 
lymphoid tissues of B6 =*► BDFi mice. Previous studies have also highlighted the 
importance of CD8+ cells in the pathogenesis of acute GvHD, and their depletion 
from the B6 spleen cell inoculum prevents the lethality usually associated with the 
disease [30]. However, it is not known whether CD8+ T cells contribute to 
cytokine production during disease, despite their capacity to produce several 
cytokines in other systems, including IFN-y [85, 86,88], IL-4 [90, 94], IL-5 [91, 
168] and IL-10 [94].
NK cells are a further potential source of cytokines during GvHD. In other 
experimental systems they have been shown to be important early producers of 
IFN^ [112-114, 117,119, 153, 169] and are believed to promote differentiation 
towards Th 1-type responses [115-117]. Furthermore, NK cells are important for 
development of GvHD in other experimental models of the disease [97,102,104- 
106,108]. In the experiments described in Chapters 4-6, it appeared that early NK
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cells activation may be restricted to the acute form of disease, supporting the idea 
that these cells could be critical for the subsequent polarisation of acute GvHD, 
perhaps via production of IFN-y.
In the next two chapters, I have therefore examined directly the cellular 
source of the cytokines produced during acute and chronic GvHD. This chapter 
will address the involvement of CD4+ and CD8+ cells in cytokine production in 
vitro, while Chapter 9 examines the role of NK cells in both cytokine production 
in vitro and disease progression in vivo.
Experimental Protocol
As usual, the GvHR was induced by i.v. injection of 10^ viable B6 or 
DBA/2 parental spleen cells into BDFi recipients, and its intensity was monitored 
by assessing splenomegaly and mortality.
To examine the source of cytokines in vitro, CD4+ and CD8+ T cell 
subsets were depleted from pooled spleen cell suspensions isolated on days 2, 7, 
10 and 14 of GvHD by complement-mediated lysis using YTS 191.1 (anti-CD4) or 
YTS 169.4 (anti-CD8) mAbs and rabbit complement. The percentage of residual 
CD4+ or CD8+ cells remaining after depletion was consistently 0.2%. A typical 
example of the efficiency of the depleting mAbs is shown in Fig. 9.1.
IFN-y, IL-2, IL-10, IL-5 and IL-4 production was measured by culturing 
spleen cells from GvHD mice either in medium alone or with Con A.
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Results
Systemic GvHD
Splenomegaly was assessed in GvHD mice to provide an indication of 
disease progression. As before, B6 ==> BDFi mice had significant splenomegaly 
by day 2 (Fig. 9.2). This increased throughout the early period of the acute 
disease, peaked on day 10 and had returned to control levels by day 16. The first 
deaths in this group also occurred on day 16, when two of the five mice died (data 
not shown). As insufficient lymphocytes were available from the surviving B6 =>
BDFi mice for analysis of proliferation or cytokine production on day 16, the last
data point for all groups in this study was day 14.
The splenomegaly observed in DBA/2 => BDFi mice was characteristically 
less intense than that observed in B6 => BDFi mice, but as in my previous
::44-.
studies, it persisted for the remainder of the study (Fig. 9.2). Furthermore, none 
of these mice died during the period of study. %
Role of CD4+ and CD8+ T cells in Production of IFN-y in GvHD
:>■"4a) Spontaneous
Unseparated spleen cells from B6 => BDFi mice produced IFN-y |
ispontaneously at all time points examined (Fig. 9.3a). On day 2, depletion of I
.4either CD4+ or CD8+ T cells did not affect these levels, suggesting that a non-T 
cell population was producing this early IFN-y. In contrast, by day 7, CD4+ cells 
appeared to be the main source of spontaneous IFN-y, since depletion of CD4+, |
but not CD8+ cells resulted in significantly reduced IFN-y production (Fig. 9.3a).
On day 10, removal of CD4+ cells also resulted in a significant reduction in 
spontaneous IFN-y production. At this time, depletion of CD8+ cells actually 
increased IFN-y production, suggesting that an inhibitory CD8+ population was 
present, or that removal of CD8+ cells had enriched the population of IFN-y
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producing cells in culture. On day 14, both CD4+ and CD8+ populations appeared 
to be required for spontaneous IFN-y production, since levels were totally ablated 
when either population was depleted (Fig, 9.3a).
Cells from DBA/2 => BDFi mice produced some spontaneous IFN-y on 
days 2 and 10 of the GvHD (Fig. 9.3b). Although this was in contrast to earlier 
experiments, these levels were very low compared to those produced by B6 => 
BDFi cells and were dependent entirely on CD4+ T cells at both time points.
Control cells did not produce IFN-y spontaneously at any time during this 
study and depletion of either T cell subset did not affect this (data not shown).
f.s:
b) Con A Induced
As anticipated, unseparated B6 => BDFi splenocytes produced 
significantly higher levels of Con A stimulated IFN-y than control cells at all times 
examined (Figs. 9.4a & c respectively). In contrast to the T cell-independent 
spontaneous IFN-y production during the initial phase of disease, on day 2, 
depletion of CD4+ cells from these cultures significantly reduced Con A induced 
IFN-y levels. CD8+ cell depletion had no effect (Fig. 9.4a). Depletion of either 
CD4+ or CD8+ populations on either day 7 or 14 reduced the level of Con A 
induced IFN-y production (Fig. 9.4a), suggesting that both populations were 
producing IFN-y in response to Con A stimulation at these times. However, on 
day 10, CD4+ cell depletion did not affect IFN-y levels, while depletion of CD8+ 
cells provoked a significant increase (Fig. 9.4a), consistent with the effects of 
CD4+ and CD8+ depletion on spontaneous IFN-y production at this time. Thus, a 
regulatory CD8+ T cells may be present at this stage of GvHD and a transient 
population of cells other than CD4+ or CD8+ T cells may also contribute to the 
levels of IFN-y produced spontaneously or via Con A stimulation. If time had 
allowed, this could have been confirmed by total T cell depletion or combined 
depletion of CD4+ and CD8+ populations.
& c). At all time points, both CD4+ and CD8+ populations appeared to be 
contributing to Con A induced IFN-y production by control cells and cells from 
DBA/2 => BDFi mice, as depletion of either of these cells types resulted in 
significantly reduced levels (Figs. 9.4b & c).
Role of CD4+ and CD8+ T cells in IL-2 Production
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Unseparated splenocytes from DBA/2 => BDFi mice produced similar 
levels of Con A stimulated IFN-y to control cells at all times examined (Figs. 9.4b
IL-2 was not produced spontaneously by cells from any group at any time
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On days 2 and 7, unseparated spleen cells from B6 => BDFi mice
"produced similar levels of IL-2 in response to Con A to those found with control 
mice (Fig. 9.5a & c). By day 10, IL-2 levels were significantly lower than those 
produced by controls and by day 14, no IL-2 production was detectable (Fig.
9.5a). Depletion of CD4+ cells from B6 => BDFi cultures significantly reduced, 
or totally ablated IL-2 production at all time points examined (Fig. 9.5a). This 
procedure had no effect on the inability of total B6 => BDFi splenocytes to 
produce IL-2 on day 14. Depletion of CD8+ cells also significantly reduced IL-2 
levels on day 2, but did not affect those on days 7 and 10 (Fig. 9.5a). However, 
by day 14, depletion of CD8+ T cells revealed low levels of IL-2 production, 
when none was observed using unseparated GvHD cells (Fig. 9.5a). This may be 
because the highly activated CD8+ population were consuming any available IL-2, 
or because they act as regulatoiy cells.
Unseparated spleen cells from DBA/2 => BDFi mice produced control 
levels of IL-2 in response to Con A on days 2, 7 and 14 (Fig. 9.5b & c). 
However, on day 10, chronic GvHD cells showed reduced IL-2 production 
compared with controls, perhaps reflecting enhanced consumption of IL-2 by the 
activated GvHD cells. Depletion of CD4+ cells from DBA/2 => BDFi cultures 
significantly reduced or ablated IL-2 production at all time points examined.
I
Depletion of CD8+ cells also significantly reduced IL-2 levels on day 2, but did 
not affect those observed thereafter.
Depletion of CD4+ cells from control splenocyte cultures significantly 
reduced the levels of IL-2 produced in response to Con A at all time points 
examined, while depletion of CD8+ cells had no effect on days 2-10, but 
significantly increased the levels of IL-2 on day 14 (Fig. 9.5c).
Role of CD4+ and CD8+ T cells in IL-10 Production
IL-10 was not produced spontaneously by the cells of any group at any 
time (data not shown).
Unseparated splenocytes from B6 => BDFi mice produced levels of IL-10 
in response to Con A similar to those produced by control cells at all time points 
examined (Figs. 9.6a & c). On day 2, depletion of CD4+ cells from B6 => BDFi 
cultures significantly reduced the levels of IL-10, whereas depletion of the CD8+ 
population had no effect (Fig. 9.6a). By days 7 and 10, depletion of CD4+ cells 
from B6 => BDFi cultures totally ablated IL-10 production. Thus CD4+ cells are
the main source of IL-10 early in acute GvHD. On day 14, however, depleting 
CD4+ cells had no effect on IL-10 production, despite the clear efficacy of 
depletion and by its effects on other cytokines. Removal of the CD8+ population 
on both days 10 and 14 significantly increased IL-10 levels in acute GvHD.
As 1 found previously, unseparated splenocytes from DBA/2 => BDFi 
mice produced significantly higher levels of IL-10 in response to Con A than 
control cells at all time points examined (Figs. 9.6b & c). On days 2 and 7, 
depletion of either CD4+ or CD8+ cells from DBA/2 => BDFi cultures 
significantly reduced IL-10 levels, suggesting that both populations may be 
capable of IL-10 production in these cultures (Fig. 9.6b). However on day 10, 
while depletion of CD4+ cells totally ablated IL-10 levels, depletion of CD8+ cells 
markedly increased IL-10 production, indicating that IL-10 was now being 
produced exclusively by CD4+ cells and confirming the possible presence of
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regulatory CD8+ T cells. Similarly to my finding with B6 => BDFi cells, on day 
14, depletion of either CD4+ or CD8+ cell populations had no effect on IL-10 
production, although once again, the depletion appeared to be effective. The 
source of IL-10 at this time was therefore unclear and needs to be addressed in 
future work.
On day 2, depletion of either CD4+ or CD8+ populations did not 
significantly affect the low levels of IL-10 produced by control splenocytes in 
response to Con A (Fig. 9.6c). In contrast, on days 7 and 10, depletion of CD4+ 
cells significantly reduced IL-10 levels, while depletion of CD8+ cells had no 
effect. On day 14, depletion of CD4+ cells again significantly reduced IL-10 
levels, whereas CD8+ depletion significantly increased them.
Role of CD4+ and CD8+ T cells in IL-5 Production
IL-5 was not produced spontaneously by the cells of any group at any time 
(data not shown).
Unseparated splenocytes from B6 BDFi mice did not produce 
detectable IL-5 in response to Con A at any time point examined and this was not 
affected by depleting CD4+ cells (Fig. 9.7a). On day 2, however, depleting CD8+ 
cells from B6 => BDFi cultures revealed moderate levels of IL-5 (Fig. 9.7a), 
suggesting that CD8+ cells may be directly inhibiting IL-5 production in the 
undepleted cultures at this time. On day 7 and thereafter, depletion of CDS^ cells 
did not reveal any IL-5 production.
As before, unseparated splenocytes from DBA/2 => BDFi mice produced 
high levels of IL-5 in response to Con A throughout the period of study (Fig. 
9.7b). At all time points, these levels were totally ablated by depletion of the CD4+ 
population (Fig. 9.7b). On day 2, depletion of CD8  ^cells did not affect the levels 
of IL-5 produced by splenocytes from DBA/2 => BDFi mice, but on day 7, CD8+ 
depletion resulted in a significant reduction in IL-5. On day 10, depletion of CD8+ 
cells significantly increased IL-5 levels, while on day 14, CD8+ depletion had no
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effect on IL-5 production in chronic GvHD. Thus, CD4+ cells appear to be the 
main IL-5 producing cell type in chronic GvHD, while CD8+ cells play a minor 
role in the production of this cytokine and are frequently regulatory.
Unseparated control splenocytes did not produce detectable IL-5 in 
response to Con A at any point during this study and depletion of CD4+ cells had 
no effect on this (Fig. 9.7c). In contrast, depletion of CD8+ cells, revealed the 
presence of IL-5 in control splenocytes cultures, again suggesting that CD8+ cells 
may play a regulatory role in IL-5 production.
IL .4
IL-4 production was below the level of detection for all groups at all time 
points examined (data not shown).
Summary and Conclusions
These results indicate that while CD4+ Th cells are clearly a major source 
of a variety of different cytokines during acute and chronic GvHD, CD8+ T cells 
and other cell types may also be important for the pattern of cytokines produced. 
During acute GvHD, CD4+, CD8+ and non-CD4+CD8+ populations all appear to
contribute to the high levels of both spontaneous and Con A induced IFN-y 
produced by spleen cells from B6 => BDFj mice. During chronic GvHD and also 
when control cells are stimulated with Con A in vitro, both CD4+ and CD8+ cells 
seem to produce IFN-y and there was no evidence for the involvement of other 
non-T cells. In contrast, in all groups, CD4+ cells were the main population which 
produced IL-2 in response to Con A stimulation, with CD8+ cells playing little or 
no role in its production. Con A stimulated IL-10 again appeared to be derived 
from a number of cellular sources during the two diseases. While both CD4+ and 
CD8+ cells were capable of producing IL-10 during days 2-10 of acute and 
chronic GvHD, on day 14 of either disease, depletion of CD4+ or CD8+ cells did 
not affect the levels of Con A induced IL-10. Although this may indicate that the
Ï1.
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cell populations had not been effectively removed on day 14, FACS analysis 
showed a similar degree of depletion at this time as had been observed at the 
earlier time points. Furthermore, the levels of the other cytokines were affected by 
depletion of CD4+ or CD8+ cells at this time. Thus, IL-10 may be produced by 
cells other than CD4+ or CD8+ lymphocytes, although the nature of this Con A 
responsive cell is unclear. This phenomenon was restricted to GvHD cells, since 
the levels of IL-10 produced by Con A stimulated control splenocytes could be
■reduced by depletion of CD4+ cells at all times. During chronic GvHD, the high 
levels of IL-5 were almost entirely produced by CD4+ cells and depletion of CD8+
T cells was required to reveal IL-5 production by acute GvHD or control cells, 
indicating that CD8+ T cells were inhibiting IL-5 production in these groups. The 
fact that this was evident at all times for control cells, but only on day 2 for B6 =>
■BDFi cells suggests that acute GvHD cells may have lost the capacity to produce 
IL-5 at the later time points. A regulatory effect of CD8+ T cells was a frequent 
finding in these studies, in agreement with their generally suppressive role during 
immune responses [87, 91]. In particular, CD8+T lymphocytes appeared to 
inhibit Th2 cytokine production in B6 ==> BDFi cultures, since CD8+ depletion 
increased levels of both IL-5 and IL-10.
In summary, it is clear that the cellular interactions involved in cytokine 
production during acute and chronic GvHD are extremely complex. Several 
populations can produce or regulate the production of many of the critical 
cytokines involved in GvHD and the purification of these cell types may provide a 
more definitive answer as to their importance.
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Fig. 9.1. Depletion of T cell subsets in vitro,
CD4+ (Fig. 9.1 A) and CD8+ (Fig. 9. IB) splenic lymphocyte populations were 
depleted in vitro by complement mediated lysis using either YTS 191.1 anti-CD4 
or YTS 169.4 anti-CD8a mAbs together with rabbit complement.
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Fig. 9.2. Splenomegaly during acute GvHD and chronic GvHD.
The results show the splenomegaly in BDFi mice given 10  ^B6 or DBA/2 spleen 
cells i.v., expressed as the mean spleen index of 3 GvHD mice per group ± ISD 
and calculated with reference to the mean spleen weights of 3 control mice.
(* p < 0.05 ** p < 0.001 vs chronic GvHD).
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Fig. 9.3. Effects of depleting CD4+ and CD8+ cells in vitro on 
spontaneous IFN-y production during acute and chronic GvHD.
The results show the effect of depleting CD4+ or CD8+ lymphocytes on IFN-y 
levels in unstimulated cultures of splenocytes from mice with (a) acute GvHD and 
(b) chronic GvHD. CD4+ or CD8^ cells were depleted in vitro using complement 
mediated lysis and the cells cultured in medium for 48 hours before the 
supernatants were assayed for the presence of IFN-y by ELISA. (* p < 0.05 ** p 
< 0.001 vs unseparated).
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F:g. 9.4. Effects of depleting CD4+ and CD8+ cells in vitro on Con 
A induced IFN-y production during acute and chronic GvHD.
The results show the effect of depleting CD4+ or CD8+ lymphocytes on IFN-y 
levels in Con A stimulated spleen cell cultures from mice with acute GvHD (a), 
mice with chronic GvHD (b) and control mice (c). CD4+ or CD8+ cells were 
depleted in vitro using complement mediated lysis and the cells cultured with 
lOpg/ml Con A for 48 hours before the supernatants were assayed for the 
presence of IFN-y by ELISA. (* p < 0.05 ** p < 0.001 vs unseparated).
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Fig. 9.5, Effects of depleting CD4+ and CD8+ cells in vitro on Con 
A induced IL-2 production during acute and chronic GvHD.
The results show the effect of depleting CD4+ or CD8+ lymphocytes on IL-2 
levels in Con A stimulated spleen cell cultures from mice with acute GvHD (a), 
mice with chronic GvHD (b) and control mice (c). CD4+ or CD8+ cells were 
depleted in vitro using complement mediated lysis and the cells cultured with 
lOpg/ml Con A for 24 hours before the supernatants were assayed for the 
presence of IL-2 by ELISA. (* p<  0.05 ** p < 0.005 vs unseparated).
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Fig. 9.6. Effects of depleting CD4+ and CD8+ cells in vitro on Con 
A induced IL-10 production during acute and chronic GvHD.
The results show the effect of depleting CD4+ or CD8+ lymphocytes on IL-10 
levels in Con A stimulated spleen cell cultures from mice with acute GvHD (a), 
mice with chronic GvHD (b) and control mice (c). CD4+ or CD8+ cells were 
depleted in vitro using complement mediated lysis and the cells cultured with 
lOpg/ml Con A for 48 hours before the supernatants were assayed for the 
presence of IL-10 by ELISA. (* p < 0.05 ** p < 0.001 vs unseparated).
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Fig. 9.7. Effects of depleting CD4+ and CD8+ cells in vitro on Con 
A induced IL-5 production during acute and chronic GvHD.
The results show the effect of depleting CD4+ or CD8+ lymphocytes on IL-5 
levels in Con A stimulated spleen cell cultures from mice with acute GvHD (a), 
mice with chronic GvHD (b) and control mice (c). CD4+ or CD8+ cells were 
depleted in vitro using complement mediated lysis and the cells cultured with 
lOpg/ml Con A for 96 hours before the supernatants were assayed for the 
presence of IL-5 by ELISA. (* p <  0.05 ** p < 0.005 vs unseparated).
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CHAPTER 10
THE ROLE OF NK CELLS IN GvHD
s
Introduction
I have shown in Chapters 4-8 that early production of IL-12 and IFN-y 
was required for the development of acute GvHD. There is considerable evidence 
that NK cells may be a source of IFN-y in other models of T cell-mediated 
immunity [112-114, 152, 153, 169] and I have shown that the increased IFN-y in 
acute GvHD may be derived from a non-T cell source and coincides with 
activation of NK cells. I therefore decided to carry out a detailed study of the 
involvement of NK cells in polarising immune effector responses early in acute 
GvHD. To do this, I examined whether NK cell activation was exclusively a 
feature of acute GvHD at all time points, beginning a few hours after disease 
induction. Next, I focused on the role of NK cells in the initiation of B6 => BDFi 
acute GvHD by depleting NK cells immediately before induction of disease mice 
using anti-ASGM-1 antibody treatment in vivo.
Experimental protocol
The GvHR was induced by i.v. injection of 10  ^ viable B6 or DBA/2
parental spleen cells into BDFi recipients as before. Levels of splenic NK cell-
.mediated cytotoxicity were measured throughout the first week of disease at 
effector : target (E : T) ratios from 100 : 1 to 12.5 : 1 using YAC-1 target cells. iThe results shown are for an E : T ratio of 100 : 1. NK cells were depleted from 
host mice in vivo by a single i.v. injection of anti-ASGM-1 rabbit antiserum. To 
avoid a contribution from donor-derived NK cells [103-105], I also treated donor 
mice with anti-ASGM-1 one day before cell harvest. Control mice received normal 
rabbit serum (NRS).
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The intensity of the systemic GvHD in vivo was monitored by assessing 
splenomegaly, weight loss and mortality, while immune function was determined 
by measuring the proliferative capacity of spleen cells from GvHD mice either 'ex~ 
vivo', or in response to stimulation with T or B cell mitogens. IFN-y, IL-2, IL- 
10, IL-5 and IL-4 production was measured by culturing spleen cells from GvHD 
mice either in medium alone or with Con A.
Results
Kinetics of NK cell activation during the early period of acute and 
chronic GvHD
B6 => BDFi mice displayed enhanced splenic NK cell activity from 4 
hours after induction of the GvHR and this remained elevated throughout the 
period examined (up to day 7 of the GvHD) (Figs. 10.1). In contrast, enhanced 
splenic NK cell activity was not detectable in DBA/2 => BDFi mice before day 4 
and this was markedly lower than that found in acute GvHD mice (Fig. 10.1). NK
subsequently does occur in chronic GvHD.
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cell activity then remained enhanced to a similar extent on day 7 in chronic GvHD. 
Thus, early NK cell activation is mainly a feature of acute GvHD, although it
Effects of depleting NK cells on progression of GvHD
To determine whether the enhanced NK cell activity observed in B6 => 
BDFi mice is critical for disease progression, I examined the effect of NK cell 
depletion on acute GvHD.
Anti-ASGM-1 treatment in vivo ablated the levels of resting NK cell 
activity in normal BDFi mice and dramatically reduced, but did not ablate those
observed on day 2 of acute GvHD in B6 => BDFi mice (Fig. 10.2).
f
'r,
i) Weight loss and mortality
In comparison to the previous experiments I have described in my thesis, 
the acute GvHD in this experiment was much less aggressive. Thus, weight loss 
was exhibited by only 1 of the 5 unmanipulated B6 ^  BDFi mice, was not 
apparent until day 20 and continued until day 24, when the mouse died. The 
remaining 4 mice showed no weight loss and did not die during the period of the 
experiment (12 weeks). However, 3 of 6 NK cell depleted B6 => BDFi mice lost 
weight from day 18 onwards. One of these mice died on day 21 and a further one 
on day 28. The third mouse which had lost weight recovered and there were no 
other deaths in this group.
ii) Splenomegaly
Despite the reduced morbidity and mortality observed in this experiment, 
unmodified B6 => BDFi mice showed splenomegaly on both days 2 (Fig. 10.3a) 
and 10 (Fig. 10.3b) which was comparable to that seen in previous experiments.
Treatment with anti-ASGM-1 antiserum significantly reduced the splenomegaly on 
day 2 of the disease (Fig. 10.3a), but by day 10, treated mice showed significantly 
greater splenomegaly than untreated animals (Fig. 10.3b). Anti-ASGM-1 
antiserum had no effect on the size of control spleens at either time point (Fig.
10.3a & b).
ill) Immune function
a) Spontaneous 'ex-vivo' proliferation
In parallel with the splenomegaly observed in unmanipulated B6 => BDFi
■V;.mice, spleen cells from these animals displayed an enhanced ability to proliferate 
spontaneously 'ex-vivo' on both day 2 (Fig. 10.4a) and day 10 (Fig. 10.4b).
Treatment with anti-ASGM-1 significantly reduced the spontaneous proliferation
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observed on day 2 (Fig. 10.4a) and significantly increased that observed on day 
10 (Fig. 10.4b).
On both days 2 and 10, spleen cells from control mice which had received 
anti-ASGM-1 anti-serum showed significantly increased levels of spontaneous 
proliferation compared with cells from unmodified control mice (Figs, 10.4a and 
10.4b).
b) Proliferative responses to Con A stimulation
On day 10, spleen cells from unmanipulated B6 => BDFi mice showed 
similar proliferative responses to Con A stimulation to control cells (Fig. 10.5). 
This was in contrast to my findings in previous experiments, where the day 10 
Con A responses of B6 => BDFi mice were suppressed and again highlighted the 
less aggressive GvHD in this experiment. Anti-ASGM-1 treatment significantly 
reduced the Con A responses of these mice, although it did not affect those of cells 
from control animals (Fig. 10.5).
c) Proliferative responses to LPS stimulation
As in previous experiments, on day 10, spleen cells from unmanipulated 
B6 => BDFi mice showed significantly reduced proliferative responses to LPS 
stimulation compared with control cells. This immunosuppression was enhanced 
further by treatment with anti-ASGM-1, but the antibody did not affect the LPS 
responses of cells from control animals (Fig. 10.6).
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10.8a). By day 10, however, the levels produced by cells from B6 => BDFi mice 
were similar to those of controls (Fig, 10.8b). At both times, this IFN-y
produced by Con A stimulated control cells on either day 2 (Fig. 10.8a) or day 10 
(Fig. 10.8b).
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iv) Cytokine production 
IFN-y
a) Spontaneous
Cells from unmodified B6 => BDFi mice spontaneously produced high 
levels of IFN-y on days 2 (Fig. 10.7a) and 10 (Fig. 10,7b). Treatment with anti- 
ASGM-1 did not significantly affect this at either time point (Figs. 10.7a & b). 
However, the results on day 2 were rather difficult to interpret, as spleen cells 
from both unmodified and anti-ASGM-1 treated control mice produced IFN-y 
spontaneously at levels much higher than usually seen (Fig. 10.7a). The reasons 
for this are unclear and it did not occur on day 10 (Fig. 10.7b).
b) Con A stimulated
On day 2, cells from unmodified B6 => BDFi mice produced significantly 
enhanced levels of IFN-y in response to Con A compared with control cells (Fig.
*
production was unaffected by anti-ASGM-1 antiserum treatment (Figs. 10.8a &
b). Furthermore, anti-ASGM-1 treatment did not affect the levels of IFN-y
IL-2
IL-2 was not produced spontaneously by cells from any group (data not 
shown).
On both days 2 and 10, cells from untreated B6 => BDFi mice produced 
significantly lower levels of IL-2 in response to Con A stimulation than control 
cells (Fig. 10.9a & b). At both time points, treatment with anti-ASGM-1
207
1
antiserum significantly lowered IL-2 production by B6 => BDFi cells even further 
(Fig. 10.9a & b) and also reduced the levels of IL-2 produced by Con A
'3:;:stimulated control cells (Fig. 10.9a & b).
'S:
%IL-10
IL-10 was not produced spontaneously by cells from any group (data not 
shown).
On both days 2 and 10, cells from untreated B6 => BDFi mice produced 
significantly higher levels of IL-10 in response to Con A stimulation compared 
with control cells (Fig. 10.10a & b). Once again, this was in contrast to my 
previous findings, since in other experiments B6 => BDFi cells and control cells
1 'produced similar levels of Con A stimulated IL-10. The reason for this disparity
was unclear, but it should be noted that the levels of IL-10 produced by both 
groups in this study were very low. At both time points, treatment with anti- 
ASGM-1 antiserum did not affect IL-10 levels produced by either group (Fig.
10.10a &b).
IL-5
IL-5 was not produced spontaneously by cells from any group (data not 
shown).
On day 2, cells from untreated B6 => BDFi mice produced significantly 
higher levels of IL-5 in response to Con A stimulation compared with control cells #
(Fig. 10.11a). Anti-ASGM-1 treatment did not significantly affect this (Fig.
10.1 la). On day 10, the level of IL-5 produced by cells from both untreated and 
anti-ASGM-1 treated B6 => BDFi mice were below the level of detection (Fig.
10.11b).
Anti-ASGM-1 treatment significantly increased the levels of IL-5 produced 
by Con A stimulated control cells on day 2 (Fig. 10.1 la), but had no effect on the 
levels observed on day 10 (Fig. 10.11b).
1
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v) CTL Activity
As before, untreated B6 => BDFi mice showed high levels of splenic CTL 
activity on day 10 of acute GvHD (Fig. 10.12). This was consistently reduced at 
every E:T ratio by anti-ASGM-1 treatment, but it should be noted that these treated 
mice still showed marked anti-host CTL activity (Fig. 10.12).
Summary and Conclusions
The results detailed in this chapter confirm that NK cell activation is a 
particular feature of the early stages of acute GvHD. Increased splenic NK cell 
activity was observed within 4 hours of the induction of acute GvHD in B6 => 
BDFi mice and this remained elevated throughout the first week of disease. In 
contrast, although increased NK cell activity was also observed in DBA/2 => 
BDFi mice with chronic GvHD, this was not evident until day 4 of the disease 
and was less marked than the levels observed in mice with acute GvHD. The exact 
role of NK cells in the development of acute GvHD was not straightforward and
several effects were left unclear by my study, particularly since the GvHD was
less aggressive than normal. Weight loss and mortality in B6 => BDFi GvHD 
were not dependent on increased NK cell activity early in the disease. Indeed, my 
results suggested that NK cell depletion may slightly increase the intensity of 
systemic GvHD since weight loss and mortality were higher in the treated group, 
as was the degree of T and B cell suppression. In contrast, anti-ASGM-1 reduced 
the early (day 2) lymphoid hyperplasia in B6 => BDFi mice, but this effect was 
transient. Anti-ASGM-1 treatment had a limited effect on immune function in 
control mice, although it increased the spontaneous proliferation of control cells on 
both days 2 and 10. The reason for this increase was not clear, but was consistent 
with reports suggesting ASGM-1 is expressed on a population of cells with 
'suppressor-activity' [170]. However, anti-ASGM-1 treatment did not affect the 
Con A or LPS responses of control cells.
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Anti-ASGM-1 treatment had very little effect on cytokine production by 
either B6 => BDFi or control cells. In particular, it did not affect the levels of 
IFN-y produced by cells from B6 => BDFi mice either spontaneously, or in 
response to Con A. Anti-ASGM-1 did not affect IL-10 or IL-5 production by cells 
from B6 => BDFi mice at either time point and similarily, did not affect IL-10 
production by control cells. It did however cause a striking increase in control IL- 
5 levels on day 2. The reason for this was unclear and by day 10 it was no longer 
evident. Finally, consistent with previous reports that anti-ASGM-1 antibody
treatment prevents the full development of alloreactive CTL in vitro [171], I found 
that B6 => BDFi mice given anti-ASGM-1 in vivo showed somewhat reduced ■|
CTL activity compared with NRS treated B6 => BDFi mice. However, it should 
be noted that there was residual NK cell activity in the spleens of anti-ASGM-1 
treated B6 => BDFi mice.
In conclusion, a single injection of anti-ASGM-1 antiserum on day -1 of 
acute GvHD had little consistent effect on either the progression of the disease or 
the cytokines produced during its course. Most importantly, my results suggested 
that NK cells did not seem to be a major source of IFN-y during acute GvHD.
Although there was residual NK cell activity in anti-ASGM-1 treated B6 => BDFi 
mice, these findings suggest that NK cells are not involved in the initial 
polarisation of acute vs chronic GvHD.
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Fig. 10.1. Kinetics of NK cell activation in acute and ch ron ic  
GvHD.
Splenic NK cell activity in BDFi mice with acute or chronic GvHD. The results 
are shown as the % cytotoxicity against YAC-1 target cells from quadruplicate 
assays measured at an E : T ratio of 100: 1, using spleen cells pooled from 3 mice 
per group.
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Fig, 10.2. Effects of anti-ASGM-1 treatment on splenic NK cell 
activity
The results show the effects of a single injection of anti-ASGM-1 antiserum on 
NK cell activity in control BDFi mice and BDFi mice given 10  ^B6 spleen cells 
i.v. The results are shown as the % cytotoxicity against YAC-1 target cells from 
quadruplicate assays measured at E : T ratios from 50 : 1 to 12.5 : 1, using spleen 
cells pooled from 3 mice per group on day 2 of GvHD.
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Fîg. 10.3. Effects of anti-ASGM-1 treatment on splenomegaly in 
acute GvHD.
The results show the effects of a single injection of anti-ASGM-1 antiserum on 
splenomegaly in BDFi mice given 10  ^B6 spleen cells i.v. and are the mean 
spleen indices ± 1 SD for 3 mice per group on day 2 (Fig. 10.3a) and day 10 (Fig. 
10.3b) of disease. (* p < 0.05 vs unmodified acute GvHD)
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Fig. 10.4. Effects of anti-ASGM-1 treatment on spontaneous 'ex-
viva' proliferation in acute GvHD.
The results show the effect of a single injection of anti-ASGM-1 antiserum on the 
spontaneous proliferative capacity of splenocytes from BDFi mice given 10  ^B6
spleen cells i.v. and are the mean uptake of 3H-TdR ± 1 SD after 4 hours in
quadruplicate cultures using spleen cells pooled from 3 mice per group on day 2 
(Fig. 10.4a) and day 10 (Fig. 10.4b) of disease. (* p < 0.001 vs unmodified 
controls; t  P < 0.005 t t  P < 0.001 vs unmodified acute GvHD)
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Fig. 10.5. Effects of anti-ASGM-1 treatment on Con A induced 
proliferation in acute GvHD.
The results show the effect of a single injection of anti-ASGM-1 antiserum on the 
proliferative capacity of splenocytes from BDFi mice given 10  ^B6 spleen cells 
i.v. in response to stimulation with lOpg/ml Con A. The data are the mean uptake 
of 3H-TdR ± 1 SD after 48 hours in quadruplicate cultures, using spleen cells 
pooled from 3 mice per group on day 10 of acute GvHD. (t p < 0.005 vs 
unmodified acute GvHD)
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Fig. 10.6. Effect of anti-ASGM-1 treatment on LPS induced 
proliferation in acute GvHD.
The results show the effect of a single injection of anti-ASGM-1 antiserum on the 
proliferative capacity of splenocytes from BDFi mice given 10® B6 spleen cells 
i.v. in response to stimulation with lOpg/ml LPS. The data are the mean uptake of
3H-TdR ± 1 SD after 24 hours in quadruplicate cultures, using spleen cells pooled 
from 3 mice per group on day 10 of GvHD. (* p < 0.001 vs unmodified controls; 
t  p < 0.001 vs unmodified acute GvHD)
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Fig. 10.7. Effects of anti-ASGM-1 treatment on spontaneous IFN-y 
production in acute GvHD.
The results show the effect of a single injection of anti-ASGM-1 antiserum on 
spontaneous IFN-y production in mice given 10  ^B6 spleen cells. Splenocytes
were cultured in medium for 48 hours on day 2 (Fig. 10.7a) and day 10 (Fig. 
10.7b) of acute GvHD before the supernatants were assayed for the presence of 
IFN-y by ELISA. The results shown are means ± SD of triplicate samples. (* p < 
0.05 vs unmodified controls).
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Fig. 10.8. Effects of anti-ASGM-1 treatment on Con A induced 
IFN-y production in acute GvHD.
The results show the effect of a single injection of anti-ASGM-1 antiserum on 
IFN-y production in BDFl mice given 10® B6 spleen cells i.v. Splenocytes were 
cultured with lOpg/ml Con A for 48 hours on day 2 (Fig. 10.8a) and day 10 (Fig. 
10.8b) of acute GvHD before the supernatants were assayed for the presence of 
IFN-y by ELISA. The results shown are means ± SD of triplicate samples. (* p < 
0.001 vs unmodified controls)
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Fig. 10.9. Effects of anti-ASGM-1 treatment on IL-2 production in 
acute GvHD.
The results show the effect of a single dose of anti-ASGM-1 antiserum on IL-2 
production in BDFi mice given 10® B6 spleen cells i.v. Splenocytes were cultured 
with of lOpg/ml Con A for 24 hours on day 2 (a) and day 10 (b) of acute GvHD 
before the supernatants were assayed for the presence of IL-2 by ELISA. The 
results shown are means ± SD of triplicate samples. (* p < 0.001 vs unmodified 
controls; t  P < 0,001 vs unmodified acute GvHD)
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Fig. 10,10. Effects of anti-ASGM-1 treatment on IL-10 production 
in acute GvHD.
The results show the effect of a single dose of anti-ASGM-1 antiserum on IL-10 
production in BDFi mice given 10® B6 spleen cells i.v. Splenocytes were cultured 
with lO^ig/ml Con A for 48 hours on day 2 (Fig. 10.10a) and day 10 (Fig. 
10.10b) of acute GvHD before the supernatants were assayed for the presence of 
IL-10 by ELISA. The results shown are means ± SD of triplicate samples. (* p < 
0.(X)5 ** p < 0.001 vs unmodified controls)
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Fig. 10.11. Effects of anti-ASGM-1 treatment on IL-5 production in 
acute GvHD.
The results show the effect of a single dose of anti-ASGM-1 antiserum on IL-5 
production in BDFi mice given 10® B6 spleen cells i.v. Splenocytes were cultured 
with lOpg/ml Con A for 96 hours on day 2 (Fig. 10.11a) and day 10 (Fig. 
10.11b) of acute GvHD before the supernatants were assayed for the presence of 
IL-5 by ELISA. The results shown are means ± SD of triplicate samples. (* p < 
0.005 ** p<  0.001 vs unmodified controls)
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Fig. 10.12. Effects of anti-ASGM-1 treatment on CTL-activity in 
acute GvHD.
The results show the effect of a single injection of anti-ASGM-1 antiserum on 
splenic CTL activity in BDFi mice given 10  ^B6 i.v. and are the % cytotoxicity 
against P815 target cells from quadruplicate assays measured at effector : target 
(E:T) ratios from 100 ; 1 to 12.5 : 1, using spleen cells pooled from 3 mice per 
group on day 10 of GvHD.
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CHAPTER 11
DISCUSSION
The results presented in this thesis have confirmed and extended previous 
findings on the distinct forms of immunopathology which develop in BDFi mice 
with acute and chronic GvHD induced by B6 or DBA/2 parental cells respectively. 
In addition, my results have demonstrated the importance of individual cytokines 
in polarising the allogeneic immune response and determining its pathological 
outcome. These studies of the cellular and molecular interactions involved in 
murine GvHD have implications for understanding the pathogenesis of clinical 
GvHD and the development of specific therapy following BMT. Furthermore, 
they provide an important insight into the regulation of immune responses during 
other immunologically-mediated diseases.
KINETICS OF ACUTE AND CHRONIC GvHD
The results described in Chapter 3 showed that both acute and chronic
.,.:Sforms of GvHD were characterised by an early period of immune activation. 
However, this stimulatory activity persisted throughout chronic GvHD, but in
acute GvHD was replaced rapidly by a destructive, suppressive phase. ï?3..
culminating in weight loss and death in the majority of animals. My results also 
showed that the distinct outcomes of the GvHR were parallelled by different 
patterns of cytokine production, with high levels of IFN-y produced 
spontaneously by cells from B6 =«> BDFi mice, while enhanced IL-5 and IL-10 
were produced by Con A stimulated DBA/2 => BDFi cells. Although the different 
forms of pathology which occur in this model of GvHD have been described 
previously [21,23,24, 27], my study was the first to examine such a wide variety 
of in vivo and in vitro indices of disease over a detailed period of time. In
2 2 2
addition, this was the first study to correlate systemic features of acute and chronic 
GvHD with cytokine production.
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Systemic Features of GvHD
The early proliferative period of both diseases was characterised by 
splenomegaly, increased numbers of splenic lymphocytes and enhanced 
spontaneous proliferative responses of GvHD cells 'ex-vivo\ B6 cells induced a 
more aggressive hyperplastic phase than DBA/2 cells, particularly between days 7 
to 10, when the splenomegaly and spontaneous proliferative response of acute
!■GvHD mice reached a peak and was 2-3 fold higher than that of mice with chronic 
GvHD. Although 1 did not determine the phenotype and origin (donor vs host) of
the proliferating cell populations, previous work implicates the involvement of a 
variety of cell types including donor CD4+ and CD8+ T cells [30], host B cells
1
[124] and possibly haemopoietic stem cells. Of particular note was the fact that the r
most striking differences between the spontaneous proliferation of B6 ==> BDFi 
and DBA/2 => BDFi cells occurred on day 10, when there was a marked 
expansion of donor CD8+ T cells in the former group. Thus at this time in B6 =>
B D F l mice, the spontaneous response may be dominated by proliferating donor 
CD8+ T cells.
This was also the time after which mice with acute GvHD exhibited 
lymphoid involution, dramatically reduced lymphocyte numbers and suppressed 
proliferative responses. This association between destructive GvHD and the |
preferential expansion of donor CD8+ T cells during acute, but not chronic GvHD, 
has been described in numerous previous studies [24, 27-29, 31]. However, the 
role of CD8+ T cells in the consequences of acute GvHD is controversial. Acute
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SGvHD is critically dependent on the presence of donor CD8+ T cells in the donor 
inoculum [30] and the differences between acute and chronic GvHD have been 
attributed to the fact that DBA/2 mice have low numbers of CD8+ T cells and %
exhibit a particularly low anti-BDFi precursor CTL (pCTL) frequency compared
with mice of the B6 background [31]. Although my finding that CTL only 
appeared in acute GvHD was consistent with this idea, other studies suggest that 
this is unlikely to be the only factor accounting for the different capacities of 
DBA/2 and B6 CD8+ T cells to expand and elicit anti-host CTL activity in BDFi 
mice [130, 131]. In addition, as I discuss below, acute GvHD-associated tissue 
destruction is not always associated with anti-host CTL activity [24, 27, 83].
When T cell function was assessed by examining the ability of GvHD 
spleen cells to proliferate to the T cell mitogen Con A, 1 found that chronic GvHD 
mice showed normal Con A responses throughout the course of disease and no 
loss of function was evident. In contrast, cells from acute GvHD mice showed 
slightly elevated proliferation until day 4 and then rapidly lost responsiveness. 
This indicated that while the spontaneous response of acute GvHD cells was 
reaching a peak on days 7-10, the Con A response was already suppressed below 
control levels. This may be explained by the fact that in other in vitro assays of T 
cell function, previously activated T cells have been shown to undergo activation- 
induced cell death (or 'apoptosis’) when the TcR is crosslinked by polyclonal 
stimuli such as Con A [172]. Why a similar phenomenon was not observed when 
DBA/2 => BDFl cells were stimulated with Con A in vitro, was not clear, but may 
be related to the lower level of spontaneous proliferation exhibited by these cells. 
Enumeration of GvHD cells following Con A stimulation in vitro, or examining 
GvHD cultures for evidence of apoptosis would help confirm this possibility.
The loss of Con A responsiveness exhibited exclusively by B6 => BDFi 
mice has been described previously [51,71, 73, 84, 165] and has been attributed 
to various mechanisms including deletion of host reactive T cells [50], defective 
lymphopoiesis [51, 52, 173-175] and active suppression mediated by anti­
proliferative cytokines such as IFN-y [71, 73]. Although defining the interactions 
underlying immune deficiency was beyond the scope of this inital study, it was 
interesting to note from my results that elevated IFN-y production correlated with 
the abrogated Con A responses of B6 => BDFi cells in vitro (see below).
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However, the fact that during the latter stages of disease, reduced T cell numbers 
were recovered from B6 => BDFi spleens compared with either DBA/2 => BDFi 
or controls, may also indicate a role for T cell deletion in vivo. Recent studies in 
GvHD suggest that host-reactive T cells may be killed by apoptosis [50, 51] and 
that both Fas/Fas ligand and perforin-dependent cytotoxic pathways are involved 
in the disease [176]. However, TNF-a can also cause T cell apoptosis [177,178] 
in synergy with IFN-y [179]. Since both are produced preferentially during acute 
GvHD [41, 61], it is therefore also possible that a cytokine-mediated killing 
pathway may contribute to T cell deletion in B6 => BDFi mice.
■ I»
Role of Cytokines In Acute and Chronic GvHD
When 1 started this work, several studies had been published which 
indicated that distinct patterns of T cell-derived cytokines were produced during 
acute and chronic GvHD in BDFi mice [42,46]. These experiments showed that 
levels of Thl cytokines were elevated during acute GvHD [41-43, 54], while Th2 
cytokine production was preferentially associated with the chronic form of disease
-
[42,46, 47]. However, these studies did not determine when polarisation of the T 
cell response occurred and more importantly, did not attempt to correlate cytokine 
production with individual aspects of the diseases. A critical finding of Chapter 3 
was therefore that the pattern of cytokines produced by acute and chronic GvHD 
mice had already started to diverge within the first 2 days of GvHD and by day 
10, when the two diseases were distinct entities, they were also characterised by 
completely different cytokine profiles.
By day 2 and throughout the first 10 days of acute GvHD, B6 BDFi 
cells produced elevated IFN-y both spontaneously and in response to stimulation
Î
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with Con A in vitro. Spontaneous and Con A induced cytokine levels in vitro 
provide different information regarding production in vivo. While spontaneous 
cytokine production indicates active secretion in vivo, Con A induced production 
provides a measure of lymphocyte priming [44]. It was therefore notable that in
my experiments, IFN-y was the only cytokine which could be detected in
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unstimulated cultures, where it was produced exclusively by B6 => BDFi cells.
:■This is consistent with the observation of Troutt et al. that up to 70% of lymph
node cells from mice with acute GvHD contain IFN-y mRNA [54].
The elevated levels of IFN-y secretion were associated primarily with the 
early hyperplastic phase of systemic acute GvHD (days 0-10), an observation 
which has been confirmed in recent work by Rus et. al. [180]. Peak IFN-y levels 
in vitro were detected on day 10, which was when the acute GvHD progressed 
into the later destructive period of the disease. Together with the results of Chapter
8, these findings indicate a potential role for IFN-y in triggering the later 
pathological events characteristic of B6 => BDFi GvHD. Nevertheless, in 
common with production of other cytokines and the immune deficiency manifest
in B6 => BDFl mice, IFN-y was severely reduced late in acute GvHD.
Although IFN-y was the predominant cytokine secreted by B6 => BDFi 
cells, enhanced levels of IL-2 and IL-5 were also produced by Con A stimulated 
cells on day 2 of acute GvHD. The priming of these cytokines was lost rapidly 
however and after day 4, levels were either similar to, or below, control levels. 
The early and transient increase in Con A stimulated IL-2 production has been 
described previously by others [23, 45, 181] and, consistent with the role of IL-2 
as a T cell growth and survival factor [182], corresponded to the early activation 
and expansion of T cells in my study. In parallel, abrogated Con A induced IL-2 
levels occurred on day 7, when these cells began to show reduced Con A driven 
proliferative responses. Although these observations may be attributed to classical 
acute GvHD-associated immunosuppression, they are difficult to interpret 
definitively since it was also possible that increased IL-2 consumption by highly 
activated cells in vitro led to reduced IL-2 levels. This would be consistent with 
the fact that B6 => BDFi cells continued to show high levels of spontaneous
proliferation until day 10. Addition of soluble anti-IL-2 receptor (IL-2R) mAb to
<
GvHD cell cultures would help differentiate between reduced production vs 
increased production.
On days 2 and 4, B6 => BDFi cells produced enhanced levels of the Th2 
cytokine, IL-5, as well as the Thl cytokine, IFN-y when stimulated with Con A in 
vitro. This was an important finding as it suggested that early in the disease, the 
immune response of B6 => BDFi mice was not completely polarised towards a 
T hl phenotype. IL-5 priming was lost from day 7 onwards, at the time when 
IFN-y levels were maximal, suggesting that the production of these cytokines is 
coordinately regulated in established acute GvHD. This is consistent with current
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views of Thl/Th2 cell development [132] and my later findings that neutralising 
IFN-y in vivo increased IL-5 levels during the early period of B6 => BDFi GvHD 
supports the view that the high levels of IFN-y actively suppress Th2 responses in
these mice. Despite the increase in IL-5 in acute GvHD, I did not find priming of 
the other Th2-associated cytokines IL-10 and IL-4. Although studies published 
when I was carrying out my research reported elevated levels of IL-4 mRNA in 
acute GvHD [180], these workers were also unable to detect IL-4 cytokine 
product in vitro. This may reflect rapid in vitro consumption of transiently 
produced cytokine [183, 184], and/or the relative insensitivity of the assays 
employed.
In contrast to the Thl-dominated response found in acute GvHD, a more 
mixed pattern of cytokine production was seen during the initial phase of chronic 
GvHD. Although there was no spontaneous production of any cytokine by DBA/2 
=s> BDFl cells at any time, from day 4 onwards, these cells were primed to 
produce high levels of IL-2, IL-5 and IL-10 when stimulated with Con A in vitro. 
In addition, there was some priming of IFN-y production in the first 16 days of 
chronic GvHD, although the levels were markedly lower than those associated 
with the acute disease. Thus, the cytokine response of chronic GvHD mice was 
not completely polarised towards a Th2 phenotype at this time. However, it 
should be noted that the level of IFN-y priming exhibited by DBA/2 => BDFi cells
f
was considerably lower than that shown by B6 => BDFi cells, and clearly 
insufficient to provoke the immunosuppression and destructive pathology
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associated with acute Thl-mediated GvHD.
In parallel with the persistent lymphoid stimulation in DBA/2 => BDFi 
mice, cells from these mice were primed to produce enhanced levels of IL-2 when 
stimulated with Con A in vitro at all time points. This contrasts with the 
suppressed IL-2 production in B6 => BDFi mice and correlated with my finding 
that the Con A induced proliferative response of chronic GvHD mice was normal 
at all time points examined. Furthermore, this is consistent with IL-2 being a 
product of precursor Th cells, rather than Thl cells [132].
The chronically elevated levels of the Th2 cytokines IL-5 and IL-10 
correlated with the persistent B cell activation and increased imunoglobulin levels 
which I observed in DBA/2 => BDFi mice. However, once again, I was unable to 
detect any IL-4. This was somewhat surprising given that Th2 responses are 
critically dependent on the presence of IL-4 [134, 135, 141] and appears to 
contrast with studies showing that the high levels of serum immunoglobulin, 
elevated proteinuria and death observed during chronic GvHD can be reduced by 
anti-IL-4 antibody in vivo [48,128]. Although others have also been unable to 
detect IL-4 production in chronic GvHD cultures using ELISA [180], the
upregulation of MHC class II on chronic GvHD spleen cells has been shown to be 
IL-4-dependent [46]. I decided to examine cytokine protein production rather than 
mRNA, since mRNA expression does not necessarily correlate with secretion. 
However, my results show that ELISA may not be the most appropriate means of 
assessing IL-4 production in vivo, and in future studies, I would utilise alternative 
detection systems such as ELISPOT, immunohistochemistry, or intracellular 
cytokine staining to detect IL-4.
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B Cell Activation in GvHD
Between days 1-10 of GvHD, I found that spleen cells from both B6 =>
BDFl mid DBA/2 => BDFi mice exhibited enhanced responsiveness to the B cell 
mitogen, LPS. At this time, both groups of mice also showed markedly increased 
levels of serum IgG and exhibited anti-ds DNA antibodies. From these results, B 
cell activation appeared to be an event common to the early period of both forms of 
disease, in agreement with studies showing that host B cell numbers initially 
increased in the lymphoid tissue of both acute and chronic GvHD mice [23]. After
.. iday 10, however, I found that B cell function in acute and chronic GvHD mice
•Idiffered dramatically. The LPS response of B6 => BDFi cells was virtually absent 
by day 14, as were levels of serum IgG and anti-ds DNA antibodies.
Furthermore, there was no evidence of oedema or antibody-mediated kidney 
pathology in the few long-term surviving B6 => BDFi mice, consistent with 
previous reports [33]. Thus the brief B cell hyperplasia in these mice was 
insufficient to provoke ICGN. In contrast, the hyperresponsiveness of DBA/2 =>
BD Fl cells to LPS persisted for the duration of the study, their serum 
immunoglobulin levels continued to increase and several of these mice developed 
oedema and died from ICGN.
The reason why B cell activation and antibody production persisted during
■chronic GvHD, yet declined after day 10 of the acute disease, is the subject of 
much debate. Early studies showed that the B cell population of DBA/2 => BDFi 
mice continued to expand, whereas host B cell numbers were dramatically reduced 
during the latter stages of acute GvHD. This removes the source of pathogenic 
antibodies and risk of autoimmunity [23,31]. Because anti-host CTL activity was 
readily detectable in B6 => BDFi mice, but not DBA/2 => BDFi mice at this time, 
it was assumed that CTL destroyed B cells during acute GvHD. In agreement with 
this, I found that the onset of B cell suppression coincided with expansion of 
CD8+ T cells during acute GvHD. However, it is also possible that the loss of B 
cell function during acute GvHD reflected the polarised cytokine response. It is
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now well established that while Th2 cytokines support the development of 
humoral immunity, Thl cytokines actively inhibit antibody responses by reducing 
priming for Th2 cytokine production [132,1851. Thus, the persistently high levels 
of IL-5 and IL-10 found in chronic GvHD correlated with B cell hyperplasia and
-
immunoglobulin production. In contrast, although acute GvHD mice initially 
showed B cell hyperplasia and enhanced production of IL-5, B cell function and 
priming for IL-5 was lost when IFN-y levels became maximal. The kinetics of 
these events suggests that IFN-y plays a role in suppressing B cell responses 
during B6 => BDFi GvHD. Further support for IFN-y as a regulator of B cell 
responses during GvHD is provided by the work of Umland et ai which shows 
that elevated serum IgG and IgE, proteinuria and death from chronic GvHD can be 
reduced by exogenous IFN-y [128]. Although my later results showed that 
neutralising either IL-12 or IFN-y had little effect on the reduced LPS responses of 
B6 => BDFl mice, the possibility of incomplete cytokine neutralisation cannot be 
excluded. Therefore, whether CTL, or cytokines such as IFN-y and TN F-a 
mediate B cell death in acute GvHD could be addressed directly by examining the 
effect of using either IFN-y gene Knockout (KO) mice as a source of donor cells, 
or inducing GvHD in IFN-y or TNF-a receptor KO recipients.
Therefore this initial study confirmed previous reports that differential 
activation of CD4+ Th subsets may mediate the distinct systemic features of acute 
and chronic GvHD [42, 46]. However, I also found that the polarisation of the 
cytokine response occurred very rapidly after transfer of donor cells and I went on 
to examine how this might occur.
1
THE ROLE OF IL-12 IN GvHD
As IL-12 has been shown to be important in regulating Thl/Th2 cell
.development, I focused on its role in polarising GvHD. In my first series of 
experiments, I examined the effect of a single dose of neutralising anti-IL-12 
polyclonal antibody given one day before induction of acute and chronic GvHD.
inflammatory cells [58], reduced early priming for IFN-y may be responsible for
The rationale for this limited treatment period was that in a variety of systems, Th 
cell responses could be modified by manipulating the cytokine environment in 
which initial priming occurs [78, 82, 134, 135, 164]. My results indicated that 
although early depletion of IL-12 reduced the intensity of the initial period of acute 
GvHD, it did not affect subsequent disease progression.
Acute GvHD
A single injection of anti-IL-12 antibody reduced the splenomegaly, 
elevated NK cell activity and enhanced spontaneous and mitogenic responses 
observed on day 2 of acute GvHD. It also dramatically reduced the early priming 
of IFN-y and IL-2 on day 2 of disease and increased priming of the Th2 cytokine 
IL-10. These effects were all consistent with the role of IL-12 as an enhancer of 
NK cell-mediated cytotoxicity [118, 120, 121, 150] and with its ability to induce 
IFN-y production by T and NK cells [121, 151]. However, the reason why anti- 
IL-12 reduced the early splenomegaly in B6 =» BDFi mice was less clear and may 
be related to the down-regulated IFN-y levels observed in antibody treated mice.
Since IFN-y plays an important role in the recruitment and activation of
lowering the level of splenomegaly. This hypothesis was supported by my studies 
on the role of IFN-y in acute GvHD (Chapter 8), which showed that the IL-12 
induced increase in splenomegaly during GvHD in DBA/2 => BDFi mice, could 
be reduced by coadministration of neutralising anti-IFN-y antibody. Furthermore, 
in the present study, when IFN-y priming subsequently returned in anti-IL-12 
treated B6 BDFi mice on day 10, a simultaneous increase in spleen size was 
observed. Alternatively, since a noted biological effect of IL-12 in vivo is to 
provoke extramedullary haemopoiesis in the liver and spleen, resulting in 
splenomegaly [121], anti-IL-12 may inhibit this effect during acute GvHD.
Despite these findings early in disease, the effects of anti-IL-12 had
■
disappeared by day 10. This was unexpected as IL-12 is usually held to be critical
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for the permanent differentiation of Thl-type responses from uncommitted 
precursor CD4 T cells [78, 186]. The most likely explanation for my results is 
that the temporal window for Th cell phenotype comittment in acute GvHD 
exceeded the pêriod of IL-12 neutralisation afforded by antibody treatment. I 
therefore went on to examine whether repeated administration of anti-IL-12 during 
the first week of acute GvHD had a more dramatic effect on disease progression.
Administration of anti-IL-12 to B6 => BDFi mice until day 8 after donor cell 
transfer not only down-regulated several of the early proliferative features of acute 
GvHD, but also produced a marked reduction in the later pathological 
consequences of the disease. As with mice given a single injection of anti-IL-12, 
these mice had reduced levels of NK cell activity, IFN-y production and 
splenomegaly compared with unmanipulated B6 => BDFi mice early in disease.
However, anti-IL-12 had no effect on spontaneous proliferation and the degree of 
splenomegaly was unaltered after day 10, suggesting that anti-IL-12 may have 
prolonged the prolferative phase of disease. This was supported by the fact that 
anti-IL-12 treated mice did not show the lymphoid involution and reduced 
spontaneous and Con A proliferative responses evident in unmodified acute 
GvHD mice during the latter stages of disease.
Mice surviving after repeated neutralisation of IL-12 had consistently 
reduced IFN-y production and increased IL-10 and IL-5 levels both at the early 
time points and later in the study. This contrasted with the temporary effects of a 
single injection of anti-IL-12 and indicates that the presence of IL-12 is required 
throughout the first week of disease for maximal production of IFN-y. Some IFN- 
y production remained in mice given anti-IL-12 repeatedly, although it was not 
clear if this reflected IL-12-independent IFN-y, or the transience of the antibody 
effect. Although the residual levels of IFN-y were insufficient to provoke lethal 
pathology, they may explain why these mice retained some of the proliferative 
alterations of acute GvHD.
I
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.Anti-IL-12 treatment prevented weight loss and mortality for up to 18 
weeks and permitted full repopulation with donor B6 lymphocytes. However, 
engraftment of donor CD4+ T cells appeared to occur more gradually in anti-IL-12 
treated B6 =» BDFi mice than in unmodified GvHD mice. This was particularly 
evident on day 70 of the GvHD, when only 30% of the CD4+ T cell population in 
anti-IL-12 treated GvHD mice was donor-derived, compared with 96% in 
unmodified B6 => BDFi animals. Since IL-12 synergises with cytokines such as 
IL-3 and steel factor to stimulate the proliferation and differentiation of early 
lymphohaemopoietic progenitors [187,188], blockade of IL-12 may have reduced 
the rate of donor stem cell haemopoiesis and therefore slowed down the 
repopulation process. However, anti-IL-12 did not adversely affect repopulation 
by donor CD8+ T cells and both T cell compartments were fully replaced by 
donor-derived cells by day 130. Complete repopulation of the recipient immune 
system by donor cells in the absence of overt pathology would be consistent with 
the development of tolerance to host alloantigen, as previously described in 
survivors of acute GvHD [33, 52]. This explanation seems more likely than the 
alternative possibility that there was complete destruction of host MHC expressing 
tissues, as anti-IL-12 treated mice did not display major pathology at any time.
However, it would have been interesting to determine directly whether the T cells 
which had repopulated anti-IL-12 treated B6 => BDFi mice were tolerant to Fi
:alloantigen in the long-term by examining the ability of T cells from these mice to 
respond to BDFi stimulator cells in an MLR in vitro. Nevertheless, the fact that 
chimeric mice had normal proliferative responses to Con A and did not succumb to 
opportunistic infections while housed in standard animal house conditions, shows 
that short-term IL-12 blockade allows full and long-term recovery of immune 
function.
Despite inhibiting the lethal outcome of the disease, anti-IL-12 was unable 
to significantly reverse the suppressed B cell responses or reduce the anti-host 
CTL activity normally found in B6 => BDFi mice. These findings may be related.
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as others have suggested that the profound B cell immune deficiency during acute 
GvHD is at least partially due to CTL-mediated destruction of host B cells [23, 
31]. My results also indicate that the mechanisms of B and T cell suppression 
during acute GvHD may be distinct, since IL-12-dependent Thl cytokines appear 
to be important in abrogating T cell responses, but are less involved in B cell 
suppression. Similar results have been obtained by others [71] and are consistent 
with the more dramatic effect of anti-IFN-y mAb on T cell function, compared 
with B cell function, I found in Chapter 8. My observation that anti-IL-12 treated 
B6 ==> BDFl mice survived in the presence of high levels of specific cytotoxic 
activity also raises important questions about the mechanisms of tissue pathology 
and mortality in acute GvHD, as previous reports have suggested that mortality in 
B6 => BDFl mice is dependent on activation of CD8+ anti-host CTL [31]. 
Instead, my results agree with studies in which there was no correlation between 
anti-host CTL activity and mortality or intestinal damage in acute GvHD [24, 27, 
83] and suggest that anti-IL-12 may prevent immunopathology by down- 
regulating IFN-y production and/or by promoting preservation of T lymphocyte 
function in these animals, hence reducing their susceptibility to secondary 
infections. Furthermore, although exogenous IL-12 facilitates antigen-specific 
CTL responses in normal mice [121], the results of my study showed that IL-12 
was not essential for anti-host cytotoxicity during acute GvHD. The fact that IL-12 
KG mice have also recently been reported to mount normal allogeneic CTL 
responses [189], supports my finding that IL-12 is not critical for this aspect of 
cell-mediated immunity.
The reduced levels of IFN-y and increased IL-10 and IL-5 production 
observed in anti-IL-12 treated B6 => BDFi mice, suggested that anti-IL-12 may be 
mediating its protective effect during acute GvHD by polarising the CD4+ 
alloresponse towards a Th2 phenotype, similar to that observed during chronic, 
autoimmune GvHD. Furthermore, despite a limited capacity to reverse the 
suppressed LPS responses of B6 => BDFi mice early in acute GvHD, anti-IL-12
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;treated B6 => BDFi mice then had enhanced LPS responses in the longer term. 
Previous reports showed that mice which recover from unmodified acute GvHD 
develop a mild stimulatory disorder termed "secondary chronic GvHD", which is 
characterised by a degree of lymphoid stimulation and autoantibody production 
[28, 58]. Taken together, these observations raised the possibility that anti-IL-12 
treated long-term survivors might develop the B cell hyperreactivity and antibody- 
mediated kidney pathology associated with chronic GvHD. Although my anti-IL- 
12 treated mice had mildly elevated total serum IgG and IgE, these levels were 
severalfold lower than those associated with chronic GvHD in DBA/2 BDFi 
mice. Anti-IL-12 treated animals also remained healthy and neither light nor 
electron microscopy revealed evidence of the antibody-mediated renal pathology 
apparent in mice with chronic GvHD. The heightened response of B cells from 
anti-IL-12 treated animals when stimulated in vitro with LPS may therefore simply 
reflect the fact that these cells were resident in a milieu rich in Th2 cytokines and 
were therefore primed to respond avidly to B cell mitogens. However, this was 
clearly insufficient to provoke the consequences of a classical chronic GvHD in 
vivo. This may be because the anti-IL-12 treated acute GvHD mice had full donor 
chimerism, whereas in DBA/2 => BDFi mice there is persistence of host B cells 
and other lymphohaemopoietic cells. Allorecognition of host B cells by donor 
CD4+ T cells thus stimulates polyclonal B cell activation and the production of 
high levels of autoantibodies [39, 124, 126]. Although I did not confirm the 
absence of host B cells directly by assessing MHC expression on B cells in 
surviving anti-IL-12 treated B6 ==> BDFi mice, studies in unmodified B6 => BDFi 
mice show that newly generated donor-derived B cells appear in the spleens of 
recovering unmodified B6 ==> BDFi mice after 6-8 weeks and replace host cells 
[51].
In conclusion, the results from this study demonstrated that IL-12 
blockade is an effective therapy for murine acute GvHD. Anti-IL-12 antibody 
prevented lethal immunopathology whilst allowing the survival of sufficient
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donor-derived haemopoetic cells to permit full repopulation of the host by a 
functioning immune system. Although anti-IL-12 therapy prevented T hl- 
dependent lethality by permanently polarising the alloimmune response towards a 
Th2 phenotype, this did not result in the development of chronic GvHD-associated 
glomerulonephritis. In future studies, it would be important to directly assess the 
role of IL-12 in GvHD target organs such as the small intestine, liver and bone 
marrow by histological examination. In addition, since TNF-a causes cachexia 
during acute GvHD [65], IL-12 could indirectly enhance TNF-a release from 
activated m<j)S by increasing IFN-y levels. Whether increased serum TNF-a levels 
paralleled the increased weight loss and death in IL-12 treated B6 => BDFi mice 
would again be a subject for future studies.
Further support for the central role of IL-12 during acute GvHD was that 
administration of exogenous IL-12 exacerbated virtually all of the features of the 
systemic disease. Thus, IL-12 increased the level of splenomegaly and NK cell 
activity early in the disease and accelerated the onset of immunosuppression, 
weight loss and mortality found in established GvHD. One rather surprising effect 
of exogenous IL-12 was that it increased IL-10 levels in B6 => BDFi mice. Since 
IL-10 is a product of Th2 cells [53, 190, 191] and was initially defined as an 
inhibitor of Thl responses [192, 193] this result was difficult to explain. However 
others have also shown that i.p. injection of IL-12 can cause increased IL-10 gene 
expression [163, 194, 195] and have suggested that this serves as a homeostatic 
function to control an excessive Thl response. IL-12 did not increase either IFN-y 
production or CTL activity in B6 => BDFi mice, possibly because these responses 
were already maximal and the peaks may already have passed.
Chronic GvHD
In contrast to my findings in acute GvHD, neutralising IL-12 had little 
effect on the early phase of chronic GvHD. However, it did slightly augment 
several of the Th2-mediated aspects of the disease in the long-term. Thus, anti-IL-
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12 caused a further increase in the elevated serum IgE levels observed in treated 
DBA/2 => BDFl mice and increased the overall mortality rate associated with the 
chronic disease. In addition, the characteristic decline in serum IgG levels 
observed during the late stages of chronic GvHD, occurred more rapidly in anti- 
IL-12 treated DBA/2 => BDFi mice than in similar untreated animals. The ability 
of IL-12 to regulate Th2 responses has also been described in murine models of 
candidiasis, schistosomiasis, and toxoplasmosis [79, 152, 153, 194-196]. 
However, since others have shown that anti-IFN-y antibody also decreased serum 
immunoglobulin levels during chronic GvHD [128], anti-IL-12 may act indirectly 
to reduce Th2 cytokines via IFN-y down-regulation.
Administration of exogenous IL-12 induced an acute GvHD in DBA/2 = >  
BDFl mice identical to that found normally in B6 ==> BDFi recipients, with a
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characteristic biphasic pattern of early hyperplasia progressing to activation of 
CTL, immunosuppression and death. Furthermore, IL-12 converted the Th2 
cytokine profile associated with chronic GvHD into a Thl dominated response. 
The systemic disease provoked in DBA/2 BDFi mice given IL-12 was more 
aggressive than that observed in B6 => BDFi animals, with earlier and higher 
mortality rates. This may have reflected the effect of giving repeated high doses of 
exogenous IL-12, as opposed to the possibly lower, physiological levels induced 
in unmanipulated B6 => BDFi mice. However, it is important to note that the dose 
of IL-121 used was not toxic per se in control mice. One aspect of acute GvHD
I
not induced in DBA/2 => BDFi mice by IL-12 was enhanced NK cell activity on 
day 1. This was surprising in view of the reported stimulatory effect of IL-12 on
NK cell-mediated cytotoxicity [121]. The dose of IL-12 used was also insufficient 
to induce more than a slight increase in NK cell activity in either B6 BDFi or 
normal mice at this time, suggesting that the wrong time point was examined and 
more kinetic studies are indicated. The ability of exogenous IL-12 to elicit high 
levels of anti-host CTL activity in DBA/2 => BDFi mice contrasted with my own 
and other findings [189] that endogenous IL-12 is not required for allogeneic CTL
I
responses. Again, this may reflect differences between administration of
cell types produce IFN-y in response to IL-12 [121, 151]. As discussed above, I 
did not observe an increase in NK cell mediated cytotoxicity in IL-12 treated
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ÎIpharmacological doses of IL-12 vs the physiological function of the cytokine.The acute GvHD induced in IL-12 treated DBA/2 => BDFi mice was, as 
expected, accompanied by a shift in the cytokine profile from a Th2 to a Thl 
phenotype, with extremely high levels of IFN-y production. A similar switch in 
cytokine pattern has been observed in other models of Th2 immunity modified by 
exogenous IL-12 [81, 194-196]. In DBA/2 => BDFi GvHD, this could reflect the 3#
S t im u la to r y  e f f e c t  o f  IL-12 o n  CD4+, CD8+ a n d /o r  NK c e l l s ,  s i n c e  e a c h  o f  t h e s e
DBA/2 => BDFl mice, suggesting that, at least on day 1 of GvHD, NK cells were 
not the source of the IL-12-induced IFN-y. However, it was important to note that 
on day 1, while IL-12 had a pronounced effect on spontaneous IFN-y levels in 
DBA/2 => BDFl mice. Con A induced IFN-y production was not significantly 
increased. A possible explanation for this was that T cells were not yet primed to 
produce increased IFN-y on day 1 of disease and a non-T cell was the main source 
of the cytokine at this time.
The differential role of IL-12 in acute and chronic GvHD was supported 
by the finding that although spleen cells from both groups produced enhanced 
levels of IL-12 p75 heterodimer when stimulated in vitro with LPS, this 
continued to increase for up to 10 days only in B6 => BDFi mice. The kinetics of 
IL-12 priming in GvHD thus closely resembled those of IFN-y production. I
Although I did not determine the source of IL-12 during the course of these 
studies, the main IL-12-producing cells in vivo are believed to be m<j)S [76, 122,
152], although other AFC types are emerging as alternative IL-12 producers e.g.
B cells and DCs [118, 158, 197]. It will therefore be very important for future 
studies to explore the source of IL-12 in acute GvHD using either 
immunohistochemistry, or by enriching different cell populations and examining 
their IL-12-producing potential. Furthermore, the relative contribution of host and
' 1
donor-derived cells to IL-12 production could be assessed in vivo by utilising 
appropriate combinations of IL-12 deficient and wild-type host and donor animals. 
Since both foims of GvHD are initiated by recognition of alloantigen,
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presumably expressed on the same host APC, the similar levels of IL-12 produced 
initially during acute and chronic GvHD were not surprising. The difference in the 
persistence of IL-12 production may therefore be secondary to differences in T cell 
IL-12 responsiveness between the two donor strains, as has been suggested in
Î
studies of genetic susceptibility to L. major infection in BALB/c and B10.D2 mice 
[139, 140, 198]. Here, T cells from the two strains are equally capable of 
initiating antigen specific T hl responses, but BALB/c T cells become 
unresponsive to IL-12 and acquire a Th2 phenotype, whereas B10.D2 T cells 
maintain IL-12 responsiveness and produce the IFN-y required for eliminating the 
parasite. The Th2 phenotype default which BALB/c mice exhibit can also be 
reversed by early administration of rm IL-12 [80,82,139]. Whether T cells from 
DBA/2 and B6 mice also have intrinsic differences in their ability to sustain IL-12 
responsiveness to BDFi alloantigen has not been investigated directly. There are, 
however, a number of pieces of circumstantial evidence which suggest that a 
similar genetic bias could be operative during BDFi GvHD. Firstly, it is known 
that DBA/2 mice preferentially elicit Th2-type responses [79, 140, 199], while B6 
mice are biased towards making Thl responses to a variety of stimuli [200, 201]. 
In addition, an inability to retain IL-12 responses would explain why DBA/2 => 
BDFl mice did not produce high levels of IFN-^, despite exhibiting some early 
IL-12 production. A disparity at the level of the donor T cells is also supported by 
studies which have attributed the dichotomy between acute and chronic GvHD in 
BDFl mice to differences in the ability of the donor CD8+ T cells to engraft and
generate CTL responses [23, 31]. Although my results show that CTL activity 
itself does not appear to be responsible for the lethal consequences of acute
GvHD, other aspects of CD8+ T cell function, such as IFN-y production, may 
also differ between B6 and DBA/2 mice and could be a manifestation of inherent
differences in the ability of these T cells to respond to IL-12. A final similarity 
between the BDFi model of GvHD and susceptibility to L. major is that the 
putative default Th2 response exhibited by BALB/c mice (in the case of L. major) 
and DBA/2 donor cells (in GvHD) could be overcome when rm IL-12 is given at 
the time of antigen contact, but not if IL-12 treatment was delayed [81, 82, 139, 
166].
If time had allowed, it would have been interesting to further examine the 
genetic basis for Th subset development during BDFi GvHD. T cells from B6 and 
DBA/2 mice could be analysed directly to determine whether they are genetically 
predisposed to mount preferential Thl and Th2 responses to in vitro stimulation 
with BDFl alloantigen respectively. In addition, the hypothesis that B6 and 
DBA/2 donor cells show differential responsiveness to IL-12 could be tested using 
a similar system as that utilised by Guler et al [139], in which T cells were 
stimulated with antigen for several days under neutral conditions in vitro and then 
restimulated in the presence or absence of IL-12. T cells which retained IL-12 
responsiveness during primary culture were thus primed to produce high levels of 
IFN-y when restimulated, whereas cells which lost IL-12 responsiveness did not 
show such priming.
My finding that IL-12 plays a pathological role in acute GvHD contrasts 
with recent work which shows that anti-IL-12 treatment can actually reverse the 
protective effect of combined CD80 and CD86 blockade in irradiated mice with 
acute GvHD [202]. However, this study used irradiated mice and the requirement 
for IL-12 in haemopoiesis [188, 203] may conflict with its enhancing effect on 
Thl-mediated immunopathology. Furthermore, the blockade of costimulatory 
pathways may exaggerate any immunosuppressive effect of anti-IL-12 in these 
mice. Others have also suggested that IL-12 was protective during certain models 
of GvHD [204]. Thus, a single, high dose injection of IL-12 was found to inhibit 
GvHD in lethally irradiated mice receiving allogeneic bone marrow. Although the 
mechanism of protection was not defined, it was suggested that this dose of IL-12
24 0
may exhaust host-reactive CD8+ T cells and induce their deletion. A similar IL-12- 
induced phenomenon has also been described in murine viral models [205]. Why
lower doses of IL-12, as used in my studies may not lead to clonal deletion and its 
associated protection. Dose-response studies of IL-12 effects in B6 => BDFi mice 
would help address this possibility. However, most reports support my
potential therapeutic use of IL-12 blockade would therefore be to prevent Thl-
ROLE OF IFN-y IN XL-12-DEPENDENT ACUTE GvHD
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IL-12 did not similarly ameliorate acute GvHD in B6 => BDFi mice is unclear, 
although one possible critical difference may be the different dosing protocols
;Utilised in my experiments compared to those of Sykes et al [204]. Thus, repeated,
demonstration that Thl cytokines, such as IFN-y, play a pathogenic role in B6 =>
BDFi mice [55, 57, 180]. Furthermore, as in the studies by Saito et al described 
above [202], in irradiated models, the requirement for IL-12 in haemopoiesis 
[188, 203] may be greater than in unirradiated mice. An important concept for the
mediated pathology, without preventing donor BM engraftment.
Î
The principal role of IL-12 is to regulate IFN-y production [123, 147] and 
the effects of anti-IL-12/rm IL-12 were paralleled by changes in IFN-y production. 
However, it is currently controversial as to how much of the effects of IL-12 in 
immune responses are secondary to IFN-y. I therefore examined the effects of I!.a
neutralising IFN-y both during IL-12-dependent acute GvHD in B6 => BDFi mice 
and in IL-12 treated DBA/2 => BDFi mice with acute GvHD. My results showed 
that IFN-y played a significant role in many of the characteristic features of acute 
GvHD, including splenomegaly, immunosuppression, lymphoid involution, 
weight loss and mortality. Furthermore, IFN-y appeared to be involved in the 
regulation of the cytokine response during acute GvHD.
Overall, anti-IFN^ mAh treatment had similar beneficial effects on both 
forms of GvHD and the results supported a role for IFN-y both during the early 
proliferative phase and also later, when tissue destruction, weight loss and
I
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mortality were evident. In both models, anti-IFN-y mAb ameliorated the acute 
GvHD without reducing anti-host CTL activity, further indicating that CTL 
activity does not necessarily correlate with mortality. One difference between the 
effects of anti-IFN-y on the two models of acute GvHD, was that anti-IFN-y 
reduced the level of T cell suppression in unmodified B6 =>BDFi mice, but not in 
IL-12 treated DBA/2 =>BDFi mice. This may be because IL-12 treated DBA/2 => 
BDFi mice have a more aggressive GvHD, with higher mortality and IFN-y 
production. In addition, others have reported that immunosuppression in B6 => 
BDFi mice with acute GvHD may not be solely due to IFN-y and may also 
involve other factors such as TGF-p [71, 73], or deletion of host-reactive 
lymphocytes [50] and deficient lymphopoiesis [173-175]. These additional factors 
may therefore be more important in IL-12 treated DBA/2 ==>BDFi mice.
An interesting finding was that neutralisation of IFN-y in vivo did not 
reduce the stimulation of IFN-y production by GvHD. Indeed, IFN-y levels may 
even have been increased. This may reflect a compensatory mechanism activated 
in the absence of biologically active IFN-y, since similar over-production of IFN-y 
is observed in mice which are defective in the gene coding for the IFN-y cytokine 
receptor [206]. In addition, these findings suggest that the IL-12 induced IFN-y 
production during acute GvHD does not require endogenous IFN-y. This is in 
agreement with other in vitro [78] and in vivo [163,164] studies of Th phenotype 
development, which have demonstrated that IL-12 exerts its effects directly on T 
cells. However, this contrasts with the findings of other recent in vitro and in vivo 
studies suggesting that significant IL-12 production requires priming of m<|)s by 
IFN-y [148, 160]. The possibility that the antibody did not competely neutralise 
IFN-y in vivo cannot be excluded, however, and studies using either IFN-y 
receptor or gene knockout mice would help to rule this out.
Despite exerting little influence over Thl cytokine production, anti-IFN-y 
mAh treatment dramatically increased priming for IL-5 production by acute GvHD 
cells, suggesting that IFN-y directly regulates IL-5 production during the disease.
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This finding is consistent with recent work showing that IFN-y directly inhibits 
Th2 cytokine production [162, 163, 194, 196]. Whether IFN-y exerted a similar 
regulatory influence over production of the other Th2 cytokine, IL-10, was less 
clear from my studies. IL-10 production by B6 => BDFi cells was below the 
level of detection and although anti-IFN-y increased IL-10 production by IL-12 
treated DBA/2 => BDFi cells on day 2, a similar effect was not evident on day 10, 
when biologically active IFN-y would presumably be present.
Overall, I found that the effects of neutralising IFN-y and IL-12 were very 
similar. Both treatments prevented the weight loss and mortality observed during 
the first 3 weeks of acute GvHD and prolonged the early proliferative features of 
disease. In addition, both anti-IFN-y and anti-IL-12 treatment reduced the T cell 
immunosuppression observed late in the acute disease, although there was a less 
marked effect on the abrogated B cell responses in GvHD mice. Despite these 
effects, both antibodies failed to reduce the high levels of anti-host CTL activity. 
Anti-IL-12 and anti-IFN-y also increased the levels of IL-5 and IL-10 production. 
A final critical finding was that although DBA/2 => BDFi mice given IL-12 and 
anti-IFN-y showed increased levels of Th2 cytokine production, they did not 
exhibit any of the symptoms of classical chronic GvHD. Thus, I found IL-12- 
mediated inhibition of chronic GvHD-associated autoimmunity to be IFN-y- 
independent, in agreement with other recent studies [166]. As in anti-IL-12 treated 
B6 => BDFi mice with acute GvHD, this may be because anti-IFN-y treated 
DBA/2 => BDFi mice given IL-12 retained anti-host CTL activity which could 
destroy host B cells. In support of this, others recently showed that DBA/2 => 
BDFI mice given IL-12 and anti-IFN-y mAh had profoundly reduced B cell 
numbers [166].
Taken together, my results show that many of the effects of IL-12 in 
GvHD are IFN-y dependent including; lymphoid involution, T cell immune 
deficiency, regulation of Th2 cytokine production, weight loss and mortality,
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whereas others, such as CTL activity, induction of IFN-y production and possibly 
B cell destruction/suppression are IFN-y-independent.
CELLULAR SOURCE OF CYTOKINES DURING GvHD
An important finding of my T cell subset depletion studies was that since 
depletion of CD4+ or CDS*- T cells did not affect the eaily spontaneous IFN-y 
production by B6 => BDFi cells, it appeared to be non-T cell-derived. NK cells 
are an important source of IFN-y early during other T cell-dependent immune 
responses [112-114, 152, 153]. However, when I examined whether NK cells 
were involved in IFN-y production during acute GvHD, I found that NK cell 
depletion did not affect either spontaneous or Con A induced IFN-y production at 
any time during the disease. However, this work needs to be repeated as control 
mice given either NRS or anti-ASGM-1 produced uncharacteristically high levels 
of spontaneous IFN-y on day 2 of this study. Furthermore, the dose of anti- 
ASGM-1 used to deplete NK cells did not completely inhibit NK cell activity in 
B6 => BDFi mice, making it impossible to exclude NK cells as IFN-y producers 
in acute GvHD.
A more complex picture was found at the later time points in the acute 
disease, when I could not identify any single population that was responsible for 
IFN-y production. Both CD4+ and CD8+ T cells and possibly non-T cell 
populations all appeared to contribute to the high levels of spontaneous and Con A 
induced IFN-y at different times, in agreement with studies which highlight the 
potential of each of these cell types to produce IFN-y [53, 86, 87, 180, 207]. 
CD4+ and CD8+ T cells also contributed to the lower levels of Con A induced 
IFN-y which were found in chronic GvHD,
CD4+ T cells appeared to be the main source of IL-2, IL-10 and IL-5 
during both acute and chronic GvHD, although there were a few exceptions. On 
day 2 of chronic GvHD, for example, CD8 depletion also reduced IL-2 levels, 
presumably because the highly activated CD4+ T cells in these cultures were
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utilising IL-2. Furthermore, on day 14 of both acute and chronic forms of disease, 
neither CD4+ nor CD8+ T cells appeared to be responsible for IL-10 production.
An alternative source of IL-10 are activated m<()s [190,191, 208]. IL-10 was only 
induced in Con A stimulated cultures and m<j)s would not be expected to respond
■directly to a T cell mitogen. However it is possible that m<|)S were activated 
secondary to T cell stimulation with Con A. Some IL-10 production during 
chronic GvHD also appeared to be CD8+ T cell-derived, IL-lO-producing CD8+ T 
cells have been described in other systems [94] and since IL-10 inhibits Thl 
differentiation [192, 193], this may be important to the preferential Th2 response 
in DBA/2 =>BDF% mice. Paradoxically, there was also evidence that CD8+ T cells 
were responsible for down-regulating IL-10 levels during chronic GvHD, since
i
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on day 10, CD8+T cell depletion caused a severalfold increase in IL-10. Depleting 
CD8+ cells also increased IL-10 levels in B6 => BDFi cultures at all times during
the disease. Similarly, CD8 depletion revealed some IL-5 production on day 2 of 
acute GvHD. These observations raised the possibility that CD8+ T cells down- 
regulated Th2 cytokine production during acute GvHD. A similar phenomenon 
has been observed in other experimental systems in which CD8+ T cells inhibited 
Th2 development [87,209, 210], at least in part through their production of IFN-y 
[87, 210]. This was also consistent with my own and other [180, 207] findings 
that CD8+ T cells were primed to produce IFN-y production during acute GvHD. 
The absence of IFN-y-mediated inhibition of Th2 cytokine production by CD8+ T 
cells could explain the uncontrolled Th2 response in chronic GvHD. Also, recent
i:
studies have demonstrated that BDFi mice given DBA/2 donor cells which had 
been enriched with either total T lymphocytes [211] or purified CD8+ T cells [180] 
developed features typical of acute GvHD, together with a small increase in IFN-y 
levels [180].
The results detailed above indicated that cytokines produced by both CD4+
and CD8+ T cells may be important in determining the outcome of GvHD. 
However, the pattern was very complex and negative depletion may not be the
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ideal wasy to assess the source of cytokines. If time had allowed, I would 
therefore have used alternative strategies to determine the cell types involved. 
Positively selecting individual cell populations using magnetic beads may have 
provided more information than depletion, since in the absence of one population, 
other cell type(s) may compensate. In order to study the possible interactions 
between cells, however, it may be advantageous to adopt an in vivo approach such 
as immunohistochemistry or the recently developed intracellular cytokine staining 
[183, 184, 186].
Finally, my studies did not attempt to assess whether the T cell populations 
involved in cytokine production during acute and chronic GvHD were of host or 
donor origin. Because the GvHR in parent => Fi mice is unidirectional, 
alloreactive donor T cells should be the main cytokine producing cells during the 
disease. However, the local production of high levels of T cell growth factors 
such as IL-2 may also lead to bystander host T cell activation and cytokine 
production. If time had allowed, I would have utilised Thy-1 congenic mouse 
strains in order to examine the contribution of host cells. Thus, by using donor 
cells and host cells which expressed different forms of the T cell-specific Thy-1 
marker, it would be possible to specifically purify or deplete cells of donor/host 
origin before culture and examine the effect on cytokine levels.
THE ROLE OF NK CELLS IN GvHD
A notable feature of my studies was that, during the first week of GvHD, 
B6 donor cells induced earlier and higher levels of NK cell activity in BDFi mice 
than DBA/2 cells. The greater enhancement of NK cell activity evident after 
injection of B6 cells correlated with the high levels of IFN-y in these mice, 
implicating NK cells as a source of IFN-y production during acute GvHD. 
Although I did not examine the reason for differential NK cell activation during 
acute versus chronic GvHD, the augmented NK activity observed in B6 ==> BDFi 
mice, correlated with the known ability of H-2  ^ parental cells to provoke Fi
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resistance to donor haemopoietic cells [49, 110, 111, 212, 213]. This "hybrid 
resistance” is elicited when NK cells of appropriate Fi mice recognise 
haemopoieitic histoincompatibility antigens (Hh) on the homozygous parental cells 
and is induced by H-2^, but not H-2^ strains such as DBA/2 [110, 111, 212].
However, previous work in our laboratory found no evidence that the activation of 
NK cells during acute GvHD was associated with in vivo host resistance to 
parental cells and instead suggested that both donor and host NK cells are non­
specific effector cells recruited into lymphoid tissues by cytokines such as IL-2 
and IFN-y produced during the anti-host inflammatory response [95]. Thus the 
higher levels of NK cell activity observed in B6 => BDFi vs DBA/2 => BDFi 
mice probably reflect the superior ability of B6 cells to induce IL-12-dependent 
IFN-y production and recruit and activate inflammatory cells. Unfortunately, I was 
unable to directly examine whether neutralising IFN-y reduced NK cell activity.
When NK cells were depleted by injection of anti-ASGM-1 antiserum, 
there was a transient reduction in the degree of lymphoid hyperplasia early in the 
disease and a slight reduction in CTL levels. However, I found little effect on 
other aspects of systemic GvHD. If anything, NK cell depletion slightly 
exacerbated acute GvHD, as higher numbers of anti-ASGM-1 treated mice lost 
weight and died than equivalent NRS treated GvHD controls. Furthermore, on 
day 10, anti-ASGM-1 treated GvHD mice showed lower T and B cell proliferative 
responses than GvHD mice given NRS. Although most studies suggest a 
pathogenic role for NK cells during GvHD by showing that NK cell depletion 
prevents tissue pathology and death [102, 104-106], some evidence also exists 
which supports a protective role for NK cells in GvHD [214, 215]. However, my 
results were rather inconclusive, perhaps because of the unusually mild acute 
GvHD that occurred in NRS treated B6 => BDFi animals. It would be important 
to repeat these studies using both untreated and NRS treated recipients to exclude 
the possibility that giving foreign immunoglobulin to GvHD mice affects disease 
progression. There should also be similar reservations about the effect of depleting
■t
NK cells on IFN-y production, as control mice given either NRS or anti-ASGM-1 
antiserum produced uncharacteristically high levels of spontaneous IFN-y on day 
2 of this study. In addition, as noted above, the dose of anti-ASGM-1 used in this 
study did not completely inhibit NK cell activity in B6 => BDFi mice and it was 
not possible to rule out NK cells as a potential source of IFN-y during the disease.
Anti-NKl.l treatment in vivo may provide an alternative, more efficient method of
,
depleting NK cells for future studies. In addition, if time had allowed, I would 
have repeated this study and also examined IFN-y production by NK cells purified 
from the spleens of B6 => BDFi mice using magnetic beads.
THE ROLE OF CYTOKINES IN THE PATHOGENESIS 
OF MURINE GvHD
The results which I have presented in this thesis have extended previous 
work on the distinct forms of GvHD which develop in BDFi mice given different
parental donor splenocytes. I have shown that cells and cytokines of the early non­
specific immune response may be important in determining the outcome of the 
alloresponse and in particular, my studies have highlighted the importance of the 
proinflammatory cytokine, IL-12, in polarising the specific T cell response. 
Furthermore on the basis of my findings, it is tempting to hypothesise that 
targetting IL-12 may be an effective and specific therapy for GvHD following 
BMT.
Murine models of GvHD are useful tools for examining the complex 
cellular interactions which lead to GvHD following clinical BMT and other forms 
of tissue-specific immunopathology [7, 8, 21-23, 37, 83]. An advantage of the 
parent =*• Fi model employed in this thesis is that a predominantly cell-mediated 
immune response or a predominantly humoral response can be elicited in the same 
Fi hybrid mouse depending on the genotype of the injected parental cells [24, 27]. 
This allowed me to trace the development of these distinct diseases from the 
common starting point of parental donor cell transfer, in order to determine when
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polarisation of the alloimmune response occurred and what caused its divergence. 
Taken together, the findings detailed in this thesis agreed with previous reports 
suggesting that differential activation of CD4+ T helper cell subsets may underlie 
the distinct forms of GvHD in BDFi mice [42, 46]. However, other cell types, 
particularly APC, CD8+ and possibly NK cells are inextricably involved in the 
development and regulation of the anti-host response.
The responses elicited by B6 and DBA/2 parental cells diverged rapidly, 
since as early as 4 hours after donor cell transfer, enhanced NK cell activity was 
observed only in B6 => BDFi mice and within two days, increased spontaneous 
and primed IFN-y production were evident in acute, but not chronic GvHD mice. 
These distinguishing features of early acute GvHD were IL-12 dependent, which 
strongly suggested that the first critical events in B6 => BDFi GvHD involved 
interactions between APC, NK cells and CD4+ T cells. The possible events 
occurring in acute and chronic GvHD in BDFi mice are illustrated in Figs. 11.1A 
& B. These clearly proceed more efficiently in acute GvHD. After injection of 
parental donor cells, donor CD4+ T cells recognise alloantigen expressed on the 
surface of host dendritic cells (DC). As with responses to nominal antigen [216- 
218], engagement of the TcR by host alloantigen results in T cell activation and 
CD40 ligand (CD40L) expression on the T cell surface. Expression of CD40L 
allows donor T cells to bind to and activate host m<f>s via CD40 : CD40L 
interactions [216, 217, 219, 220], provoking IL-12 release by the m<j> population 
[148, 149]. IL-12 then exerts a number of effects on a variety of different cell 
types to induce the symptoms of acute GvHD. Because DBA/2 cells exhibit 
defective IL-12 responses, the manifestations of acute GvHD are not induced. In 
the absence of IL-12-dependent effects, a default Th2 response and autoimmune 
pathology are elicited as oulined below.
IL-12 stimulates IFN-y production by CD4+ and CD8+ T cells and 
possibly NK cells during acute GvHD. The initial IFN-y production then induces 
more IL-12 production from m<j>s, followed by even greater levels of IFN-y,
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which will eventually provoke many of the pathological alterations associated with 
acute GvHD, including immune deficiency and pathology in target tissues like the 
gut, weight loss and mortality. In addition, as my results suggested, IFN-y may 
also directly inhibit Th2 cytokine production, thus preventing the B cell 
hyperplasia and autoimmunity which accompany chronic GvHD, The high levels 
of anti-host CTL activity found in B6 => BDFi mice may also preven t 
autoimmunity by directly destroying host B cells [23, 31], although this was not 
examined directly in these studies.
Several additional elements may contribute to this basic pathway and 
warrant future study. Firstly, although I showed that IFN-y was not essential for 
IL-12 to appear, I did not examine directly if IFN-y was required for optimal IL- 
12 production, as suggested by other work [148, 152, 160]. This could be 
determined by examining if IL-12 production occurs normally during GvHD in B6 
=> BDFi host mice which are deficient in the gene coding for the IFN-y receptor. 
It will also be important to determine the kinetics of IFN-y and IL-12 production 
during acute GvHD in unmanipulated B6 => BDFi mice using a more sensitive 
method such as PCR. In addition, the source of IFN-y and in particular, whether 
NK cells are involved, needs to be explored directly. One conflicting aspect of my 
studies was the inability of anti-IL-12 to prevent CTL activation despite induction 
of CTL by exogenous IL-12. This was possibly due to incomplete neutralisation 
of IL-12 by the antibody and could be better examined in appropriate combinations 
of IL-12 deficient donor and host mice.
A further focus for future studies is the source of IL-12. In the model 
above I cite host m<()S as the major IL-12-producing population. Although m<j)s 
purified from mice undergoing acute GvHD produce high levels of mRNA for the 
inducible p40 subunit of IL-12 [221], activated m<j>s are not the only cell type 
capable of IL-12 production in vivo. In particular, DCs have also been described 
as potential IL-12-producers [123], suggesting that the initial host DC-donor
CD4+ T cell interaction could potentially elicit some IL-12 production. Future
2 5 0
whether donor T ceils from B6 and DBA/2 mice show an inherent predilection to
251
studies should explore the role of m<J)S in IL-12 production by enriching them from 
spleen cell cultures and measuring IL-12 production. Furthermore, given the 
potent cytokine environment which acute GvHD elicits, it is likely that donor- 
derived m(j)S may also be stimulated to produce IL-12. The relative contribution of 
host and donor-derived cells to IL-12 levels could again be assessed using 
appropriate combinations of IL-12 gene knockout and replete host and donor 
mice.
The simplest explanation for the fact that chronic GvHD in DBA/2 => 
BDFi mice was largely unaffected by IL-12 blockade, but could be converted into 
an acute Thl-mediated GvHD by the administration of exogenous IL-12, would 
be that DBA/2 donor cells cannot elicit IL-12 production in BDFi recipients. Since 
IL-12 is essential for T hl differentiation [76-78], the Th2 response which 
develops in DBA/2 => BDFi mice may therefore be a default which occurs in the 
absence of a Thl polarising signal. However, despite the absence of early IL-12 
dependent effects such as NK cell activation and enhanced IFN-y production, I 
found that DBA/2 => BDFi mice had equivalent initial priming of IL-12 
production as B6 => BDFi animals. It would be useful to study the full kinetics of 
IL-12 p40 mRNA expression in vivo using a senstive method such as PCR. Time 
did not permit me to do this.
An alternative explanation is that there are genetically controlled differences 
in the IL-12 responsiveness of B6 and DBA/2 donor cells, as reported in other 
models [139, 140]. According to this idea, T cells from both strains induce similar
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initial levels of IL-12, but only the B6 cells can respond by producing IFN-y and 
then inducing more IL-12. This is consistent with studies of L. major and with my 
finding that initial IL-12 priming was similar in both acute and chronic GvHD. In 
addition, DBA/2 mice preferentially elicit Th2 dominated responses in other 
systems [79, 140, 199], while B6 mice tend to make strong Thl responses to a 
variety of stimuli [200, 201]. It would therefore be important to assess directly
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%produce Thl and Th2 cytokines in response to allostimulation and to assess 
whether regulation of the IL-12 signalling pathway differed between the two 
strains of mice. The inability of DBA/2 donor T cells to respond to IL-12 could 
explain why the high levels of IFN-y released by IL-12 stimulated CD4+ and 
CD8+ T cells during acute GvHD, are not observed. As a result, the feed-back 
loop which operates between IL-12 and IFN-y production in B6 => BDFi GvHD 
is eliminated and IFN-y-dependent immunopathology will not occur. 
Furthermore, since IFN-y regulates Th2 cytokine production during GvHD, a 
preferential Th2 response is allowed to develop. The high levels of Th2 cytokines 
then provide help for host B cells, already activated due to their recognition by 
donor T cells [124], provoking autoantibody production and ICGN. The defective 
IL-12 response of DBA/2 CD8+ T cells could also explain why CD8+T cell 
engraftment is not observed during chronic GvHD and why potentially 
autoreactive B cells are not eliminated by anti-host CTL.
I-
Therapeutic Potential of IL-12 Neutralisation in GvHD
Acute GvHD remains a major obstacle for the use of BMT to treat 
leukaemia and many congenital immunodeficiencies and the results presented in 
this thesis have practical implications for the development of specific therapy 
during GvHD. Traditional approaches to GvHD prophylaxis depend on
immunosuppressive drugs such as methotrexate and cyclosporine which often 
have to be used in combination, resulting in severe side effects [10]. Recent 
attempts to use the more selective approach of depleting T cells from the donor 
BM have been largely unsuccessful, since clinical trials showed that T cell
.«■
depletion led to an increased incidence of leukaemic relapse and failure of 
engraftment [20]. An ideal strategy for GvHD prophylaxis would therefore be to 
prevent anti-host immunopathology, while allowing the survival of sufficient 
donor-derived haemopoetic cells to permit full repopulation of the host. Recent 
approaches have therefore included selective depletion of individual donor T cell
2 5 2
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subsets from the donor inoculum [18, 19], or blocking T cell activation in vivo by 
inhibiting the CD28/CTLA4 : B7/BB1 or CD40 : CD40L T cell costimulatory 
pathways [202, 222-225], This latter approach has been moderately effective in 
reducing GvHD lethality, but in many cases the disease was not completely 
prevented and recurred when treatment was ceased [222, 223]. Furthermore, in 
one study [225] the use of high doses of CTLA4-Ig (a chimeric fusion protein 
with high affinity for B7 molecules on APC) largely prevented donor cell 
engraftment. Although combined blockade of several costimulatory pathways was 
more effective in alleviating lethality [226], this type of therapy may also be
accompanied by deficits in T cell function. Neutralising individual effector
'Ï :
cytokines in vivo has therefore become an attractive alternative to inhibiting 
lymphoid responses during GvHD [55, 57, 64, 65, 227]. My results show that
■■■•SI
IL-12 blockade was particularly useful in treating murine GvHD and may be of 
therapeutic use following clinical BMT. Most importantly, neutralising 
endogenous IL-12 for a brief period during the initiation of acute GvHD conferred 
long-term protection from the pathological outcome of the disease. Because IL-12
“■t
was critical for the afferent phase of GvHD, selective targetting of this cytokine 
prevented the cascade of events which culminates in lethal immunopathology.
Importantly, IL-12 blockade did not prevent engraftment of donor cells, but 
permitted full repopulation with donor B6 lymphocytes and long-term survivors 
showed normal T cell function and remained visibly healthy for over four months 
after withdrawal of antibody treatment. Finally, although anti-IL-12 therapy 
prevented Thl-dependent lethality in B6 => BDFi mice by permanently polarising 
the alloimmune response towards a Th2 phenotype, this did not result in the 
development of autoimmune pathology in the kidney, which might otherwise limit 
its application. In order to fully capitalise on the beneficial effects of IL-12 
blockade, future studies will have to compare different strategies for neutralising 
IL-12 in vivo. Possible candidates are polyclonal and monoclonal anti-IL-12 
antibodies, soluble IL-12 receptor-Fc fusion protein or recombinant IL-12 p40
I
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protein. These latter agents may be particularly useful since they can block IL-12 
binding to its receptor at very low concentrations [123] and may thus avoid 
hypersensitivity reactions provoked by heterologous antibodies.
I
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%Fig. 11.lA. Model of the Cellular and Molecular Interactions 
Involved in the Pathogenesis of Acute GvHD
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